Crystalline salt forms of a kinase inhibitor
Crystalline salt forms of Compound 1 effectively inhibit TAM receptor tyrosine kinases, addressing the inadequacies of current cancer treatments by enhancing stability, solubility, and bioavailability to combat tumor growth and metastasis.
Patent Information
- Application Number
- UA202107797
- Authority / Receiving Office
- UA · UA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-03
- Filing Date
- 2019-12-12
- Publication Date
- 2026-10-21
- Estimated Expiration
- 2039-12-12
AI Technical Summary
Current treatments for cancers mediated by TAM receptor tyrosine kinases, such as Axl and Mer, are inadequate, leading to uncontrolled tumor growth and metastasis due to overexpression and activation of these kinases.
Development of specific crystalline salt forms of Compound 1, including forms like besylate, camsylate, and citrate, which inhibit TAM receptor tyrosine kinases, thereby modulating protein kinase activity and treating associated cancers.
The crystalline salt forms of Compound 1 enhance stability, solubility, and bioavailability, providing effective inhibition of TAM kinases, thereby reducing tumor growth and metastasis.
Smart Images

Figure 00000081_0000 
Figure 00000081_0001 
Figure 00000082_0000
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATION This application claims priority to a prior U.S. patent application under the prior application to U.S. Patent Serial No. 62 / 856404, the entire contents of which are incorporated herein by reference. using the link. TECHNICAL FIELD OF THE INVENTION This invention relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions containing solid crystalline salts of Compound 1. In addition, the invention relates to methods of treating a disease, disorder or syndrome mediated by at least in part, by modulation of protein kinase activity in vivo. LEVEL OF TECHNOLOGY Human Axl belongs to the Tyro3, Axl and Mer (TAM) receptor tyrosine kinase subfamily, which includes Mer. TAM kinases are characterized by an extracellular ligand-binding domain that consists of two immunoglobulin-like domains and two fibronectin type III domains. Axl is overexpressed in a number of tumor cell types and was originally cloned from patients with chronic myeloid leukemia. When overexpressed, Axl exhibits transforming potential. It is believed that Axl signaling induces tumor growth by activating proliferative and antiapoptotic signaling pathways. Axl is associated with cancers such as lung cancer, myeloid leukemia, uterine cancer, ovarian cancer, gliomas, melanoma, thyroid cancer, renal cell carcinoma, osteosarcoma, gastric cancer, prostate cancer and breast cancer. Overexpression of Axl leads to a poor prognosis for patients with these types of cancer. Mer activation, like Axl, transmits downstream signaling pathways that induce growth and activation tumors. Mer binds ligands such as the soluble protein Gas-6. Binding of Gas-6 to Mer induces autophosphorylation of Mer at its intracellular domain, leading to activation downstream signaling. Overexpression of Mer in cancer cells leads to increased metastasis, most likely, due to the formation of a soluble protein of the extracellular domain Mer as a receptor- traps. Tumor cells secrete a soluble form of the extracellular receptor Mer, which reduces the ability of the soluble ligand Gas-6 to activate Mer on endothelial cells, leading to cancer progression. Therefore, there is a need for compounds that inhibit TAM receptor tyrosine kinases, such as Axl and Mer, to treatment of selected cancers. ESSENCE OF THE INVENTION The present invention provides crystalline forms of salts of Compound 1, N-(4-fluorophenyl)-N-(4-((7- methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide, which has structure: N H About N H About FO N N H About About . Compound 1 Compound 1 is disclosed in WO 2019 / 148044, the contents of which are incorporated herein by reference in their entirety. using the link. Specific crystalline salt forms of an active pharmaceutical ingredient (API), such as Compound 1, may have a number of advantages compared to other polymorphic or amorphous forms, for example, increased stability during storage or processing, more favorable solubility, and increased bioavailability. This document presents several stable crystalline salt forms of Compound 1. In one aspect, the invention includes a crystalline salt form of Compound 1. N H About N H About FO N N H About About , Compound 1 wherein the crystalline form of the salt is selected from Form A of Compound 1 besylate, Form B of Compound 1 besylate, Form A of benzoate of Compound 1, Form A of camsylate of Compound 1, Form B of camsylate of Compound 1, Form A Compound 1 citrate, form B Compound 1 citrate, form A esylate Compound 1, form B esylate Compounds 1, HBr-form A Compounds 1, HBr-form B Compounds 1, lactate form A Compounds 1, form A malate Compound 1, maleate form A Compound 1, maleate form B Compound 1, mesylate form A Compound 1, Form B mesylate Compound 1, Form C mesylate Compound 1, Form A oxalate Compound 1, Compound 1 oxalate form B, Compound 1 oxalate form C, Compound 1 propionate form A, Compound 1 form A succinate Compound 1, sulfate form A Compound 1, sulfate form B Compound 1, sulfate form C Compounds 1, tartrate form A Compounds 1, hemitartrate form B Compounds 1, tartrate form C Compounds 1, Form A tosylate of Compound 1 and Form B tosylate of Compound 1. In one aspect, the present invention includes a pharmaceutical composition comprising crystalline a salt form described herein, and a pharmaceutically acceptable excipient. In another aspect, the invention includes a method of treating a disease, disorder or syndrome, mediated, at least in part, by modulation of protein kinase activity in vivo, including administering to a subject in need thereof a crystalline form of the salt, or a pharmaceutical composition, described in this document. In one embodiment of this aspect, the disease, disorder or syndrome mediated at least in part, by modulating protein kinase activity in vivo, is cancer. In another aspect, the invention includes a method of inhibiting a protein kinase, the method comprising: contacting the protein kinase with a crystalline salt form or pharmaceutical composition, described in this document. In one embodiment of this aspect, the protein kinase is Axl, Mer, c-Met, KDR or their combination. In another aspect, methods for obtaining the solid forms described herein are provided. BRIEF DESCRIPTION OF FIGURES Fig. 1 shows the X-ray diffraction pattern of Form A of the besylate of Compound 1. Fig. 2 shows a DSC thermogram of Form A of the besylate of Compound 1. Fig. 3 shows the TGA thermogram of Form A of the besylate of Compound 1. Fig. 4 shows the X-ray diffraction pattern of Form B of the besylate of Compound 1 (mixture with Form A). besylate Compound 1). Fig. 5 shows the XRD diffractogram of Form A of Compound 1 benzoate. Fig. 6 shows the XRD diffractogram of Form A of the camsylate of Compound 1. Fig. 7 shows a DSC thermogram of Form A of the camsylate of Compound 1. Fig. 8 shows the TGA thermogram of Form A of the camsylate of Compound 1. Fig. 9 shows the XRD diffractogram of Form B of the camsylate of Compound 1. Fig. 10 shows the XRD diffractogram of Form A citrate of Compound 1 (mixture with Form A Compounds 1). Fig. 11 shows the XRD diffractogram of Form B citrate of Compound 1. Fig. 12 shows a DSC thermogram of the citrate form B of Compound 1. Fig. 13 shows the TGA thermogram of the citrate form B of Compound 1. Fig. 14 shows a plot of the isotherm of the Form B CSP citrate of Compound 1. Fig. 15 shows the XRD diffractogram of Form A of the esylate of Compound 1. Fig. 16 shows a DSC thermogram of Form A of the esylate of Compound 1. Fig. 17 shows the TGA thermogram of Form A of the esylate of Compound 1. Fig. 18 shows the XRD diffractogram of Form B of the esylate of Compound 1 (mixture with Form A esylate Compound 1). Fig. 19 shows the XRD pattern of HBr-form A of Compound 1. Fig. 20 shows the XRD pattern of HBr-form B of Compound 1. Fig. 21 shows the XRD diffractogram of Form A lactate of Compound 1 (mixture with Form A Compounds 1). Fig. 22 shows the XRD pattern of Compound 1 malate form A (mixture with form A Compounds 1). Fig. 23 shows the XRD diffractogram of Form A of the maleate of Compound 1. Fig. 24 shows a DSC thermogram of Form A of Compound 1 maleate. Fig. 25 shows a TGA thermogram of Form A of Compound 1 maleate. Fig. 26A-26E are hot stage micrographs depicting Form A maleate. Compound 1 at (A) 28.0 C, which exhibits a crystalline form at ambient temperature environment, (B) 129.3 C without changing the crystalline form, (C) 133.0 C with some melting, (D) 140.0 C with complete melting, and (E) cooled to 28.3, demonstrating no recrystallization at ambient temperature. Fig. 27 shows a plot of the DSP isotherm of Form A of Compound 1 maleate. Fig. 28 shows the XRD diffractogram of Compound 1 maleate Form B (mixture with maleate) form A of Compound 1). Fig. 29 shows the XRD diffractogram of Form A of the mesylate of Compound 1. Fig. 30 shows the XRD diffractogram of Form B of the mesylate of Compound 1. Fig. 31 shows the XRD diffractogram of Form C of the mesylate of Compound 1. Fig. 32 shows a DSC thermogram of Form C of the mesylate of Compound 1. Fig. 33 shows a TGA thermogram of Form C of the mesylate of Compound 1. Fig. 34 shows a plot of the DSP isotherm of Form C mesylate of Compound 1. Fig. 35 shows the XRD diffractogram of Form A oxalate of Compound 1. Fig. 36 shows the XRD diffractogram of Form B oxalate of Compound 1. Fig. 37 shows the XRD diffractogram of Form C oxalate of Compound 1. Fig. 38 shows the XRD diffractogram of Form A propionate of Compound 1 (mixture with Form A Compounds 1). Fig. 39 shows the XRD diffractogram of Form A succinate of Compound 1 (mixture with Form A Compounds 1). Fig. 40 shows the XRD diffractogram of Form A sulfate of Compound 1. Fig. 41 shows the XRD diffractogram of Form B sulfate of Compound 1. Fig. 42 shows the XRD diffractogram of Form C sulfate of Compound 1. Fig. 43 shows the XRD diffractogram of Form A succinate of Compound 1 (mixture with Form A Compounds 1). Fig. 44 shows the XRD diffractogram of Form B hemitartrate of Compound 1. Fig. 45 shows a DSC thermogram of Form B hemitartrate of Compound 1. Fig. 46 shows a TGA thermogram of Form B hemitartrate of Compound 1. Fig. 47 shows the XRD diffractogram of Form A tosylate of Compound 1. Fig. 48 shows a DSC thermogram of Form A tosylate of Compound 1. Fig. 49 shows a TGA thermogram of Form A tosylate of Compound 1. Fig. 50 shows a plot of the DSP isotherm of Form A tosylate of Compound 1. Fig. 51A-51D are hot stage micrographs depicting Form A tosylate. Compound 1 at (A) 29.9 °C, which exhibits a crystalline form at ambient temperature environment, (B) 199.3 °C without changing the crystalline form, (C) 214.4 °C with slight melting, (D) 217.9 °C with complete melting. Fig. 52 shows the XRD diffractogram of Form B tosylate of Compound 1. Fig. 53 shows a DSC thermogram of Form B tosylate of Compound 1. Fig. 54 shows the TGA thermogram of Form B tosylate of Compound 1. Fig. 55 shows a plot of the DSP isotherm of Form B tosylate of Compound 1. Fig. 56A-56E are hot-stage micrographs depicting Form B tosylate. Compound 1 at (A) 25.5 °C, which exhibits a crystalline form at ambient temperature environment, (B) 172.0 °C without change in crystal form, (C) 188.0 °C with very slight melting, (D) 194.0 °C with almost complete melting, and (E) 200.1 °C with complete melting, (E) 28.4 °C with initial recrystallization. Fig. 57 presents the indexing results for Form A of Compound 1 besylate, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 58 presents the indexing results for Form A of the camsylate of Compound 1, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 59 shows the indexing results for Form B of Compound 1 besylate, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 60 presents the indexing results for Form A of the esylate of Compound 1, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 61 presents the indexing results for Hbr-form B of Compound 1, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 62 presents the indexing results for Form A of Compound 1 maleate, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 63 presents the indexing results of Form A mesylate of Compound 1, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 64 shows the indexing results of Form B mesylate of Compound 1, including a tabulated space group, according to the given extinction coefficient, the parameters of the elementary cells and derived quantities. Fig. 65 shows the indexing results of the C-form of the mesylate of Compound 1, including a tabulated space group, according to the given extinction coefficient, the parameters of the elementary cells and derived quantities. Fig. 66 presents the indexing results of Form B hemitartrate of Compound 1, including tabulated space group, according to the given attenuation coefficient, parameters unit cell and derived quantities. Fig. 67 shows the indexing results of Form A tosylate of Compound 1, including a tabulated space group, according to the given extinction coefficient, the parameters of the elementary cells and derived quantities. Fig. 68 shows the indexing results of Form B tosylate of Compound 1, including a tabulated space group, according to the given extinction coefficient, the parameters of the elementary cells and derived quantities. Fig. 69 shows the XRD diffractogram of Form C tartrate of Compound 1. DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS, ABBREVIATIONS AND ACRONYMS Analytical techniques Abbreviations / Acronyms Full name / description DSC Differential Scanning Calorimetry Particleboard Dynamic sorption of vapors (water) TMV High Temperature Microscopy NMR Nuclear Magnetic Resonance Spectroscopy OM Optical microscopy MPS Polarized Light Microscopy TGA Thermogravimetry or Thermogravimetric Analysis X-ray powder diffraction Experimental techniques Abbreviations / Acronyms Full name / description SS Sudden cooling Wed Sharp precipitation SH Rapid cooling SHV Rapid evaporation RC Reaction Crystallization Slow cooling software PV Slow evaporation DP Vapor Diffusion NP Vapor Pressure Other information Abbreviations / Acronyms Full name / description ~ About or approximately API Active Pharmaceutical Ingredient PP / E Birefringence and extinction Endo / endo Endotherm or endothermic eq Equivalent Exo / exo Exothermic or exothermic VO Free base VF Free form MK Freezer LIMS Laboratory Information Management System Max / max Maximum or maxima Obs Observation or observed Preferred orientation ppt Precipitation or precipitation Hall Refrigerator Relative humidity CT Room temperature Diluent / diluent Solution vac Vacuum % mass Mass percentage Solvents Abbreviations / Acronyms Full name / description ACN Acetonitrile AcOH Acetic acid DCM Dichloromethane DMSO Dimethyl sulfoxide EtOAc Ethyl acetate EtOH Ethanol HFIPA Hexafluoroisopropanol IPA Isopropyl alcohol, 2-propanol MEK Methyl ethyl ketone MeOH Methanol MTBE methyl tert-butyl ether TFE 2,2,2-trifluoroethanol THF Tetrahydrofuran In the context of this document, the following definitions apply unless otherwise specified. For the purposes of this invention, chemical elements are identified according to the Periodic Table. of the elements, CAS version, Handbook of Chemistry and Physics, 95th ed. In addition, the general principles of organic chemistry is described in "Organic Chemistry," 2nd ed., Thomas Sorrell, University Science Books, Sausalito: 2006, and "March's Advanced Organic Chemistry", 7th ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2013, the full contents of which are incorporated herein by reference. In the context of this document, the term "low / limited / significant hygroscopicity" refers to material that exhibits water absorption <0.5 / <2.0 / ≥ 2.0 wt. % in the specified range of relative humidity. In the context of this document, the term "stoichiometric hydrate" refers to a crystalline material with a certain water content in an extended range of HV. Typical stoichiometric hydrates are hemihydrates, monohydrates, one and a half hydrates, dihydrates, etc. In the context of this document, the term "variable hydrate" refers to a crystalline material with a variable water content in an extended range of relative humidity, but without phase transition. In the context of this document, the chemical term designated as "form" refers to a chemical compound or its salt, which consists of a single phase. In the context of this document, the term "low / limited / medium / good / high solubility" refers to a material having a solubility < 1 / 1-20 / 20-100 / 100-200 / > 200 mg / mL. In the context of this document, the term "crystalline" refers to a material that gives a diffractogram RPD with sharp peaks (similar to the width of the hardware peaks) and weak diffuse scattering relative to peaks. In the context of this document, the term "disordered crystalline" refers to a material that gives a DFT diffractogram with broad peaks (relative to the width of the hardware peaks) and / or strong diffuse scattering relative to the peaks. Materials with a disordered structure can be: 1) microcrystalline, 2) crystalline with a high density of defects, 3) mixtures of crystalline and X-ray amorphous phases or 4) a combination of the above. In the context of this document, the term "insufficient signal" means that the spectrographic analysis of the sample yields a spectrum or plot (output) that has insufficient signal above the expected background noise. As used in this document, the term "single-crystalline phase" refers to the diffraction pattern RPD, which is believed to contain evidence of a single-crystal form because the Bragg peaks are indexed one unit cell. Indexing is the process of assigning each peak to a diffractogram of Miller index marks. In addition, the size and shape of the indexing process are determined elementary crystal cell. In the context of this document, the term "suspension" refers to a suspension prepared by adding sufficient solids to this solvent under ambient conditions medium so that undissolved solids are present. A typical suspension includes mixing (usually by stirring or vibration), an action also called "suspension", in a sealed vial at a given temperature for a long time. Typically, solid particles are removed after a certain period of time using the method described herein. method document. In the context of this document, the term "X-ray amorphous" or "amorphous" refers to a material in which which has diffuse scattering but no signs of Bragg peaks in the RPD diffractogram. In the context of this document, the term "crystalline" refers to compounds in the solid state that have periodic and repeating three-dimensional internal arrangement of atoms, ions, or molecules, characteristic of crystals, for example, arranged in fixed geometric patterns or lattices that have strict long-range order. The term "crystalline" does not necessarily mean that the compound exists in the form of crystals, but means that it has a crystal-like internal organization. In the context of this document, the term "predominantly crystalline" refers to a solid material, which is mainly arranged in the form of fixed geometric patterns or grids that have strict long-range order. For example, mostly crystalline materials have crystallinity greater than than about 85% (e.g., crystallinity greater than about 90%, crystallinity greater than about 95% or crystallinity greater than about 99%). It should also be noted that the term "in "mainly crystalline" includes the descriptor "crystalline", which is defined in the previous paragraph. The term "patient" for the purposes of the present invention includes humans and any other animals, especially mammals, and other organisms. Thus, these methods are used in both human therapy and veterinary medicine. In a preferred embodiment, the patient is a mammal, and in the most preferred embodiment, the patient is a mammal. In a preferred embodiment, the patient is a human. Examples of Preferred Mammals include mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses and primates. "Kinase-dependent diseases or conditions" refers to pathological conditions that depend on activity of one or more kinases. Kinases are directly or indirectly involved in the transmission pathways signal in various types of cellular activity, including proliferation, adhesion, migration, differentiation and invasion. Diseases associated with kinase activity include growth tumors, pathological neovascularization that supports solid tumor growth, and associated with other diseases in which excessive local vascularization is observed, for example, eye diseases (diabetic retinopathy, age-related macular degeneration, etc.) and inflammation (psoriasis, rheumatoid arthritis, etc.). A "therapeutically effective amount" is an amount of the crystalline salt form of Compound 1 that when administered to a patient, it alleviates the symptom of the disease. Amount of crystalline salt form of Compound 1 which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, etc. Therapeutically the effective amount can be determined in a conventional manner by one skilled in the art taking into account his own knowledge and this disclosure. The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions and / or dosage forms which, within the limits of sound medical opinion, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, immunogenicity or other problems or complications comparable to a reasonable benefit-risk ratio. In the context of this document, the phrase "pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid excipient, diluent, solvent or encapsulating material. Excipients are generally safe, not toxic and are neither biologically nor otherwise undesirable and include excipients acceptable for veterinary use, as well as for pharmaceutical use in humans. In one In one embodiment, each component is "pharmaceutically acceptable" as defined herein. document. See, for example, Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al. Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Pref or mulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009. "Cancer" refers to cell-proliferative disease states, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Head and neck: squamous cell carcinoma of the head and neck, laryngeal and hypopharyngeal cancer, nasal cavity and paranasal sinus cancer, cancer nasopharynx, salivary gland cancer, oral cavity and oropharynx cancer; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, non-small cell lung cancer), alveolar (bronchiolar) carcinoma, alveolar sarcoma, alveolar soft tissue sarcoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma. Mesothelioma; Colon: colorectal cancer, adenocarcinoma, stromal tumors Gastrointestinal tract, lymphoma, carcinoids, Turco syndrome; Gastrointestinal tract: stomach cancer, adenocarcinoma of the esophageal-gastric junction, esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), colon (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Mammary gland: metastatic breast cancer glands, ductal carcinoma in situ, invasive ductal carcinoma, tubular cancer, medullary carcinoma, mucinous carcinoma, lobular carcinoma in situ, triple negative breast cancer glands; Genitourinary tract: kidneys (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia, renal cell carcinoma, metastatic renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma), prostate (adenocarcinoma, sarcoma, castration-resistant prostate cancer, bone metastases, bone metastases associated with castration-resistant prostate cancer), testicle (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma), clear cell carcinoma, Papillary carcinoma, penile cancer, penile squamous cell carcinoma; Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum- cell sarcoma), multiple myeloma, malignant giant cell chordoma, osteochondroma, (bone- cartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Thyroid: medullary thyroid cancer, differentiated thyroid cancer, papillary thyroid cancer, follicular cancer thyroid cancer, Hurtley cell thyroid cancer, and anaplastic thyroid cancer glands; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis); brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma, [pinealoma], glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), neurofibroma of the spinal cord, meningioma, glioma, sarcoma), NF1, neurofibromatosis, plexiform neurofibromas; Gynecological: uterus (endometrial cancer), cervix (cervical cancer, precancerous cervical dysplasia), ovaries (ovarian cancer [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosathecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma carcinoma), botryoid sarcoma, (embryonic rhabdomyosarcoma], fallopian tube (carcinoma); Hematological: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), myelofibrosis, polycythemia vera, essential thrombocythemia, Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell cancer, Karposi's sarcoma, dysplastic nevi, moles, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. Thus, the term "cancer cell" as provided in herein, includes a cell affected by any of the above conditions. In some embodiments In one embodiment, the compound or combination disclosed herein can be used to treat diseases, including HIV, sickle cell anemia, graft-versus-host disease host", acute "graft-versus-host" disease, chronic "graft-versus-host" disease "vs. host" and sickle cell anemia. In general, the nomenclature used in this application is based on naming conventions, adopted by the International Union of Pure and Applied Chemistry (IUPAC). Presented in this The chemical structures in this document were obtained using CHEMDRAW®. Any open valence, which appears on a carbon, oxygen or nitrogen atom in the structures given in this document, indicates the presence of a hydrogen atom. IMPLEMENTATION OPTIONS In one aspect, the invention includes a crystalline salt form of Compound 1. N H About N H About FO N N H About About , Compound 1, which is 1-N'-(4-Fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4- yl]oxyphenyl]cyclopropane-1,1-dicarboxamide, or N'-(4-Fluorophenyl)-N-[4-[7-methoxy-6- (methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide, where the crystalline salt a form selected from Compound 1 besylate form A, Compound 1 besylate form B, benzoate form A Compound 1, form A of camsylate Compound 1, form B of camsylate Compound 1, form A of citrate Compound 1, Compound 1 citrate form B, Compound 1 esylate form A, Compound 1 esylate form B, Compound 1 esylate form A, HBr form A Compounds 1, HBr-form B Compounds 1, lactate form A Compounds 1, malate form A Compounds 1, form A maleate Compound 1, maleate form B Compound 1, mesylate form A Compound 1, mesylate form B Compound 1, Form C of the mesylate of Compound 1, Form A of the oxalate of Compound 1, Form B of the oxalate of Compound 1, Compound 1 oxalate form C, Compound 1 propionate form A, Compound 1 succinate form A, Compound 1 Compound 1 sulfate, form B Compound 1 sulfate, form C Compound 1 sulfate, form A tartrate Compounds 1, hemitartrate form B Compounds 1, tartrate form C Compounds 1, tosylate form A Compounds 1 and Form B tosylate of Compound 1. In one embodiment of this aspect, the crystalline form is characterized as Form A. besylate Compound 1. In one embodiment, Form A of the besylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 3.78, 7.56, 10.08, 10.42, 11.70, 11.78, 12.00, 12.71, 13.20, 13.92, 14.06, 14.44, 14.93, 15.18, 15.96, 16.21, 16.40, 16.73, 16.86, 17.38, 18.32, 19.07, 20.07, 20.26, 20.51, 20.94, 21.45, 21.60, 22.30, 22.90, 23.05, 23.28, 23.71, 24.28, 24.97, 25.30, 25.69, 26.33, 26.71, 27.29, 27.65, 28.07, 29.22 and 29.50. In another embodiment, Form A of the besylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 3.78, 7.56, 10.42, 20.51, 20.94, 21.60 and 25.30. In another embodiment, Form A of the besylate of Compound 1 is characterized by all of the following: peaks in the 2 theta RPD diffractogram selected from 3.78, 7.56, 10.42, 20.51, 20.94, 21.60 and 25.30. In another embodiment, Form A of the besylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 3.78, 7.56, 10.08, 10.42, 11.70, 11.78, 12.00, 12.71, 13.20, 13.92, 14.06, 14.44, 14.93, 15.18, 15.96, 16.21, 16.40, 16.73, 16.86, 17.38, 18.32, 19.07, 20.07, 20.26, 20.51, 20.94, 21.45, 21.60, 22.30, 22.90, 23.05, 23.28, 23.71, 24.28, 24.97, 25.30, 25.69, 26.33, 26.71, 27.29, 27.65, 28.07, 29.22 and 29.50. In another embodiment, Form A of the besylate of Compound 1 is characterized by a first endotherm at a temperature of about 144 °C and a second endotherm at a temperature of about 170 °C on the thermogram DSK. In another embodiment, Form A of the besylate of Compound 1 is characterized by a weight loss about 7.9% in the temperature range 39-177 °C on the TGA thermogram. In one embodiment of this aspect, the crystalline form is characterized as Form B. besylate Compound 1. In one embodiment, Form B of the besylate of Compound 1 is characterized by the diffractogram The RPD is essentially identical to that shown in Figure 4. In one embodiment of this aspect, the crystalline form is characterized as Form A. benzoate Compounds 1. In one embodiment, Form A of the benzoate of Compound 1 is characterized by the diffractogram The RPD is essentially identical to that shown in Figure 5. In one embodiment of this aspect, the crystalline form is characterized as Form A. Camsylate Compounds 1. In one embodiment, Form A of the camsylate of Compound 1 is characterized by one or more peaks in the 2 theta RPD diffractogram, where one or more peaks are selected from 5.55, 7.90, 8.25, 8.38, 9.55, 9.87, 10.26, 11.12, 11.34, 12.50, 12.94, 13.40, 13.65, 14.79, 15.83, 16.16, 16.41, 16.54, 16.82, 17.10, 17.69, 18.02, 18.22, 18.47, 18.91, 19.10, 19.47, 20.04, 20.87, 21.05, 22.16, 22.36, 22.93, 23.71, 24.55, 25.33, 26.02, 26.40, 27.09, 27.33, 27.97, 28.32, 28.68 and 28.98. In another embodiment, Form A of the camsylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.55, 9.87, 10.26, 16.16, 16.82, 20.87, 22.36 and 23.71. In another embodiment, Form A of the camsylate of Compound 1 is characterized by all of the the following peaks in the 2 theta RPD diffractogram selected from 5.55, 9.87, 10.26, 16.16, 16.82, 20.87, 22.36 and 23.71. In another embodiment, Form A of the camsylate of Compound 1 is characterized by all of the the following peaks in the 2 theta RPD diffractogram selected from 5.55, 7.90, 8.25, 8.38, 9.55, 9.87, 10.26, 11.12, 11.34, 12.50, 12.94, 13.40, 13.65, 14.79, 15.83, 16.16, 16.41, 16.54, 16.82, 17.10, 17.69, 18.02, 18.22, 18.47, 18.91, 19.10, 19.47, 20.04, 20.87, 21.05, 22.16, 22.36, 22.93, 23.71, 24.55, 25.33, 26.02, 26.40, 27.09, 27.33, 27.97, 28.32, 28.68 and 28.98. In another embodiment, Form A of the camsylate of Compound 1 is characterized by a first endotherm at a temperature of about 110 °C and a second one at about 174 °C on the DSC thermogram. In another embodiment, Form A of the camsylate of Compound 1 is characterized by a weight loss about 5.9% in the temperature range 38-170 °C on the TGA thermogram. In one embodiment of this aspect, the crystalline form is characterized as Form B. Camsylate Compounds 1. In one embodiment, Form B of the camsylate of Compound 1 is characterized by one or more peaks in the 2 theta RPD diffractogram, where one or more peaks are selected from 5.25, 8.32, 8.51, 8.76, 9.05, 9.58, 9.88, 10.00, 10.52, 10.80, 11.06, 11.96, 12.24, 12.58, 13.98, 15.62, 15.81, 16.15, 16.70, 17.12, 17.42, 17.71, 18.41, 19.37, 19.55, 20.63, 21.13, 21.56, 21.89, 22.50, 23.04, 24.43, 26.08, 27.07, 27.97, 28.22 and 28.73. In another embodiment, Form B of the camsylate of Compound 1 is characterized by one or more peaks in the 2 theta RPD diffractogram, where one or more peaks are selected from 5.25, 10.52, 16.15, 21.13, 21.56 and 21.89. In another embodiment, Form B of the camsylate of Compound 1 is characterized by all of the the following peaks in the 2 theta RPD diffractogram selected from 5.25, 10.52, 16.15, 21.13, 21.56 and 21.89. In another embodiment, Form B of the camsylate of Compound 1 is characterized by all of the the following peaks in the 2 theta RPD diffractogram selected from 5.25, 8.32, 8.51, 8.76, 9.05, 9.58, 9.88, 10.00, 10.52, 10.80, 11.06, 11.96, 12.24, 12.58, 13.98, 15.62, 15.81, 16.15, 16.70, 17.12, 17.42, 17.71, 18.41, 19.37, 19.55, 20.63, 21.13, 21.56, 21.89, 22.50, 23.04, 24.43, 26.08, 27.07, 27.97, 28.22 and 28.73. In one embodiment of this aspect, the crystalline form is characterized as Form A. citrate Compound 1. In another embodiment, Form A of the citrate of Compound 1 is characterized by the diffractogram The RPD is essentially identical to that shown in Figure 10. In one embodiment of this aspect, the crystalline form is characterized as Form B. citrate Compound 1. In one embodiment, Form B citrate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.58, 5.95, 7.61, 8.88, 9.19, 9.94, 11.93, 13.26, 13.79, 14.29, 14.68, 15.26, 15.95, 16.64, 17.11, 17.87, 18.21, 18.43, 18.90, 19.36, 19.67, 20.14, 20.57, 21.47, 22.30, 22.64, 23.06, 23.80, 24.25, 24.55, 24.81, 25.10, 25.45, 25.54, 25.85, 26.35, 26.51, 26.83, 27.16, 27.57, 27.85, 28.08 and 28.47. In another embodiment, Form B citrate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.58, 5.95, 8.88, 11.93, 13.79, 14.29, 16.64, 18.90, 21.47, 23.80, 24.25 and 25.85. In another embodiment, Form B citrate of Compound 1 is characterized by all of the following: peaks in the 2 theta RPD diffractogram selected from 4.58, 5.95, 8.88, 11.93, 13.79, 14.29, 16.64, 18.90, 21.47, 23.80, 24.25 and 25.85. In another embodiment, Form B citrate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.58, 5.95, 7.61, 8.88, 9.19, 9.94, 11.93, 13.26, 13.79, 14.29, 14.68, 15.26, 15.95, 16.64, 17.11, 17.87, 18.21, 18.43, 18.90, 19.36, 19.67, 20.14, 20.57, 21.47, 22.30, 22.64, 23.06, 23.80, 24.25, 24.55, 24.81, 25.10, 25.45, 25.54, 25.85, 26.35, 26.51, 26.83, 27.16, 27.57, 27.85, 28.08 and 28.47. In another embodiment, Form B citrate of Compound 1 is characterized by an endotherm at about 175 °C on the DSC thermogram. In another embodiment, Form B citrate of Compound 1 is characterized by an endotherm with an onset temperature at about 175 °C on the DSC thermogram. In another embodiment, Form B citrate of Compound 1 is characterized by a mass loss of above temperature of 175 °C on the TGA thermogram. In another embodiment, Form B citrate of Compound 1 is characterized by a mass loss that starts at a temperature of about 159 °C and ends at 220 °C on the TGA thermogram. In one embodiment, Form B citrate of Compound 1 is characterized by an increase in about 4.1% by weight, as determined by the particle board, when transferred from an environment with a relative humidity of 5% to environment with a relative humidity of 95%. In one embodiment of this aspect, the crystalline form is characterized as Form A. Compound 1 esylate. In one embodiment, Form A of the esylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 3.97, 7.95, 9.89, 10.62, 10.92, 11.03, 11.34, 11.77, 12.03, 12.53, 12.71, 13.27, 14.00, 14.70, 15.08, 15.94, 16.17, 16.92, 17.01, 17.19, 17.35, 17.61, 18.15, 18.76, 19.03, 19.66, 19.89, 20.26, 20.65, 20.78, 21.44, 22.08, 23.14, 23.27, 23.99, 24.32, 25.43, 25.66, 25.85, 26.52, 26.87, 27.61, 27.96, 28.18, 28.40 and 28.91. In one embodiment, Form A of the esylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 3.97, 7.95, 9.89, 10.62, 13.27, 15.08, 16.17, 16.92, 17.01, 20.65, 20.78, 21.44, 22.08, 23.99, 25.43 and 26.52. In another embodiment, Form A of the esylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 3.97, 7.95, 9.89, 10.62, 13.27, 15.08, 16.17, 16.92, 17.01, 20.65, 20.78, 21.44, 22.08, 23.99, 25.43 and 26.52. In another embodiment, Form A of the esylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 3.97, 7.95, 9.89, 10.62, 10.92, 11.03, 11.34, 11.77, 12.03, 12.53, 12.71, 13.27, 14.00, 14.70, 15.08, 15.94, 16.17, 16.92, 17.01, 17.19, 17.35, 17.61, 18.15, 18.76, 19.03, 19.66, 19.89, 20.26, 20.65, 20.78, 21.44, 22.08, 23.14, 23.27, 23.99, 24.32, 25.43, 25.66, 25.85, 26.52, 26.87, 27.61, 27.96, 28.18, 28.40 and 28.91. In another embodiment, Form A of the esylate of Compound 1 is characterized by a first endotherm at a temperature of about 69 °C, a second endotherm at a temperature of about 156 °C, and a third endotherm at a temperature of about 190 °C on the DSC thermogram. In another embodiment, Form A of the esylate of Compound 1 is characterized by a weight loss of about 8.5% in the temperature range 38-188 °C on the TGA thermogram. In one embodiment of this aspect, the crystalline form is characterized as Form B. Compound 1 esylate. In another embodiment, Form B of the esylate of Compound 1 is characterized by the diffractogram The RPD is essentially identical to that shown in Figure 18. In one embodiment of this aspect, the crystalline form is characterized as the HBr form. A Compounds 1. In one embodiment, Form A HBr of Compound 1 is characterized by an X-ray diffraction pattern, essentially identical to that shown in Figure 19. In one embodiment of this aspect, the crystalline form is characterized as the HBr form. In Compounds 1. In one embodiment, HBr Form B of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.26, 8.29, 9.75, 9.91, 10.56, 10.72, 12.25, 12.50, 12.75, 13.31, 13.54, 14.11, 14.72, 14.89, 15.87, 16.29, 16.50, 17.36, 17.78, 18.09, 18.44, 18.75, 19.12, 19.24, 19.56, 19.92, 20.40, 20.55, 20.69, 21.18, 22.09, 22.64, 23.24, 24.56, 25.80, 26.52, 27.23, 27.43, 28.13, 28.46, 28.76, 29.08, 29.66 and 30.07. In another embodiment, HBr Form B of Compound 1 is characterized by one or more peaks in a 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.26, 9.91, 10.72, 20.55, 20.69, 21.18, 22.09, 23.24, 24.56, and 25.80. In another embodiment, HBr Form B of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 5.26, 9.91, 10.72, 20.55, 20.69, 21.18, 22.09, 23.24, 24.56 and 25.80. In another embodiment, HBr Form B of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 5.26, 8.29, 9.75, 9.91, 10.56, 10.72, 12.25, 12.50, 12.75, 13.31, 13.54, 14.11, 14.72, 14.89, 15.87, 16.29, 16.50, 17.36, 17.78, 18.09, 18.44, 18.75, 19.12, 19.24, 19.56, 19.92, 20.40, 20.55, 20.69, 21.18, 22.09, 22.64, 23.24, 24.56, 25.80, 26.52, 27.23, 27.43, 28.13, 28.46, 28.76, 29.08, 29.66 and 30.07. In one embodiment of this aspect, the crystalline form is characterized as Form A. lactate Compound 1. In another embodiment, Form A lactate of Compound 1 is characterized by the diffractogram The RPD is essentially identical to that shown in Figure 21. In one embodiment of this aspect, the crystalline form is characterized as Form A. malate Compounds 1. In another embodiment, Form A malate of Compound 1 is characterized by the diffractogram The RPD is essentially identical to that shown in Figure 22. In one embodiment of this aspect, the crystalline form is Form A maleate. Compounds 1. In one embodiment, Form A maleate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 7.58, 8.34, 10.92, 12.38, 12.87, 14.17, 15.13, 15.78, 16.43, 16.91, 17.51, 18.09, 18.71, 20.30, 21.60, 21.99, 22.30, 22.49, 23.32, 23.56, 23.92, 24.79, 26.04, 26.41, 26.92, 27.62, 28.18, 28.54 and 29.01. In one embodiment, Form A maleate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 10.92, 15.13, 15.78, 16.43, 18.09, 18.71, 20.30, 21.99, 22.30, 22.49, 23.32, 23.56, 24.79, 26.41, 26.92 and 29.01. In another embodiment, Form A maleate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 10.92, 15.13, 15.78, 16.43, 18.09, 18.71, 20.30, 21.99, 22.30, 22.49, 23.32, 23.56, 24.79, 26.41, 26.92 and 29.01. In another embodiment, Form A maleate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 7.58, 8.34, 10.92, 12.38, 12.87, 14.17, 15.13, 15.78, 16.43, 16.91, 17.51, 18.09, 18.71, 20.30, 21.60, 21.99, 22.30, 22.49, 23.32, 23.56, 23.92, 24.79, 26.04, 26.41, 26.92, 27.62, 28.18, 28.54 and 29.01. In another embodiment, Form A of the maleate of Compound 1 is characterized by an endotherm at at a temperature of about 117 °C on the DSC thermogram. In another embodiment, Form A maleate of Compound 1 is characterized by a weight loss of about 3.1% in the temperature range 42-146 °C on the TGA thermogram. In another embodiment, Form A maleate of Compound 1 is characterized by an increase of about 2.5% by weight, as determined by the particle board, when transferred from an environment with a relative humidity of 5% to environment with a relative humidity of 95%. In one embodiment of this aspect, the crystalline form is characterized as Form B. maleate Compound 1. In another embodiment, Form B maleate of Compound 1 is characterized by the diffractogram RPD, essentially identical to that shown in Figure 28. In one embodiment of this aspect, the crystalline form is characterized as Form A. mesylate Compound 1. In one embodiment, Form A of the mesylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.06, 6.65, 7.66, 8.35, 10.16, 10.72, 11.98, 12.62, 13.32, 14.41, 14.79, 15.42, 15.72, 15.89, 16.23, 16.77, 17.20, 17.59, 18.08, 18.40, 18.81, 19.33, 19.53, 19.71, 20.14, 20.38, 20.73, 21.05, 21.56, 21.83, 22.16, 23.14, 24.06, 24.54, 24.77, 25.75, 26.82, 27.71, 27.94, 28.71, 29.27 and 29.85. In another embodiment, Form A of the mesylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.06, 7.66, 14.79, 15.42, 16.23, 17.20, 17.59, 18.40, 19.33, 19.53, 20.38, 20.73, 21.83, 22.16, 23.14, 24.06 and 24.77. In another embodiment, Form A of the mesylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 5.06, 7.66, 14.79, 15.42, 16.23, 17.20, 17.59, 18.40, 19.33, 19.53, 20.38, 20.73, 21.83, 22.16, 23.14, 24.06 and 24.77. In another embodiment, Form A of the mesylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 5.06, 6.65, 7.66, 8.35, 10.16, 10.72, 11.98, 12.62, 13.32, 14.41, 14.79, 15.42, 15.72, 15.89, 16.23, 16.77, 17.20, 17.59, 18.08, 18.40, 18.81, 19.33, 19.53, 19.71, 20.14, 20.38, 20.73, 21.05, 21.56, 21.83, 22.16, 23.14, 24.06, 24.54, 24.77, 25.75, 26.82, 27.71, 27.94, 28.71, 29.27 and 29.85. In one embodiment of this aspect, the crystalline form is characterized as Form B. mesylate Compound 1. In one embodiment, Form B mesylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.14, 6.62, 7.72, 7.89, 10.33, 10.73, 12.74, 13.31, 13.88, 14.23, 14.61, 15.21, 15.52, 15.87, 16.17, 17.18, 17.41, 17.88, 18.15, 18.46, 18.73, 19.13, 19.54, 20.15, 20.53, 20.75, 20.98, 21.27, 21.60, 22.03, 22.28, 23.07, 23.32, 24.16, 24.42, 24.87, 25.13, 25.64, 26.24, 26.95, 27.17, 27.49, 27.77, 28.42 and 29.54. In another embodiment, Form B maleate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 14.61, 15.21, 16.17, 17.18, 17.41, 18.46, 19.13, 19.54, 20.15, 20.53, 20.75, 20.98, 21.27, 21.60, 22.03, 23.32, 24.16, 24.42, 24.87 and 25.13. In another embodiment, Form B of the mesylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 14.61, 15.21, 16.17, 17.18, 17.41, 18.46, 19.13, 19.54, 20.15, 20.53, 20.75, 20.98, 21.27, 21.60, 22.03, 23.32, 24.16, 24.42, 24.87 and 25.13. In another embodiment, Form B of the mesylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 5.14, 6.62, 7.72, 7.89, 10.33, 10.73, 12.74, 13.31, 13.88, 14.23, 14.61, 15.21, 15.52, 15.87, 16.17, 17.18, 17.41, 17.88, 18.15, 18.46, 18.73, 19.13, 19.54, 20.15, 20.53, 20.75, 20.98, 21.27, 21.60, 22.03, 22.28, 23.07, 23.32, 24.16, 24.42, 24.87, 25.13, 25.64, 26.24, 26.95, 27.17, 27.49, 27.77, 28.42 and 29.54. In one embodiment of this aspect, the crystalline form is characterized as Form C. mesylate Compound 1. In one embodiment, Form C mesylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 7.55, 9.53, 10.25, 11.04, 11.49, 11.65, 12.24, 12.51, 13.88, 14.44, 15.36, 15.66, 16.29, 16.58, 17.16, 17.54, 19.04, 19.20, 19.79, 20.54, 21.12, 21.24, 21.62, 22.22, 23.15, 23.57, 23.99, 24.61, 24.77, 25.22, 25.61, 25.99, 26.60, 26.89, 27.29, 27.91, 29.03 and 29.29. In another embodiment, Form C mesylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 7.55, 9.53, 11.49, 12.51, 14.44, 19.04, 20.54, 21.12, 21.24 and 23.15. In another embodiment, Form C of the mesylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 7.55, 9.53, 11.49, 12.51, 14.44, 19.04, 20.54, 21.12, 21.24 and 23.15. In another embodiment, Form C of the mesylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 7.55, 9.53, 10.25, 11.04, 11.49, 11.65, 12.24, 12.51, 13.88, 14.44, 15.36, 15.66, 16.29, 16.58, 17.16, 17.54, 19.04, 19.20, 19.79, 20.54, 21.12, 21.24, 21.62, 22.22, 23.15, 23.57, 23.99, 24.61, 24.77, 25.22, 25.61, 25.99, 26.60, 26.89, 27.29, 27.91, 29.03 and 29.29. In another embodiment, Form C of the mesylate of Compound 1 is characterized by a first endotherm at a temperature of about 96-98 °C and a second endotherm at a temperature of about 198-203 °C on DSC thermogram. In another embodiment, Form C mesylate of Compound 1 is characterized by the first endotherm with a peak at a temperature of about 69 °C, and the first endotherm has a lower a temperature limit of about 36 and an upper temperature limit of about 96 °C, and a second endotherm with a peak at a temperature of about 208 °C, with the second endotherm having a lower temperature limit of about 169 and an upper temperature limit of about 219 °C. In another embodiment, Form C of the mesylate of Compound 1 is characterized by a weight loss of 0.5 up to 3.0 wt. % in the temperature range 36-130 ºC on the TGA thermogram. In another embodiment, Form C of the mesylate of Compound 1 is characterized by an increase in about 5.1% by weight, as determined by the particleboard, when transferred from an environment with a relative humidity of 5% to environment with a relative humidity of 95%. In one embodiment of this aspect, the crystalline form is characterized as Form A. oxalate Compound 1. In one embodiment, Form A oxalate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.90, 5.25, 6.20, 8.05, 9.87, 10.54, 12.29, 14.79, 15.35, 15.84, 16.49, 16.89, 17.55, 18.27, 18.67, 19.12, 19.40, 19.81, 20.26, 20.50, 21.06, 21.74, 22.17, 22.93, 23.26, 23.50, 23.81, 24.66, 25.06, 25.95, 26.90, 27.82 and 28.24. In another embodiment, Form A oxalate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.90, 5.25, 9.87, 10.54, 12.29, 15.35, 18.67, 19.40, 19.81, 20.26, 22.93 and 24.66. In another embodiment, Form A oxalate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.90, 5.25, 9.87, 10.54, 12.29, 15.35, 18.67, 19.40, 19.81, 20.26, 22.93 and 24.66. In another embodiment, Form A oxalate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.90, 5.25, 6.20, 8.05, 9.87, 10.54, 12.29, 14.79, 15.35, 15.84, 16.49, 16.89, 17.55, 18.27, 18.67, 19.12, 19.40, 19.81, 20.26, 20.50, 21.06, 21.74, 22.17, 22.93, 23.26, 23.50, 23.81, 24.66, 25.06, 25.95, 26.90, 27.82 and 28.24. In one embodiment of this aspect, the crystalline form is characterized as Form B. oxalate Compound 1. In one embodiment, Form B oxalate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.20, 7.59, 8.02, 8.42, 10.53, 12.36, 12.66, 13.09, 13.35, 13.88, 14.15, 14.46, 15.06, 15.23, 17.42, 17.75, 18.28, 19.07, 19.52, 20.33, 21.18, 21.43, 21.74, 22.08, 22.59, 23.53, 24.21, 24.52, 24.71, 25.24, 25.85, 26.24, 26.55, 26.90, 27.43, 28.56, 29.30 and 29.51. In another embodiment, Form B oxalate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.20, 7.59, 10.53, 15.06, 15.23, 19.52, 21.18, 21.43, 22.59, 24.21 and 25.85. In another embodiment, Form B oxalate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.20, 7.59, 10.53, 15.06, 15.23, 19.52, 21.18, 21.43, 22.59, 24.21 and 25.85. In another embodiment, Form B oxalate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.20, 7.59, 8.02, 8.42, 10.53, 12.36, 12.66, 13.09, 13.35, 13.88, 14.15, 14.46, 15.06, 15.23, 17.42, 17.75, 18.28, 19.07, 19.52, 20.33, 21.18, 21.43, 21.74, 22.08, 22.59, 23.53, 24.21, 24.52, 24.71, 25.24, 25.85, 26.24, 26.55, 26.90, 27.43, 28.56, 29.30 and 29.51. In one embodiment of this aspect, the crystalline form is characterized as Form C. oxalate Compound 1. In one embodiment, the Form C oxalate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.13, 7.70, 10.29, 10.59, 13.09, 13.70, 14.13, 15.33, 15.87, 16.57, 17.19, 17.50, 17.83, 18.15, 18.61, 19.24, 19.42, 20.11, 20.34, 20.64, 21.07, 21.47, 21.59, 21.91, 22.56, 22.92, 23.37, 23.87, 24.35, 25.35, 25.91, 26.47, 26.68, 27.74, 28.47 and 29.14. In another embodiment, the Form C oxalate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 7.70, 10.29, 10.59, 13.09, 13.70, 15.33, 17.83, 18.15, 20.11, 21.07, 21.91 and 22.56. In another embodiment, Form C oxalate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 7.70, 10.29, 10.59, 13.09, 13.70, 15.33, 17.83, 18.15, 20.11, 21.07, 21.91 and 22.56. In another embodiment, Form C oxalate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.13, 7.70, 10.29, 10.59, 13.09, 13.70, 14.13, 15.33, 15.87, 16.57, 17.19, 17.50, 17.83, 18.15, 18.61, 19.24, 19.42, 20.11, 20.34, 20.64, 21.07, 21.47, 21.59, 21.91, 22.56, 22.92, 23.37, 23.87, 24.35, 25.35, 25.91, 26.47, 26.68, 27.74, 28.47 and 29.14. In one embodiment of this aspect, the crystalline form is characterized as Form A. propionate Compound 1. In one embodiment, Form A propionate of Compound 1 is characterized by the diffractogram RPD, essentially identical to that shown in Figure 38. In one embodiment of this aspect, the crystalline form is characterized as Form A. Succinate Compound 1. In another embodiment, Form A of the succinate of Compound 1 is characterized by the diffractogram RPD, essentially identical to that shown in Figure 39. In one embodiment of this aspect, the crystalline form is characterized as Form A. sulfate Compound 1. In one embodiment, Form A of the sulfate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.74, 5.85, 9.47, 10.04, 11.74, 11.95, 13.77, 14.99, 15.42, 15.71, 16.48, 17.36, 17.66, 17.92, 18.59, 18.95, 19.36, 19.74, 20.22, 20.77, 21.38, 21.86, 22.74, 23.30, 23.70, 24.33, 25.07, 25.32, 25.67, 26.23 and 27.00. In another embodiment, Form A sulfate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.74, 5.85, 9.47, 10.04, 11.74, 11.95, 16.48, 20.22 and 22.74. In another embodiment, Form A of the sulfate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.74, 5.85, 9.47, 10.04, 11.74, 11.95, 16.48, 20.22 and 22.74. In another embodiment, Form A of the sulfate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.74, 5.85, 9.47, 10.04, 11.74, 11.95, 13.77, 14.99, 15.42, 15.71, 16.48, 17.36, 17.66, 17.92, 18.59, 18.95, 19.36, 19.74, 20.22, 20.77, 21.38, 21.86, 22.74, 23.30, 23.70, 24.33, 25.07, 25.32, 25.67, 26.23 and 27.00. In one embodiment of this aspect, the crystalline form is characterized as Form B. sulfate Compound 1. In one embodiment, Form B sulfate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.27, 8.57, 9.32, 10.95, 11.29, 12.07, 12.87, 13.25, 13.82, 14.13, 14.67, 16.94, 17.21, 17.64, 19.99, 20.26, 21.03, 21.44, 22.00, 22.71, 23.85, 25.20 and 26.02. In another embodiment, Form B sulfate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.27, 8.57, 9.32, 16.94, 19.99, 21.03, 21.44, 22.00 and 26.02. In another embodiment, Form B sulfate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.27, 8.57, 9.32, 16.94, 19.99, 21.03, 21.44, 22.00 and 26.02. In another embodiment, Form B sulfate of Compound 1 is characterized by all of the following: peaks in the 2 theta RPD diffractogram selected from 4.27, 8.57, 9.32, 10.95, 11.29, 12.07, 12.87, 13.25, 13.82, 14.13, 14.67, 16.94, 17.21, 17.64, 19.99, 20.26, 21.03, 21.44, 22.00, 22.71, 23.85, 25.20 and 26.02. In one embodiment of this aspect, the crystalline form is characterized as Form C. sulfate Compound 1. In one embodiment, the sulfate form C of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 3.19, 5.35, 9.04, 9.62, 10.73, 11.31, 11.60, 12.27, 12.67, 13.76, 14.31, 14.65, 15.21, 15.63, 16.11, 16.33, 16.63, 17.11, 18.32, 18.75, 18.99, 19.36, 19.47, 20.16, 20.55, 21.01, 21.52, 21.62, 21.89, 22.19, 22.53, 23.19, 23.79, 24.23, 24.81, 25.07, 25.41, 26.06, 26.73, 27.58, 28.16, 28.63, 28.90, 29.22, 29.47 and 29.73. In another embodiment, the sulfate form C of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 3.19, 5.35, 9.62, 12.27, 16.33, 17.11, 18.75, 18.99, 19.36, 19.47, 20.55, 21.01, 21.52, 21.62, 21.89, 22.19, 23.79, 25.07 and 26.06. In another embodiment, the sulfate form C of Compound 1 is characterized by all of the the following peaks in the 2 theta RPD diffractogram selected from 3.19, 5.35, 9.62, 12.27, 16.33, 17.11, 18.75, 18.99, 19.36, 19.47, 20.55, 21.01, 21.52, 21.62, 21.89, 22.19, 23.79, 25.07 and 26.06. In another embodiment, the sulfate form C of Compound 1 is characterized by all of the the following peaks in the 2 theta X-ray diffraction pattern selected from 3.19, 5.35, 9.04, 9.62, 10.73, 11.31, 11.60, 12.27, 12.67, 13.76, 14.31, 14.65, 15.21, 15.63, 16.11, 16.33, 16.63, 17.11, 18.32, 18.75, 18.99, 19.36, 19.47, 20.16, 20.55, 21.01, 21.52, 21.62, 21.89, 22.19, 22.53, 23.19, 23.79, 24.23, 24.81, 25.07, 25.41, 26.06, 26.73, 27.58, 28.16, 28.63, 28.90, 29.22, 29.47 and 29.73. In one embodiment of this aspect, the crystalline form is characterized as Form A. of Compound 1 tartrate. In another embodiment, Form A tartrate of Compound 1 is characterized by the diffractogram RPD, essentially identical to that shown in Figure 43. In one embodiment of this aspect, the crystalline form is characterized as Form B. Compound 1 hemitartrate. In one embodiment, Form B of Compound 1 hemitartrate is characterized by one or more peaks in the 2 theta RPD diffractogram, where one or more peaks are selected from 5.17, 5.66, 7.22, 9.27, 10.10, 10.40, 11.37, 11.55, 12.77, 13.94, 14.51, 15.60, 16.06, 16.48, 17.09, 17.69, 17.90, 18.27, 18.94, 19.15, 19.59, 19.81, 20.06, 20.32, 21.23, 21.83, 22.34, 22.84, 23.53, 24.26, 24.70, 25.26, 25.80, 26.78, 27.29, 27.90, 29.04 and 29.45. In another embodiment, Form B of Compound 1 hemitartrate is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.17, 5.66, 10.10, 10.40, 11.37, 11.55, 14.51, 17.09, 21.23, 21.83, 23.53, 24.26, 25.26 and 26.78. In another embodiment, Form B of Compound 1 hemitartrate is characterized by all of the the following peaks in the 2 theta X-ray diffraction pattern selected from 5.17, 5.66, 10.10, 10.40, 11.37, 11.55, 14.51, 17.09, 21.23, 21.83, 23.53, 24.26, 25.26 and 26.78. In another embodiment, Form B of Compound 1 hemitartrate is characterized by all of the the following peaks in the 2 theta RPD diffractogram selected from 5.17, 5.66, 7.22, 9.27, 10.10, 10.40, 11.37, 11.55, 12.77, 13.94, 14.51, 15.60, 16.06, 16.48, 17.09, 17.69, 17.90, 18.27, 18.94, 19.15, 19.59, 19.81, 20.06, 20.32, 21.23, 21.83, 22.34, 22.84, 23.53, 24.26, 24.70, 25.26, 25.80, 26.78, 27.29, 27.90, 29.04 and 29.45. In another embodiment, Form B of Compound 1 hemitartrate is characterized by the first an endotherm at a temperature of about 111 °C and a second endotherm at a temperature of about 148 °C on DSC thermogram. In another embodiment, Form B hemitartrate of Compound 1 is characterized by a weight loss about 7.4 wt. % in the temperature range 39-157 °C on the TGA thermogram. In one embodiment of this aspect, the crystalline form is characterized as Form C. of Compound 1 tartrate. In another embodiment, Form C tartrate of Compound 1 is characterized by the diffractogram RPD, essentially identical to that presented in Figure 69. In one embodiment of this aspect, the crystalline form is characterized as Form A. tosylate Compound 1. In one embodiment, Form A tosylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 5.81, 7.05, 8.52, 9.74, 10.40, 10.99, 11.26, 11.66, 12.58, 12.81, 14.28, 14.62, 15.30, 15.80, 16.03, 16.34, 17.12, 17.55, 18.03, 18.94, 19.26, 19.67, 20.31, 20.65, 21.02, 21.43, 22.11, 22.44, 22.66, 22.94, 23.07, 23.54, 23.79, 24.55, 24.88, 25.42, 25.83, 26.10, 26.53, 27.70, 28.11, 28.62, 29.18, 29.40, 29.66 and 29.83. In another embodiment, Form A tosylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 8.52, 9.74, 14.28, 16.03, 17.55, 18.94, 19.26, 20.31, 21.02, 21.43, 22.11, 22.44, 22.66, 23.07, 24.55 and 27.70. In another embodiment, Form A tosylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 8.52, 9.74, 14.28, 16.03, 17.55, 18.94, 19.26, 20.31, 21.02, 21.43, 22.11, 22.44, 22.66, 23.07, 24.55 and 27.70. In another embodiment, Form A tosylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 5.81, 7.05, 8.52, 9.74, 10.40, 10.99, 11.26, 11.66, 12.58, 12.81, 14.28, 14.62, 15.30, 15.80, 16.03, 16.34, 17.12, 17.55, 18.03, 18.94, 19.26, 19.67, 20.31, 20.65, 21.02, 21.43, 22.11, 22.44, 22.66, 22.94, 23.07, 23.54, 23.79, 24.55, 24.88, 25.42, 25.83, 26.10, 26.53, 27.70, 28.11, 28.62, 29.18, 29.40, 29.66 and 29.83. In another embodiment, Form A tosylate of Compound 1 is characterized by an endotherm at at a temperature of about 214 °C on the DSC thermogram. In another embodiment, Form A tosylate Compound 1 is characterized by an endotherm with an onset temperature of about 214 °C. DSC thermogram. In another embodiment, Form A tosylate of Compound 1 is characterized by a weight loss of about 0.9 wt. % in the temperature range 72-231 °C on the TGA thermogram. In another embodiment, Form A tosylate of Compound 1 is characterized by an increase in about 0.9% by weight, as determined by the particle board, when transferred from an environment with a relative humidity of 5% to environment with a relative humidity of 95%. In one embodiment of this aspect, the crystalline form is characterized as Form B. tosylate Compound 1. In one embodiment, Form B tosylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.61, 8.69, 9.25, 10.68, 12.44, 12.69, 13.76, 14.42, 14.81, 15.47, 16.08, 16.57, 17.45, 17.76, 18.44, 18.83, 19.01, 19.35, 20.42, 20.84, 21.15, 21.69, 22.09, 22.86, 23.12, 24.08, 24.53, 24.86, 25.22, 25.91, 26.33, 26.82, 27.63, 28.61, 29.11 and 29.77. In another embodiment, Form B tosylate of Compound 1 is characterized by one or more peaks in the 2 theta X-ray diffraction pattern, where one or more peaks are selected from 4.61, 9.25, 12.44, 15.47, 17.76, 19.01, 19.35, 25.91, 26.33 and 27.63. In another embodiment, Form B tosylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.61, 9.25, 12.44, 15.47, 17.76, 19.01, 19.35, 25.91, 26.33 and 27.63. In another embodiment, Form B tosylate of Compound 1 is characterized by all of the following: peaks in the 2 theta X-ray diffraction pattern selected from 4.61, 8.69, 9.25, 10.68, 12.44, 12.69, 13.76, 14.42, 14.81, 15.47, 16.08, 16.57, 17.45, 17.76, 18.44, 18.83, 19.01, 19.35, 20.42, 20.84, 21.15, 21.69, 22.09, 22.86, 23.12, 24.08, 24.53, 24.86, 25.22, 25.91, 26.33, 26.82, 27.63, 28.61, 29.11 and 29.77. In another embodiment, Form B tosylate of Compound 1 is characterized by an endotherm at at ~183 °C on the DSC thermogram. In another embodiment, Form B of Compound 1 tosylate is characterized by an endotherm with an onset temperature at ~183 °C on the DSC thermogram. In another In one embodiment, Form B tosylate of Compound 1 is characterized by an endotherm at a temperature of ~191 °C on the DSC thermogram. In another embodiment, Form B tosylate of Compound 1 is characterized by a weight loss about 0.7 wt % in the temperature range 39-214 °C on the TGA thermogram. In another embodiment, Form B tosylate of Compound 1 is characterized by an increase in about 0.9% by weight, as determined by the particle board, when transferred from an environment with a relative humidity of 5% to environment with a relative humidity of 95%. In one aspect, the present invention includes a pharmaceutical composition comprising crystalline a salt form described herein, and a pharmaceutically acceptable excipient. In another aspect, the invention includes a method of treating a disease, disorder or syndrome, mediated, at least in part, by modulation of protein kinase activity in vivo, including administering to a subject in need thereof a crystalline form of the salt, or a pharmaceutical composition, described in this document. In one embodiment of this aspect, the disease, disorder or syndrome mediated at least in part, by modulating protein kinase activity in vivo, is cancer. In another aspect, the invention includes a method of inhibiting a protein kinase, the method comprising: contacting the protein kinase with a crystalline salt form or pharmaceutical composition, described in this document. In one embodiment of this aspect, the protein kinase is Axl, Mer, c-Met, KDR or their combination. Crystalline forms according to the invention Form A besylate of Compound 1 Form A of the besylate of Compound 1 is a salt of Compound 1 and benzenesulfonic acid in in a 1:1 ratio and, in addition, includes one molar equivalent of acetone in the crystal lattice. The XRD diffractogram of Form A of the besylate of Compound 1 is presented in Figure 1, and the peak list of this The diffraction pattern is given in Table 1 below. Table 1 RPD peaks of form A besylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 3,78±0,20 23,386±1,238 78 7,56±0,20 11,677±0,308 28 10,08±0,20 8,766±0,173 12 10,42±0,20 8,480±0,162 49 11,70±0,20 7,561±0,129 8 11,78±0,20 7,506±0,127 6 12,00±0,20 7,369±0,122 10 12,71±0,20 6,958±0,109 11 13,20±0,20 6,702±0,101 7 13,92±0,20 6,358±0,091 8 14,06±0,20 6,294±0,089 8 14,44±0,20 6,128±0,084 3 14,93±0,20 5,928±0,079 3 15,18±0,20 5,833±0,076 6 15,96±0,20 5,547±0,069 13 16,21±0,20 5,465±0,067 4 16,40±0,20 5,401±0,065 15 16,73±0,20 5,295±0,063 21 16,86±0,20 5,254±0,062 14 17,38±0,20 5,099±0,058 7 18,32±0,20 4,840±0,052 2 19,07±0,20 4,650±0,048 9 20,07±0,20 4,420±0,044 10 20,26±0,20 4,380±0,043 10 20,51±0,20 4,327±0,042 100 20,94±0,20 4,238±0,040 66 21.45±0.20 4.139±0.038 14 21.60±0.20 4.112±0.038 27 22.30±0.20 3.984±0.035 4 22.90±0.20 3.880±0.033 8 23.05±0.20 3.856±0.033 12 23.28±0.20 3.818±0.032 7 23.71±0.20 3.750±0.031 4 24.28±0.20 3.662±0.030 6 24.97±0.20 3.564±0.028 9 25.30±0.20 3.518±0.027 48 25.69±0.20 3.464±0.027 18 26.33±0.20 3.382±0.025 6 26.71±0.20 3.335±0.025 20 27.29±0.20 3.265±0.023 3 27.65±0.20 3.224±0.023 3 28.07±0.20 3.176±0.022 7 29.22±0.20 3.054±0.020 4 29.50±0.20 3.025±0.020 5 The XRD pattern of Form A besylate of Compound 1 was successfully indexed, suggesting that the material consists mainly or exclusively of a single-crystalline phase. Unit cell data for Form A besylate of Compound 1 Type Brave Triclinna a [Å] 8.913 b [Å] 9.121 s [Å] 23.727 [degrees] 93.17 [degrees] 98.70 [degrees] 105.12 Volume [Å3 / cell] 1831.6 Chiral content? Not specified The extinction symbol P- Space group(s) P1(1)3P (2) The DSC and TGA thermograms of Form A of Compound 1 besylate are shown in Fig. 2 and 3, respectively. Loss mass % ~ 7.9 in the temperature range 39–177 °C, determined by TGA, corresponds to 1 molar equivalent of acetone. The DSC thermogram shows two broad endotherms at ~ 144 °C and ~ 170 °C. Form B besylate of Compound 1 Form B of the besylate of Compound 1 is the product obtained after desolvation of Form A. besylate Compound 1. It was found as a mixture with Form A of besylate. The XRD pattern of Form B of the besylate of Compound 1 is shown in Figure 4. Form A benzoate Compound 1 Form A of the benzoate of Compound 1 is a salt formed by the addition of benzoic acid to Compounds 1 in a 1:1 ratio in hot methanol. The XRD diffractogram of Form A of the benzoate of Compound 1 is shown in Figure 5. Form A of camsylate Compound 1 Form A of Compound 1 camsylate is a salt of Compound 1 and camphorsulfonic acid in in a 1:1 ratio and, in addition, includes one molar equivalent of acetone in the crystal lattice. The XRD diffractogram of Form A of the camsylate of Compound 1 is shown in Fig. 6, and the peak list of this The diffraction pattern is given in Table 2 below. Table 2 RPD peaks of form A of camsylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.55±0.20 15.916±0.573 100 7.90±0.20 11.179±0.282 3 8.25±0.20 10.704±0.259 4 8.38±0.20 10.545±0.251 7 9.55±0.20 9.250±0.193 4 9.87±0.20 8.951±0.181 18 10.26±0.20 8.617±0.168 25 11.12±0.20 7.951±0.143 9 11.34±0.20 7.800±0.137 14 12.50±0.20 7.075±0.113 7 12.94±0.20 6.837±0.105 6 13.40±0.20 6.601±0.098 10 13.65±0.20 6.480±0.094 5 14.79±0.20 5.986±0.081 6 15.83±0.20 5.593±0.070 10 16.16±0.20 5.480±0.067 25 16.41±0.20 5.397±0.065 11 16.54±0.20 5.354±0.064 9 16.82±0.20 5.266±0.062 38 17.10±0.20 5.180±0.060 8 17.69±0.20 5.010±0.056 13 18.02±0.20 4.918±0.054 15 18.22±0.20 4.866±0.053 8 18.47±0.20 4.799±0.052 7 18.91±0.20 4.689±0.049 11 Table 2 RPD peaks of form A of camsylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 19.10±0.20 4.643±0.048 10 19.47±0.20 4.556±0.046 6 20.04±0.20 4.427±0.044 4 20.87±0.20 4.254±0.040 33 21.05±0.20 4.218±0.040 18 22.16±0.20 4.008±0.036 16 22.36±0.20 3.973±0.035 27 22.93±0.20 3.876±0.033 9 23.71±0.20 3.750±0.031 38 24.55±0.20 3.623±0.029 7 25.33±0.20 3.513±0.027 8 26.02±0.20 3.421±0.026 7 26.40±0.20 3.373±0.025 5 27.09±0.20 3.289±0.024 5 27.33±0.20 3.260±0.023 6 27.97±0.20 3.187±0.022 4 28.32±0.20 3.149±0.022 6 28.68±0.20 3.110±0.021 4 28.98±0.20 3.078±0.021 5 The RPD diffractogram was successfully indexed. Unit cell data for form A of camsylate Compound 1 Brave type Primitive monoclinic a [Å] 11.413 b [Å] 31.799 s [Å] 11.622 [degrees] 90 [degrees] 101.91 [degrees] 90 Volume [Å3 / cell] 4127.1 Chiral content? Chiral Extinction symbol P 1 21 1 Spatial(s) group(s) P21 (4) The proton NMR spectrum of Form A of the camsylate of Compound 1 is consistent with the chemical structure of Compound 1 with the presence of 1 molar equivalent of acetone. TGA analysis shows that the material is easily desolvated upon heating, losing 5.9 wt. % in in the range 38 °C - 170 °C (Figure 8), which corresponds to one molar equivalent of acetone. Thermogram DSC shows two broad endotherms at 110 °C and 174 °C (Figure 7). Form B of camsylate Compound 1 Form B of the camsylate of Compound 1 is the material obtained after desolvation of Form A. Camsylate Compounds 1. The XRD diffractogram of Form B of Compound 1 camsylate is shown in Fig. 9, and the peak list of this The diffraction pattern is given in Table 3 below. Table 3 RPD peaks of form B of camsylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.25±0.20 16.830±0.641 100 8.32±0.20 10.620±0.255 3 8.51±0.20 10.376±0.243 5 8.76±0.20 10.084±0.230 6 9.05±0.20 9.765±0.215 5 9.58±0.20 9.221±0.192 6 9.88±0.20 8.942±0.180 10 10.00±0.20 8.838±0.176 10 10.52±0.20 8.406±0.159 14 10.80±0.20 8.182±0.151 10 11.06±0.20 7.997±0.144 7 11.96±0.20 7.395±0.123 4 12.24±0.20 7.225±0.118 6 12.58±0.20 7.029±0.111 3 13.98±0.20 6.331±0.090 3 15.62±0.20 5.669±0.072 9 15.81±0.20 5.602±0.070 10 16.15±0.20 5.483±0.067 18 16.70±0.20 5.303±0.063 7 17.12±0.20 5.175±0.060 5 17.42±0.20 5.086±0.058 5 17.71±0.20 5.005±0.056 9 18.41±0.20 4.816±0.052 4 19.37±0.20 4.579±0.047 4 19.55±0.20 4.538±0.046 5 20.63±0.20 4.302±0.041 4 21.13±0.20 4.200±0.039 15 21.56±0.20 4.118±0.038 27 21.89±0.20 4.057±0.037 12 22.50±0.20 3.949±0.035 8 23.04±0.20 3.857±0.033 3 24.43±0.20 3.641±0.029 5 26.08±0.20 3.413±0.026 3 27.07±0.20 3.292±0.024 3 27.97±0.20 3.187±0.022 5 28.22±0.20 3.160±0.022 4 28.73±0.20 3.105±0.021 3 Compound 1 Citrate Form A Form A of the citrate of Compound 1 was crystallized from a mixture of Compound 1 and citric acid with in a 1:1 ratio in acetone. The XRD pattern of Form A citrate of Compound 1 demonstrates that the material is a mixture of in the free base form of Compound 1. The diffractogram is presented in Figure 10. Form B citrate Compound 1 Form B of the citrate of Compound 1 is a 1:1 salt obtained by the addition of 2 molar equivalents citric acid in acetone to Compound 1 to obtain a salt of Compound 1 and citric acid in in a ratio of 1:1. The XRD diffractogram of Form B citrate of Compound 1 is shown in Figure 11 and the XRD diffractogram of was also successfully indexed. The list of peaks in the diffractogram is given in Table 4 below. Table 4 RPD peaks of the citrate form B of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.58±0.20 19.296±0.843 40 5.95±0.20 14.840±0.498 72 7.61±0.20 11.607±0.305 19 8.88±0.20 9.945±0.223 32 9,19±0,20 9,619±0,209 10 9,94±0,20 8,894±0,179 12 11,93±0,20 7,409±0,124 76 13,26±0,20 6,673±0,100 10 13,79±0,20 6,415±0,093 33 14,29±0,20 6,193±0,086 46 14,68±0,20 6,028±0,082 27 15,26±0,20 5,801±0,076 11 15,95±0,20 5,553±0,069 10 16,64±0,20 5,323±0,064 35 17,11±0,20 5,177±0,060 16 17,87±0,20 4,959±0,055 27 18,21±0,20 4,867±0,053 21 18,43±0,20 4,811±0,052 8 18,90±0,20 4,692±0,049 74 19,36±0,20 4,582±0,047 31 19,67±0,20 4,510±0,045 22 20,14±0,20 4,406±0,043 19 20,57±0,20 4,315±0,042 29 21,47±0,20 4,135±0,038 55 22,30±0,20 3,984±0,035 25 22,64±0,20 3,925±0,034 7 23,06±0,20 3,853±0,033 14 23,80±0,20 3,736±0,031 100 24,25±0,20 3,667±0,030 89 24,55±0,20 3,623±0,029 28 24.81±0.20 3.586±0.028 32 25.10±0.20 3.545±0.028 34 25.45±0.20 3.497±0.027 18 25.54±0.20 3.485±0.027 20 25.85±0.20 3.444±0.026 43 26.35±0.20 3.379±0.025 13 26.51±0.20 3.359±0.025 19 26.83±0.20 3.320±0.024 16 27.16±0.20 3.281±0.024 7 27.57±0.20 3.232±0.023 11 27.85±0.20 3.201±0.023 10 28.08±0.20 3.176±0.022 8 28.47±0.20 3.132±0.022 31 Unit cell data for Form B citrate of Compound 1 Brave type Primitive orthorhombic a [Å] 38.495 b [Å] 23.202 s [Å] 7.473 [degrees] 90 [degrees] 90 [degrees] 90 Volume [Å3 / cell] 6,674.6 Chiral content? Achiral F extinction symbol F bca Spatial(s) group(s) Pvsa (61) The TGA thermogram of Form B citrate of Compound 1 (Figure 13) demonstrates a slight loss of mass to decomposition starting at a temperature of about 159 °C and ending at a temperature of about 220 °C. The DSC thermogram (Figure 12) also shows a sharp endotherm with an onset of ~ 175 °C, which indicates decomposition. The DST analysis (Figure 14) shows that the Form B sample of Compound 1 citrate experienced an increase in weight of ~ 4.1% at relative humidity from 5% to 95%. The water absorbed by the sample was released when the relative humidity decreased. relative humidity from 95 to 5%. The RPD analysis shows that after the analysis of the chipboard, the sample remained in the form B citrate Compound 1. Form A of the esylate of Compound 1 Form A of Compound 1 esylate is a salt of Compound 1 and ethanesulfonic acid in in a 1:1 ratio and, in addition, includes one molar equivalent of acetone in the crystal lattice. The XRD diffractogram of Form A of the esylate of Compound 1 is shown in Figure 15, and the peak list of this The diffraction pattern is given in Table 5 below. Table 5 RPD peaks of the esylate form A of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 3.97±0.20 22.255±1.122 86 7.95±0.20 11.119±0.279 100 9.89±0.20 8.937±0.180 38 10.62±0.20 8.322±0.156 63 10.92±0.20 8.096±0.148 12 11.03±0.20 8.012±0.145 12 11.34±0.20 7.798±0.137 6 11.77±0.20 7.516±0.127 16 12.03±0.20 7.348±0.122 5 12.53±0.20 7.057±0.112 11 12.71±0.20 6.960±0.109 6 13.27±0.20 6.665±0.100 54 14.00±0.20 6.321±0.090 13 14.70±0.20 6.021±0.081 5 15.08±0.20 5.870±0.077 42 15.94±0.20 5.554±0.069 17 16.17±0.20 5.477±0.067 40 16,92±0,20 5,236±0,061 32 17,01±0,20 5,209±0,061 33 17,19±0,20 5,155±0,060 7 17,35±0,20 5,108±0,058 6 17,61±0,20 5,033±0,057 7 18,15±0,20 4,883±0,053 16 18,76±0,20 4,727±0,050 5 19,03±0,20 4,661±0,049 8 19,66±0,20 4,511±0,045 18 19,89±0,20 4,461±0,044 8 20,26±0,20 4,380±0,043 22 20,65±0,20 4,297±0,041 87 20,78±0,20 4,272±0,041 81 21,44±0,20 4,141±0,038 47 22,08±0,20 4,022±0,036 51 23,14±0,20 3,840±0,033 10 23,27±0,20 3,820±0,032 11 23,99±0,20 3,706±0,030 42 24,32±0,20 3,657±0,030 17 25,43±0,20 3,500±0,027 62 25,66±0,20 3,469±0,027 26 25,85±0,20 3,444±0,026 17 26,52±0,20 3,358±0,025 35 26,87±0,20 3,315±0,024 9 27,61±0,20 3,228±0,023 7 27,96±0,20 3,189±0,022 18 28.18±0.20 3.164±0.022 22 28.40±0.20 3.140±0.022 13 28.91±0.20 3.085±0.021 7 The RPD diffractogram was successfully indexed. Unit cell data for the esylate form A of Compound 1 Type Brave Triclinna a [Å] 8.593 b [Å] 9.223 s [Å] 22.439 [degrees] 94.60 [degrees] 95.33 [degrees] 103.05 Volume [Å3 / cell] 1,715.6 Chiral content? Not specified The extinction symbol P- Space group(s) P1 (1), P (2) The DSC thermogram of Compound 1 esylate Form A is shown in Figure 16 and shows endotherms at ~ 69 °C, ~ 156 °C and ~ 190 °C. The TGA thermogram (Figure 17) shows that the material loses ~ 8.5% mass in the temperature range 38–188 °C, which corresponds to the loss of one molar equivalent acetone. Form B esylate of Compound 1 Form B of the esylate of Compound 1 was formed by desolvation of Form A of the esylate of Compound 1 and was identified as a mixture with Form A of the esylate of Compound 1. This form has not been further characterized. The XRD pattern of Compound 1 esylate Form B is shown in Figure 18. HBr-form A Compounds 1 HBr Form A of Compound 1 is a salt formed by the addition of HBr to Compound 1 in in a 1:1 ratio, hot acetone suspension. The XRD pattern of HBr-form A of Compound 1 is shown in Figure 19. HBr-form B Compounds 1 HBr Form B of Compound 1 is a salt formed by adding 1 molar equivalent of HBr to Compounds 1 in a 1:1 ratio in hot MEK suspension. The XRD diffractogram of HBr-form B of Compound 1 is presented in Figure 20, and the peak list of this The diffraction pattern is given in Table 6 below. Table 6 RPD peaks of HBr-form B of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.26±0.20 16.777±0.637 100 8.29±0.20 10.661±0.257 5 9.75±0.20 9.068±0.186 10 9.91±0.20 8.916±0.179 26 10.56±0.20 8.367±0.158 11 10.72±0.20 8.243±0.153 22 12.25±0.20 7.219±0.117 4 12.50±0.20 7.075±0.113 6 12.75±0.20 6.938±0.108 9 13.31±0.20 6.648±0.099 11 13.54±0.20 6.535±0.096 10 14.11±0.20 6.270±0.088 6 14.72±0.20 6.011±0.081 12 14.89±0.20 5.943±0.079 5 15.87±0.20 5.581±0.070 8 16.29±0.20 5.438±0.066 7 16.50±0.20 5.368±0.065 16 17.36±0.20 5.104±0.058 7 17.78±0.20 4.984±0.056 12 18.09±0.20 4.899±0.054 14 18.44±0.20 4.808±0.052 15 18.75±0.20 4.728±0.050 5 19.12±0.20 4.637±0.048 12 19.24±0.20 4.609±0.047 12 19.56±0.20 4.535±0.046 15 19.92±0.20 4.453±0.044 13 20.40±0.20 4.350±0.042 19 20.55±0.20 4.319±0.042 24 20.69±0.20 4.290±0.041 30 21.18±0.20 4.191±0.039 31 22.09±0.20 4.021±0.036 80 22.64±0.20 3.924±0.034 10 23.24±0.20 3.825±0.032 43 24.56±0.20 3.622±0.029 44 25.80±0.20 3.450±0.026 28 26.52±0.20 3.358±0.025 11 27.23±0.20 3.272±0.024 10 27.43±0.20 3.249±0.023 7 28.13±0.20 3.169±0.022 7 28.46±0.20 3.134±0.022 11 28.76±0.20 3.101±0.021 6 29.08±0.20 3.069±0.021 5 29.66±0.20 3.009±0.020 13 30.07±0.20 2.970±0.019 13 The XRD diffraction pattern of HBr-form B of Compound 1 was successfully indexed. Unit cell data for HBr form B of Compound 1 Brave type Primitive monoclinic a [Å] 10.652 b [Å] 9.460 s [Å] 33.496 [degrees] 90 [degrees] 91.13 [degrees] 90 Volume [Å3 / cell] 3,374.7 Chiral content? Achiral Symbol of extinction P 1 21 / s 1 Space group(s) P21 / c(14) Form A of lactate Compound 1 Form A of Compound 1 lactate was formed by adding one molar equivalent of lactate acid to Compound 1 in a hot acetone suspension. The material was found to be a a mixture with the crystalline form of the free base of Compound 1. The XRD pattern of Form A lactate of Compound 1 is shown in Figure 21. Form A malate Compound 1 Form A malate of Compound 1 was prepared by adding L-malic acid to Compound 1 in acetone. The material was found to be a mixture with the crystalline form of the free base of Compound 1. The XRD pattern of Compound 1 malate Form A is shown in Figure 22. Form A maleate of Compound 1 Form A of the maleate of Compound 1 is a salt obtained by adding an aqueous solution of maleic acid to a suspension of Compound 1 in a 1:1 ratio in hot MEK or acetone. The XRD diffractogram of Form A maleate of Compound 1 is shown in Figure 23, and the peak list of this The diffractogram is given in Table 7 below. Table 7 Peaks of RPD form A maleate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 7.58±0.20 11.659±0.307 9 8.34±0.20 10.593±0.254 7 10.92±0.20 8.094±0.148 34 12.38±0.20 7.141±0.115 8 12.87±0.20 6.874±0.106 13 14.17±0.20 6.244±0.088 4 15.13±0.20 5.852±0.077 47 15.78±0.20 5.612±0.071 20 16.43±0.20 5.389±0.065 21 16.91±0.20 5.238±0.061 7 17.51±0.20 5.060±0.057 7 18.09±0.20 4.900±0.054 27 18.71±0.20 4.738±0.050 21 20.30±0.20 4.372±0.043 23 21.60±0.20 4.111±0.038 14 21.99±0.20 4.039±0.036 26 22.30±0.20 3.983±0.035 34 22.49±0.20 3.951±0.035 100 23.32±0.20 3.811±0.032 24 23.56±0.20 3.773±0.032 80 23.92±0.20 3.718±0.031 11 24.79±0.20 3.588±0.028 48 26.04±0.20 3.419±0.026 12 26.41±0.20 3.372±0.025 30 26.92±0.20 3.309±0.024 39 27.62±0.20 3.228±0.023 18 28.18±0.20 3.164±0.022 8 28.54±0.20 3.125±0.021 6 29.01±0.20 3.075±0.021 23 The XRD pattern of Form A maleate of Compound 1 was successfully indexed, indicating that that the material consists of a single-crystalline phase. Unit cell data for Form A maleate of Compound 1 Type Brave Triclinna a [Å] 6.264 b [Å] 15.319 s [Å] 16.232 [degrees] 95.43 [degrees] 90.51 [degrees] 94.67 Volume [Å3 / cell] 1545.2 Chiral content? Achiral Symbol P- Space group(s) P1 (1), P (2) The TGA thermogram curve (Figure 25) demonstrates a mass loss of ~ 3.1% in the temperature range 42- 146 °C, mostly above ~ 117 °C, probably due to decomposition of maleic acid. Curve The DSC thermogram (Figure 24) shows one broad endotherm with an onset at ~117 °C. Hot-stage images (Figures 26A-26E) of Form A maleate of Compound 1 confirm the state in in the form of a melt. The particleboard isotherm (Figure 27) demonstrates a mass gain / loss of ~ 2.5% during the experiment with sorption / desorption (BB = 5% - 95%). The material removed from the experiment remained unchanged and was identified by the RPD as Form A. maleate Compound 1. Form B maleate Compound 1 Form B of Compound 1 maleate was prepared from Form A of Compound 1 maleate in acetone with increasing scale of the product preparation procedure. Form B of Compound 1 maleate was obtained only in the form mixtures with Form A maleate of Compound 1. The XRD pattern of Form B maleate of Compound 1 is shown in Figure 28. Form A of the mesylate of Compound 1 Form A of Compound 1 mesylate is a salt obtained by suspending Compound 1 and of methanesulfonic acid in a 1:1 ratio in THF at room temperature. The XRD diffractogram of Form A of Compound 1 mesylate is shown in Figure 29, and the peak list of this The diffractogram is given in Table 8 below. Table 8 RPD peaks of Form A mesylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.06±0.20 17.449±0.689 26 6.65±0.20 13.274±0.399 14 7.66±0.20 11.534±0.301 100 8.35±0.20 10.587±0.253 6 10.16±0.20 8.701±0.171 11 10.72±0.20 8.247±0.153 7 11.98±0.20 7.385±0.123 14 12.62±0.20 7.010±0.111 17 13.32±0.20 6.642±0.099 16 14.41±0.20 6.143±0.085 9 14.79±0.20 5.984±0.080 21 15.42±0.20 5.742±0.074 28 15.72±0.20 5.631±0.071 10 15.89±0.20 5.573±0.070 8 16.23±0.20 5.457±0.067 23 16.77±0.20 5.284±0.063 11 17.20±0.20 5.151±0.059 25 17.59±0.20 5.039±0.057 36 18.08±0.20 4.903±0.054 17 18.40±0.20 4.819±0.052 24 18.81±0.20 4.713±0.050 17 19.33±0.20 4.588±0.047 39 19.53±0.20 4.541±0.046 24 19.71±0.20 4.501±0.045 16 20.14±0.20 4.405±0.043 9 20.38±0.20 4.354±0.042 31 20.73±0.20 4.280±0.041 37 21.05±0.20 4.218±0.040 18 21.56±0.20 4.118±0.038 15 21.83±0.20 4.067±0.037 81 22.16±0.20 4.008±0.036 38 23.14±0.20 3.841±0.033 38 24.06±0.20 3.695±0.030 35 24.54±0.20 3.624±0.029 12 24.77±0.20 3.591±0.029 31 25.75±0.20 3.457±0.026 19 26.82±0.20 3.322±0.024 16 27.71±0.20 3.217±0.023 7 27.94±0.20 3.191±0.022 9 28.71±0.20 3.107±0.021 6 29.27±0.20 3.049±0.020 11 29.85±0.20 2.990±0.020 6 The XRD pattern of Form A of Compound 1 mesylate was successfully indexed, indicating that that the material consists of a single-crystalline phase. Unit cell data for Form A mesylate of Compound 1 Brave Type Primitive orthorhombic a [Å] 6.369 b [Å] 23.054 s [Å] 26.467 [degrees] 90 [degrees] 90 [degrees] 90 Volume [Å3 / cell] 3886.2 Chiral content? Achiral Extinction symbol P212121 Spatial(s) group(s) P212121 (19) Form B mesylate of Compound 1 Form B of Compound 1 mesylate is a salt obtained by suspending Compound 1 and methanesulfonic acid in a 1:1 ratio in hot chloroform. The material also includes about 1.5 moles of chloroform per mole of Compound 1. The XRD diffractogram of Form B of Compound 1 mesylate is shown in Figure 30, and the peak list of this The diffractogram is given in Table 9 below. Table 9 RPD peaks of Form B mesylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.14±0.20 17.169±0.667 16 6.62±0.20 13.336±0.402 14 7.72±0.20 11.441±0.296 16 7.89±0.20 11.193±0.283 10 10.33±0.20 8.556±0.165 12 10.73±0.20 8.240±0.153 8 12.74±0.20 6.945±0.109 26 13.31±0.20 6.646±0.099 10 13.88±0.20 6.377±0.091 8 14.23±0.20 6.220±0.087 17 14.61±0.20 6.057±0.082 35 15.21±0.20 5.822±0.076 44 15.52±0.20 5.704±0.073 24 15.87±0.20 5.580±0.070 12 16.17±0.20 5.477±0.067 38 17.18±0.20 5.157±0.060 78 17.41±0.20 5.090±0.058 42 17.88±0.20 4.956±0.055 12 18.15±0.20 4.883±0.053 23 18.46±0.20 4.802±0.052 36 18,73±0,20 4,733±0,050 23 19,13±0,20 4,636±0,048 60 19,54±0,20 4,539±0,046 35 20,15±0,20 4,403±0,043 40 20,53±0,20 4,323±0,042 34 20,75±0,20 4,278±0,041 75 20,98±0,20 4,230±0,040 47 21,27±0,20 4,173±0,039 49 21,60±0,20 4,110±0,038 55 22,03±0,20 4,032±0,036 100 22,28±0,20 3,986±0,035 27 23,07±0,20 3,852±0,033 31 23,32±0,20 3,811±0,032 72 24,16±0,20 3,681±0,030 34 24,42±0,20 3,642±0,029 50 24,87±0,20 3,577±0,028 37 25,13±0,20 3,541±0,028 34 25,64±0,20 3,472±0,027 26 26,24±0,20 3,393±0,025 22 26,95±0,20 3,306±0,024 18 27,17±0,20 3,279±0,024 17 27,49±0,20 3,242±0,023 21 27,77±0,20 3,210±0,023 17 28,42±0,20 3,138±0,022 19 29,54±0,20 3,022±0,020 30 The XRD pattern of Form B of the mesylate of Compound 1 was successfully indexed, indicating that that the material consists of a single-crystalline phase. Unit cell data for Form B mesylate of Compound 1 Brave type Primitive orthorhombic a [Å] 6.472 b [Å] 22.323 s [Å] 26.607 [degrees] 90 [degrees] 90 [degrees] 90 Volume [Å3 / cell] 3844.0 Chiral content? Not specified Extinction symbol P212121 Spatial(s) group(s) P212121 (19) Form C of the mesylate of Compound 1 Form C of Compound 1 is a salt obtained by mixing Compound 1 and methanesulfonic acid. acid in a 1:1 ratio in hot methanol. The material also contained ~0.1 molar equivalent of methanol. The XRD diffractogram of Form C of Compound 1 mesylate is shown in Figure 31, and the peak list of this The diffractogram is given in Table 10 below. Table 10 RPD peaks of the C-form mesylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 7.55±0.20 11.702±0.310 22 9.53±0.20 9.278±0.194 100 10.25±0.20 8.621±0.168 7 11.04±0.20 8.008±0.145 15 11.49±0.20 7.692±0.133 28 11.65±0.20 7.587±0.130 16 12.24±0.20 7.223±0.118 8 12.51±0.20 7.072±0.113 23 13.88±0.20 6.373±0.091 23 14.44±0.20 6.129±0.084 25 15.36±0.20 5.765±0.075 11 15.66±0.20 5.653±0.072 9 16.29±0.20 5.437±0.066 14 16.58±0.20 5.342±0.064 23 17.16±0.20 5.164±0.060 8 17.54±0.20 5.053±0.057 23 19.04±0.20 4.659±0.048 49 19.20±0.20 4.618±0.048 22 19.79±0.20 4.482±0.045 20 20.54±0.20 4.322±0.042 47 21.12±0.20 4.203±0.039 58 21.24±0.20 4.179±0.039 64 21.62±0.20 4.106±0.038 9 22.22±0.20 3.998±0.036 24 23.15±0.20 3.839±0.033 78 23.57±0.20 3.772±0.032 39 23.99±0.20 3.706±0.030 35 24.61±0.20 3.615±0.029 15 24.77±0.20 3.591±0.029 18 25.22±0.20 3.528±0.028 37 25.61±0.20 3.475±0.027 10 25.99±0.20 3.426±0.026 9 26.60±0.20 3.348±0.025 10 26.89±0.20 3.312±0.024 11 27.29±0.20 3.265±0.023 10 27.91±0.20 3.194±0.022 28 29.03±0.20 3.074±0.021 16 29.29±0.20 3.047±0.020 9 The XRD pattern of Form C of Compound 1 mesylate was successfully indexed, indicating that that the material consists of a single-crystalline phase. Unit cell data for the C mesylate form of Compound 1 Type Brave Triclinna a [Å] 8.884 b [Å] 11.922 s [Å] 15.312 [degrees] 88.79 [degrees] 81.68 [degrees] 78.70 Volume [Å3 / cell] 1573.6 Chiral content? Not specified The extinction symbol P- Spatial(s) group(s) P1 (1), P (2) The DSC thermogram of Form C of Compound 1 mesylate is shown in Figure 32 and demonstrates a broad endotherm with a peak at about 69 °C, with the endotherm having a lower limit of about 36 and an upper limit of about 96 °C. The thermogram also shows another sharp endotherm with a peak at about 208 °C, and the endotherm has a lower limit of about 169 and an upper limit of about 219 °C. TGA, Figure 33, indicates a mass loss of ~ 2.3% in the temperature range 38-115 °C, which corresponds to ~ 0.08 molar equivalents of methanol. The particleboard isotherm (Figure 34) shows a mass gain / loss of about 5.1% during the experiment with sorption / desorption (BB = 5% - 95%). Oxalate Form A Compound 1 Form A of the oxalate of Compound 1 is a salt obtained by the addition of oxalic acid to hot acetone to Compound 1 in a 1:1 ratio to form a suspension. The XRD diffractogram of Form A oxalate of Compound 1 is shown in Figure 35, and the peak list of this The diffraction pattern is given in Table 11 below. Table 11 RPD peaks of oxalate form A of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.90±0.20 18.008±0.734 62 5.25±0.20 16.811±0.640 100 6.20±0.20 14.248±0.459 5 8.05±0.20 10.969±0.272 8 9.87±0.20 8.951±0.181 24 10.54±0.20 8.389±0.159 21 12,29±0,20 7,195±0,117 41 14,79±0,20 5,985±0,080 7 15,35±0,20 5,768±0,075 28 15,84±0,20 5,589±0,070 9 16,49±0,20 5,371±0,065 12 16,89±0,20 5,246±0,062 5 17,55±0,20 5,049±0,057 7 18,27±0,20 4,852±0,053 5 18,67±0,20 4,750±0,050 32 19,12±0,20 4,638±0,048 12 19,40±0,20 4,572±0,047 22 19,81±0,20 4,478±0,045 32 20,26±0,20 4,380±0,043 31 20,50±0,20 4,329±0,042 12 21,06±0,20 4,215±0,040 10 21,74±0,20 4,084±0,037 21 22,17±0,20 4,007±0,036 17 22,93±0,20 3,876±0,033 46 23,26±0,20 3,822±0,032 20 23,50±0,20 3,782±0,032 23 23,81±0,20 3,734±0,031 18 24,66±0,20 3,607±0,029 30 25,06±0,20 3,550±0,028 11 25,95±0,20 3,431±0,026 20 26,90±0,20 3,312±0,024 7 27,82±0,20 3,204±0,023 9 28.24±0.20 3.157±0.022 17 Form B oxalate of Compound 1 The oxalate form of Compound 1 is a salt obtained by adding oxalic acid to Compound 1. 1 in a 1:1 ratio in hot MEK to form a suspension. The XRD diffractogram of Form B oxalate of Compound 1 is shown in Figure 36, and the peak list of this The diffractogram is given in Table 12 below. Table 12 RPD peaks of oxalate form B of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.20±0.20 21.026±1.001 34 7.59±0.20 11.640±0.306 100 8.02±0.20 11.013±0.274 16 8.42±0.20 10.496±0.249 15 10.53±0.20 8.391±0.159 90 12.36±0.20 7.154±0.115 13 12.66±0.20 6.989±0.110 21 13.09±0.20 6.759±0.103 19 13.35±0.20 6.629±0.099 27 13.88±0.20 6.377±0.091 16 14,15±0,20 6,254±0,088 15 14,46±0,20 6,119±0,084 14 15,06±0,20 5,878±0,078 40 15,23±0,20 5,815±0,076 59 17,42±0,20 5,088±0,058 21 17,75±0,20 4,994±0,056 29 18,28±0,20 4,850±0,053 20 19,07±0,20 4,649±0,048 19 19,52±0,20 4,544±0,046 32 20,33±0,20 4,365±0,042 19 21,18±0,20 4,190±0,039 44 21,43±0,20 4,143±0,038 37 21,74±0,20 4,085±0,037 24 22,08±0,20 4,022±0,036 29 22,59±0,20 3,932±0,034 43 23,53±0,20 3,778±0,032 19 24,21±0,20 3,673±0,030 37 24,52±0,20 3,627±0,029 28 24,71±0,20 3,600±0,029 25 25,24±0,20 3,525±0,027 19 25,85±0,20 3,444±0,026 41 26,24±0,20 3,393±0,025 26 26,55±0,20 3,355±0,025 30 26,90±0,20 3,312±0,024 28 27,43±0,20 3,249±0,023 24 28.56±0.20 3.123±0.021 29 29.30±0.20 3.045±0.020 17 29.51±0.20 3.024±0.020 21 Form C oxalate of Compound 1 The oxalate form of Compound 1 is a salt obtained by adding oxalic acid in hot TFE to Compound 1 in a 1:1 ratio to form a suspension. The XRD diffractogram of Form C oxalate of Compound 1 is shown in Figure 37, and the peak list of this The diffractogram is given in Table 13 below. Table 13 RPD peaks of form C oxalate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.13±0.20 21.391±1.036 30 7.70±0.20 11.473±0.298 98 10.29±0.20 8.594±0.167 34 10.59±0.20 8.351±0.157 53 13.09±0.20 6.760±0.103 51 13.70±0.20 6.459±0.094 76 14.13±0.20 6.261±0.088 13 15.33±0.20 5.774±0.075 100 15,87±0,20 5,580±0,070 12 16,57±0,20 5,346±0,064 12 17,19±0,20 5,154±0,060 15 17,50±0,20 5,063±0,057 19 17,83±0,20 4,971±0,055 42 18,15±0,20 4,883±0,053 39 18,61±0,20 4,764±0,051 14 19,24±0,20 4,610±0,047 22 19,42±0,20 4,567±0,047 18 20,11±0,20 4,412±0,043 49 20,34±0,20 4,362±0,042 34 20,64±0,20 4,299±0,041 37 21,07±0,20 4,212±0,040 69 21,47±0,20 4,135±0,038 35 21,59±0,20 4,112±0,038 36 21,91±0,20 4,053±0,037 67 22,56±0,20 3,937±0,034 69 22,92±0,20 3,877±0,033 20 23,37±0,20 3,804±0,032 34 23,87±0,20 3,725±0,031 39 24,35±0,20 3,653±0,030 18 25,35±0,20 3,511±0,027 33 25,91±0,20 3,436±0,026 33 26,47±0,20 3,364±0,025 31 26,68±0,20 3,338±0,025 36 27,74±0,20 3,213±0,023 32 28.47±0.20 3.132±0.022 27 29.14±0.20 3.062±0.021 25 Form A of Compound 1 propionate Form A of the propionate of Compound 1 is a salt obtained by the addition of propionic acid to Compound 1 in a 1:1 ratio and suspended in hot acetone. Form A of the propionate of Compound 1 was formed only as a minor part of the mixture with the free base form of Compound 1. The XRD diffractogram of Form A of Compound 1 benzoate is shown in Figure 38. Form A of Succinate of Compound 1 Form A of the succinate of Compound 1 is a salt obtained by the addition of one or two molar equivalents of succinic acid to Compound 1 and suspended in hot acetone. Form A of Compound 1 succinate was formed only as a mixture with the free base form of Compound 1. The XRD diffractogram of Form A of the succinate of Compound 1 is shown in Figure 39. Form A of the sulfate of Compound 1 Form A of the sulfate of Compound 1 is a salt obtained by the addition of one molar equivalent of sulfuric acid to Compound 1 in a 1:1 ratio, in THF. The XRD diffractogram of Form A sulfate of Compound 1 is shown in Figure 40, and the peak list of this The diffractogram is given in Table 14 below. Table 14 RPD peaks of the sulfate form A of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.74±0.20 18.617±0.785 100 5.85±0.20 15.104±0.516 14 9.47±0.20 9.327±0.196 11 10.04±0.20 8.804±0.175 15 11.74±0.20 7.534±0.128 24 11.95±0.20 7.397±0.123 13 13.77±0.20 6.428±0.093 7 14.99±0.20 5.905±0.078 12 15.42±0.20 5.742±0.074 7 15.71±0.20 5.637±0.071 7 16.48±0.20 5.374±0.065 19 17.36±0.20 5.105±0.058 11 17.66±0.20 5.019±0.056 8 17.92±0.20 4.946±0.055 8 18.59±0.20 4.768±0.051 11 18.95±0.20 4.680±0.049 12 19.36±0.20 4.581±0.047 18 19.74±0.20 4.493±0.045 23 20.22±0.20 4.388±0.043 35 20.77±0.20 4.272±0.041 25 21.38±0.20 4.153±0.038 17 21.86±0.20 4.063±0.037 13 22.74±0.20 3.907±0.034 39 23.30±0.20 3.814±0.032 15 23.70±0.20 3.751±0.031 12 24.33±0.20 3.655±0.030 14 25.07±0.20 3.549±0.028 11 25.32±0.20 3.515±0.027 14 25.67±0.20 3.467±0.027 13 26.23±0.20 3.395±0.025 19 27.00±0.20 3.299±0.024 15 Form B sulfate of Compound 1 Form B of the sulfate of Compound 1 is a salt obtained by the addition of one molar equivalent of sulfuric acid to Compound 1 in a 1:1 ratio, in hot methanol. The XRD diffractogram of Form B sulfate of Compound 1 is shown in Figure 41, and the peak list of this The diffraction pattern is given in Table 15 below. Table 15 RPD peaks of the sulfate form B of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.27±0.20 20.683±0.969 100 8.57±0.20 10.313±0.240 75 9.32±0.20 9.481±0.203 94 10.95±0.20 8.071±0.147 16 11.29±0.20 7.834±0.138 18 12.07±0.20 7.329±0.121 13 12.87±0.20 6.875±0.106 15 13.25±0.20 6.678±0.100 15 13.82±0.20 6.404±0.092 21 14.13±0.20 6.264±0.088 25 14.67±0.20 6.032±0.082 20 16.94±0.20 5.230±0.061 32 17.21±0.20 5.147±0.059 23 17.64±0.20 5.024±0.057 17 19.99±0.20 4.439±0.044 48 20.26±0.20 4.380±0.043 26 21.03±0.20 4.221±0.040 67 21.44±0.20 4.141±0.038 41 22.00±0.20 4.036±0.036 43 22.71±0.20 3.913±0.034 35 23.85±0.20 3.728±0.031 30 25.20±0.20 3.531±0.028 27 26.02±0.20 3.422±0.026 44 Form C sulfate of Compound 1 Form C of the sulfate of Compound 1 is a salt obtained by the addition of one molar equivalent of sulfuric acid to Compound 1 in a 1:1 ratio, in hot chloroform. The XRD diffractogram of Form C sulfate of Compound 1 is shown in Figure 42, and the peak list of this The diffractogram is given in Table 16 below. Table 16 RPD peaks of the sulfate form B of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 3.19±0.20 27.658±1.733 23 5.35±0.20 16.519±0.618 33 9.04±0.20 9.776±0.216 12 9.62±0.20 9.182±0.190 72 10.73±0.20 8.239±0.153 8 11,31±0,20 7,820±0,138 8 11,60±0,20 7,619±0,131 8 12,27±0,20 7,208±0,117 36 12,67±0,20 6,978±0,110 12 13,76±0,20 6,432±0,093 22 14,31±0,20 6,183±0,086 10 14,65±0,20 6,040±0,082 20 15,21±0,20 5,820±0,076 21 15,63±0,20 5,664±0,072 21 16,11±0,20 5,498±0,068 18 16,33±0,20 5,424±0,066 16 16,63±0,20 5,327±0,064 51 17,11±0,20 5,177±0,060 66 18,32±0,20 4,839±0,052 21 18,75±0,20 4,730±0,050 42 18,99±0,20 4,670±0,049 68 19,36±0,20 4,582±0,047 32 19,47±0,20 4,555±0,046 32 20,16±0,20 4,401±0,043 15 20,55±0,20 4,318±0,042 39 21,01±0,20 4,224±0,040 28 21,52±0,20 4,125±0,038 36 21,62±0,20 4,107±0,038 34 21,89±0,20 4,056±0,037 39 22,19±0,20 4,004±0,036 50 22.53±0.20 3.943±0.035 25 23.19±0.20 3.833±0.033 15 23.79±0.20 3.737±0.031 47 24.23±0.20 3.670±0.030 20 24.81±0.20 3.586±0.028 37 25.07±0.20 3.549±0.028 100 25.41±0.20 3.502±0.027 31 26.06±0.20 3.416±0.026 41 26.73±0.20 3.332±0.024 20 27.58±0.20 3.231±0.023 21 28.16±0.20 3.167±0.022 13 28.63±0.20 3.116±0.021 13 28.90±0.20 3.087±0.021 12 29.22±0.20 3.054±0.020 16 29.47±0.20 3.029±0.020 19 29.73±0.20 3.003±0.020 21 Form A tartrate of Compound 1 Form A of Compound 1 tartrate is a salt obtained by the addition of one molar equivalent of L-tartaric acid to Compound 1 in a 1:1 ratio in THF. Form A of Compound 1 tartrate was formed only as a mixture with the free base form of Compound 1. The XRD pattern of Form A tartrate of Compound 1 is shown in Figure 43. Form B of Compound 1 hemitartrate Form B of the hemitartrate of Compound 1 is a salt obtained by the addition of one molar equivalent of L-tartaric acid to Compound 1 in a 2:1 ratio in acetone. The material also contains about 0.7 molar equivalent of acetone. The XRD diffractogram of Form B hemitartrate of Compound 1 is shown in Figure 44, and the peak list is of this diffractogram is given in Table 17 below. Table 17 RPD peaks of Form B hemitartrate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.17±0.20 17.079±0.660 55 5.66±0.20 15.592±0.550 24 7.22±0.20 12.229±0.338 18 9.27±0.20 9.534±0.205 11 10.10±0.20 8.752±0.173 26 10.40±0.20 8.503±0.163 23 11.37±0.20 7.776±0.136 26 11,55±0,20 7,659±0,132 37 12,77±0,20 6,929±0,108 8 13,94±0,20 6,346±0,091 19 14,51±0,20 6,100±0,084 31 15,60±0,20 5,676±0,072 8 16,06±0,20 5,514±0,068 17 16,48±0,20 5,374±0,065 14 17,09±0,20 5,184±0,060 53 17,69±0,20 5,011±0,056 12 17,90±0,20 4,951±0,055 12 18,27±0,20 4,851±0,053 15 18,94±0,20 4,681±0,049 11 19,15±0,20 4,630±0,048 13 19,59±0,20 4,529±0,046 12 19,81±0,20 4,478±0,045 15 20,06±0,20 4,423±0,044 19 20,32±0,20 4,367±0,043 19 21,23±0,20 4,182±0,039 48 21,83±0,20 4,068±0,037 48 22,34±0,20 3,976±0,035 14 22,84±0,20 3,891±0,034 13 23,53±0,20 3,778±0,032 100 24,26±0,20 3,666±0,030 45 24,70±0,20 3,601±0,029 11 25,26±0,20 3,523±0,027 34 25.80±0.20 3.450±0.026 13 26.78±0.20 3.326±0.024 59 27.29±0.20 3.266±0.023 16 27.90±0.20 3.195±0.022 30 29.04±0.20 3.073±0.021 8 29.45±0.20 3.030±0.020 17 The XRD pattern of Form B hemitartrate of Compound 1 was successfully indexed, indicating that the material consists of a single-crystalline phase. Unit cell data for Form B hemitartrate of Compound 1 Brave type Primitive monoclinic a [Å] 5356 b [Å] 34062 s [Å] 17.503 [degrees] 90 [degrees] 92.11 [degrees] 90 Volume [Å3 / cell] 3191.0 Chiral content? Symbol of extinction Chiral P 1 21 1 Spatial(s) group(s) P21 (4) The DSC thermogram of Form B hemitartrate of Compound 1 is shown in Figure 45 and demonstrates a broad endotherm at ~ 111 °C and another sharp endotherm at ~ 148 °C. TGA, Figure 46, indicates a mass loss of ~ 7.4% in the temperature range 39-157 °C, which corresponds to ~ 0.8 molar equivalents of acetone. Form A tosylate of Compound 1 Form A of the tosylate of Compound 1 is a salt obtained by the addition of one molar equivalent of p-toluenesulfonic acid to Compound 1 in a 1:1 ratio in hot acetone. The material also contains ~0.2 molar equivalents of acetone. The XRD diffractogram of Form A tosylate of Compound 1 is shown in Figure 47, and the peak list of this The diffractogram is given in Table 18 below. Table 18 RPD peaks of Form A tosylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 5.81±0.20 15.205±0.523 10 7,05±0,20 12,532±0,355 13 8,52±0,20 10,364±0,243 55 9,74±0,20 9,076±0,186 100 10,40±0,20 8,497±0,163 5 10,99±0,20 8,042±0,146 21 11,26±0,20 7,849±0,139 12 11,66±0,20 7,582±0,130 5 12,58±0,20 7,030±0,111 9 12,81±0,20 6,904±0,107 13 14,28±0,20 6,199±0,086 57 14,62±0,20 6,053±0,082 6 15,30±0,20 5,787±0,075 23 15,80±0,20 5,606±0,071 10 16,03±0,20 5,524±0,068 37 16,34±0,20 5,420±0,066 18 17,12±0,20 5,174±0,060 6 17,55±0,20 5,050±0,057 49 18,03±0,20 4,917±0,054 7 18,94±0,20 4,682±0,049 39 19,26±0,20 4,605±0,047 34 19,67±0,20 4,509±0,045 23 20,31±0,20 4,370±0,043 84 20,65±0,20 4,297±0,041 20 21,02±0,20 4,222±0,040 58 21,43±0,20 4,143±0,038 64 22.11±0.20 4.018±0.036 52 22.44±0.20 3.960±0.035 43 22.66±0.20 3.921±0.034 41 22.94±0.20 3.874±0.033 29 23.07±0.20 3.851±0.033 35 23.54±0.20 3.776±0.032 14 23.79±0.20 3.737±0.031 20 24.55±0.20 3.623±0.029 35 24.88±0.20 3.576±0.028 9 25.42±0.20 3.501±0.027 11 25.83±0.20 3.446±0.026 9 26.10±0.20 3.412±0.026 6 26.53±0.20 3.357±0.025 12 27.70±0.20 3.218±0.023 39 28.11±0.20 3.172±0.022 7 28.62±0.20 3.116±0.021 5 29.18±0.20 3.058±0.021 8 29.40±0.20 3.036±0.020 7 29.66±0.20 3.010±0.020 9 29.83±0.20 2.993±0.020 9 The XRD pattern of Form A tosylate of Compound 1 was successfully indexed, indicating that that the material consists of a single-crystalline phase. Unit cell data for Form A tosylate of Compound 1 Type Brave Triclinna a [Å] 8.824 b [Å] 13.010 s [Å] 15.364 [degrees] 96.03 [degrees] 95.62 [degrees] 103.96 Volume [Å3 / cell] 1688.2 Chiral content? Not specified The extinction symbol P- Spatial(s) group(s) P1(1), P (2) The DSC thermogram for Form A tosylate of Compound 1 is shown in Figure 48 and demonstrates a sharp endotherm with onset at about 214 °C. TGA, Figure 49, indicates a mass loss of ~0.9% in temperature range 72-231 °C, which corresponds to ~ 0.1 molar equivalent of acetone. The hot stage micrographs shown in Figures 51A-51D confirm that the temperature The melting point of Form A tosylate of Compound 1 is about 214 °C. The particleboard isotherm (Figure 50) shows a mass gain / loss of about 0.9% during the experiment with sorption / desorption (BB = 5% - 95%). Form B tosylate of Compound 1 The tosylate form of Compound 1 is a 1:1 salt obtained during the scale-up procedure. obtaining Form A tosylate of Compound 1. The XRD diffractogram of Form B tosylate of Compound 1 is shown in Figure 52, and the peak list of this The diffractogram is given in Table 19 below. Table 19 RPD peaks of Form B tosylate of Compound 1 2θ (˚) d-spacing (Å) Intensity (%) 4.61±0.20 19.171±0.832 47 8.69±0.20 10.171±0.234 10 9.25±0.20 9.550±0.206 25 10.68±0.20 8.274±0.154 23 12.44±0.20 7.107±0.114 24 12.69±0.20 6.972±0.109 10 13.76±0.20 6.429±0.093 18 14.42±0.20 6.138±0.085 20 14,81±0,20 5,975±0,080 18 15,47±0,20 5,725±0,074 58 16,08±0,20 5,509±0,068 7 16,57±0,20 5,345±0,064 7 17,45±0,20 5,078±0,058 15 17,76±0,20 4,991±0,056 59 18,44±0,20 4,808±0,052 24 18,83±0,20 4,709±0,050 26 19,01±0,20 4,665±0,049 51 19,35±0,20 4,584±0,047 100 20,42±0,20 4,345±0,042 9 20,84±0,20 4,259±0,040 26 21,15±0,20 4,198±0,039 16 21,69±0,20 4,095±0,037 27 22,09±0,20 4,021±0,036 12 22,86±0,20 3,887±0,034 11 23,12±0,20 3,843±0,033 18 24,08±0,20 3,692±0,030 6 24,53±0,20 3,626±0,029 10 24,86±0,20 3,579±0,028 7 25,22±0,20 3,528±0,028 7 25,91±0,20 3,436±0,026 73 26,33±0,20 3,382±0,025 34 26,82±0,20 3,321±0,024 15 27,63±0,20 3,226±0,023 35 28,61±0,20 3,118±0,021 7 29.11±0.20 3.066±0.021 5 29.77±0.20 2.999±0.020 5 The XRD pattern of Form B tosylate of Compound 1 was successfully indexed, indicating that that the material consists of a single-crystalline phase. Unit cell data for Form B tosylate of Compound 1 Type Brave Triclinna a [Å] 8.501 b [Å] 10.393 s [Å] 19.667 [degrees] 98.40 [degrees] 99.75 [degrees] 97.34 Volume [Å3 / well] 1673.3 Chiral content? Achiral The extinction symbol P- Spatial(s) group(s) P1(1), P (2) The DSC thermogram for Form B tosylate of Compound 1 is shown in Figure 53 and demonstrates a sharp endotherm at ~183 °C. TGA, Figure 54, indicates a mass loss of ~0.7% in the temperature range 39- 214 °C. The hot stage micrographs shown in Figures 56A-56F demonstrate that Form B tosylate of Compound 1 starts melting at ~ 183 °C, continues melting at ~ 194 °C and is not fully melted to 200 °C. The particleboard isotherm (Figure 55) shows a mass gain / loss of about ~ 0.9% during the experiment with sorption / desorption (BB = 5% - 95%). GENERAL METHODS OF ADMINISTRATION Introduction of crystalline salt forms of Compound 1 or their pharmaceutically acceptable salts into in pure form or in a suitable pharmaceutical composition can be carried out using any any of the accepted methods of administration or agents for similar purposes. Thus, administration may be administered, for example, orally, nasally, parenterally (intravenously, intramuscularly or subcutaneously), topically, transdermally, intravaginally, intravesically, intrasystemically or rectally, in the form of a solid, semi-solid, lyophilized powder or liquid dosage forms, such as tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, aerosols, etc., mainly in single-dose in forms suitable for easy administration of precise dosages. The compositions will include a conventional pharmaceutical excipient and a crystalline form of the salt. Compounds 1 as the active agent, and may further include other drugs, pharmaceuticals, excipients, adjuvants, etc. The compositions of the present invention can be be used in combination with anticancer or other agents that are usually administered to the patient, which is to be treated for cancer. Adjuvants include agents that preserve, wetting, suspend, sweeten, flavor, perfume, emulsify and dose. Preventing action microorganisms can be provided with various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, etc. It can also be It is desirable to include isotonic agents, e.g. sugars, sodium chloride, etc. Prolonged absorption of an injectable dosage form can be achieved through the use of agents, that delay absorption, such as aluminum monostearate and gelatin. If desired, the pharmaceutical composition of the present invention may also contain minor amounts of excipients such as wetting or emulsifying agents, pH buffering agents, antioxidants and etc., such as, for example, citric acid, sorbitan, monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc. Compositions suitable for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions and sterile powders for dilution in sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous excipients, diluents, solvents or carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerin, etc.), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained by for example, by using coating materials such as lecithin, by supporting the required particle size in the case of dispersion and by using surfactants. One preferred route of administration is oral administration using a convenient regimen. daily dosage, which can be adjusted depending on the severity of the disease condition, is subject to treatment. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert conventional excipient, such as sodium citrate or dicalcium phosphate, or (a) fillers or diluents such as, for example, starches, lactose, sucrose, glucose, mannitol and cream, (b) binders, such as cellulose derivatives, starch, alginates, gelatin, polyvinylpyrrolidone, sucrose and gum arabic, (c) humectants, such as, for example, glycerin, (d) leavening agents such as, for example, agar-agar, calcium carbonate, potato starch starch or tapioca starch, alginic acid, croscarmellose sodium, complex silicates and sodium carbonate, (e) dissolution retarders such as, for example, paraffin, (f) accelerators absorption, such as, for example, quaternary ammonium compounds, (g) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, magnesium stearate and the like (h) adsorbents, such as, for example, kaolin and bentonite, and (i) lubricants, such as e.g. talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also contain buffers agents. Solid dosage forms, as described above, can be prepared with coatings and shells, such as enteric coatings and others, well known in the pharmaceutical field. They may contain sedative agents, and may also be formulated to release the active compound or compounds of a certain part of the intestinal tract in a slow manner. Examples of built-in compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if applicable, with one or more of the above fillers. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. Such dosage forms are obtained, for example, by dissolving, dispersion, etc. of the crystalline salt form of Compound 1 and optionally pharmaceutical adjuvants in the excipient, such as, for example, water, saline, aqueous dextrose, glycerin, ethanol, etc.; solubilizing agents and emulsifiers, such as, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol and dimethylformamide; oils, including cottonseed oil, peanut oil, and seed oil corn, olive oil, castor oil and sesame oil, glycerin, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan; or mixtures of these substances, etc. with the formation solution or suspension. Suspensions, in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitol esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, etc. Compositions for rectal administration are, for example, suppositories, which can be prepared by mixing the compounds of this invention with, for example, suitable non-irritating excipients or fillers, such as cocoa butter, polyethylene glycol or suppository wax, which is solid at normal temperatures but liquid at body temperature and therefore melts while in the appropriate body cavity and releases it into it active component. Dosage forms for topical administration of the compound of the present invention include ointments, powders, sprays and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable filler and any preservatives, buffers or propellants as necessary. Ophthalmic compositions, eye ointments, powders, solutions are also considered as included in scope of the present invention. Typically, depending on the intended route of administration, pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of the crystalline salt form of Compound 1 and from 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will contain from about 5% to about 75% by weight of the crystalline salt form of Compound 1, and the remainder are suitable pharmaceutical excipients. The actual methods of preparing such dosage forms are known or will be apparent to those skilled in the art. this field; for example, see Remington's Pharmaceutical Sciences, 21st Ed., (Lippincott, Williams and Wilkins Philadelphia, PA, 2006). In any case, the composition for introduction will contain a therapeutically effective amount of a crystalline salt form of Compound 1 for the treatment of diseases according to the ideas of the present invention. The crystalline salt forms of Compound 1 are administered in a therapeutically effective amount which will vary depending on a variety of factors, including the activity of Compound 1, metabolic stability and duration of action of Compound 1, age, body weight, general health, gender, diet, regimen and time of administration, rate of excretion, combination of drugs, severity of specific disease states and the patient undergoing treatment. Crystalline salt forms of Compound 1 can be administered to a patient at dosage levels ranging from about 0.1 to about 1000 mg per day. For For example, a normal adult with a body weight of about 70 kilograms can be given as an example: dosages in the range of about 0.01 to about 100 mg per kilogram of body weight per day. However The specific dosage used may vary. For example, the dosage may depend on a number of factors, including the patient's needs, the severity of the condition being treated, and the pharmacological activity of the compound used. Determining optimal dosages for a particular patient well known to those skilled in the art. Combination therapy The crystalline salt form of Compound 1 disclosed herein can be administered as monotherapy or in combination ("co-administered") with one or more additional types therapy for the treatment of a disease or disorder, for example, a disease or disorder associated with with hyperproliferation, such as cancer. Treatments that can be used in combination with disclosed herein, include: (i) surgery; (ii) radiation therapy (e.g. gamma radiation, neutron radiation therapy, electron beam radiation therapy, proton therapy, brachytherapy and systemic radioactive isotopes); (iii) endocrine therapy; (iv) adjuvant therapy, immunotherapy, CAR T-cell therapy; and (v) other chemotherapeutic agents. The term "co-administered" ("co-administration") refers to either simultaneous administration or any which method of separate sequential administration of the crystalline salt form of Compound 1 disclosed in herein, and an additional active pharmaceutical ingredient or ingredients, including cytotoxic agents and radiotherapy. If administration is not simultaneous, the compounds are introduced in close temporal proximity to each other. Furthermore, it does not matter whether they are introduced compounds in the same dosage form, for example, one compound can be administered topically and another the compound can be administered orally. Generally, any agent that has activity against the disease or condition being treated can be administered together. Examples of such agents for cancer treatment can be found, for example, on the website https: / / www.cancer.gov / about-cancer / treatment / drugs (last visited January 22, 2019) and at publicly available sources such as Cancer Principles and Practice of Oncology by VT Devita and S. Hellman (editors), 11th edition (2018), Lippincott Williams & Wilkins Publishers. Specialist in this field techniques will be able to determine which combinations of agents will be useful based on specific characteristics drugs and the corresponding disease. In one embodiment, the method of treatment includes co-administration of crystalline saline forms of Compound 1 as described herein, and at least one immunotherapy. Immunotherapy (also called biological response modifier therapy, biological therapy, biotherapy, immunotherapy or biological therapy) is a treatment in which parts of the immune system are used to fight the disease. Immunotherapy can help the immune system recognize cancer cells or to enhance the response against cancer cells. Immunotherapy involves active and passive immunotherapy. Active immunotherapies stimulate the body's own immune system, while Passive immunotherapies typically use components of the immune system created outside the body. Examples of active immunotherapy include, but are not limited to, vaccines, including: anti-cancer vaccines, tumor cell vaccines (autologous or allogeneic), vaccines based on dendritic cells, antigen vaccines, anti-idiotypic vaccines, DNA vaccines, viral vaccines or tumor-infiltrating lymphocyte (TIL) vaccine with interleukin-2 (IL-2) or therapy lymphokine-activated killer (LAK) cells. Examples of passive immunotherapies include, but are not limited to, monoclonal antibodies and targeted therapies containing toxins. Monoclonal antibodies include naked antibodies and conjugated monoclonal antibodies (also called tagged, labeled, or loaded antibodies). Naked monoclonal antibodies do not have a drug attached or radioactive material, while conjugated monoclonal antibodies attach, for example, to a chemotherapeutic drug (chemolabeled), a radioactive particle (labeled with a radioactive isotope) or toxin (immunotoxin). Examples of such preparations with naked monoclonal antibodies include, but are not limited to, Rituximab (Rituxan), an antibody against the CD20 antigen, which used to treat, for example, B-cell non-Hodgkin lymphoma; Trastuzumab (Herceptin), an antibody against the HER2 protein used to treat, for example, advanced breast cancer breast cancer; Alemtuzumab (Campath), an antibody against the CD52 antigen, which is used for the treatment of, for example, B-cell chronic lymphocytic leukemia (B-CLL); Cetuximab (Erbitux), an antibody against the EGFR protein, used, for example, in combination with irinotecan for the treatment of, for example, advanced colorectal cancer and head and neck cancer; and Bevacizumab (Avastin), which is an anti-angiogenesis therapy that acts against the VEGF protein and used, for example, in combination with chemotherapy to treat, for example, metastatic colorectal cancer. Examples of conjugated monoclonal antibodies include, but are not limited to limited to them, the radiolabeled antibody Ibritumomab tiuxetan (Zevalin), which delivers radioactivity directly to malignant B lymphocytes and is used to treatment of, for example, B-cell non-Hodgkin lymphoma; radiolabeled antibody Tositumomab (Bexar), which is used to treat, for example, certain types of non-Hodgkin lymphoma; and the immunotoxin Gemtuzumab ozogamicin (Milotarg), which contains calicheamicin and is used for treatment of, for example, acute myelogenous leukemia (AML). BL22 is a conjugated monoclonal antibody for the treatment of, for example, hairy cell leukemia, immunotoxins for treatment of, for example, leukemias, lymphomas and brain tumors, and radiolabeled antibodies such such as OncoScint, for example for colorectal cancer and ovarian cancer and ProstaScint, for example for cancer prostate. Additional examples of therapeutic antibodies that can be used include, but are not limited to: limited to, HERCEPTIN™ (Trastuzumab) (Genentech, Calif), which is a humanized monoclonal antibody against HER2 for the treatment of patients with metastatic breast cancer gland; REOPRO.RTM. (abciximab) (Centocor), which is an anti-glycoprotein receptor IIb / IIIa on platelets to prevent clot formation; ZENAPAX™ (daclizumab) (Roche Pharmaceuticals, Switzerland), which is an immunosuppressive humanized monoclonal anti-CD25 antibody to prevent acute renal allograft rejection; PANOREX™, which is a murine IgG2a antibody against cell surface antigen 17-IA (Glaxo Wellcome / Centocor); BEC2, which is a mouse anti-idiotypic (Gd3 epitope) IgG antibody (ImClone System); IMC-C225, which is a chimeric IgG antibody against EGFR (ImClone System); VITAXIN™, which is a humanized antibody against integrin alpha V beta 3 (Applied Molecular Evolution / Medlmmune); Campath 1H / LDP-03, which is a humanized IgG1 antibody against CD52 (Leukosite); Smart M195, which is a humanized IgG antibody against CD33 (Protein Design Lab / Kanebo); RITUXAN™, which is a chimeric IgG1 antibody against CD20 (IDEC Pharm / Genentech, Roche / Zettyaku); LYMPHOCIDE™, which is a humanized IgG antibody anti-CD22 (Immunomedics); LYMPHOCIDE™ Y-90 (Immunomedics); Lymphoscan (Tc-99m labeled; radioimaging; Immunomedics); Nuvion (against CD3; Protein Design Labs); CM3 is a humanized antibody against ICAM3 (ICOS Pharm); IDEC-114 is a primatized antibody against CD80 (IDEC Pharm / Mitsubishi); ZEVALIN™ is a radiolabeled murine antibody against CD20 (IDEC / Schering AG); IDEC-131 is a humanized antibody against CD40L (IDEC / Eisai); IDEC-151 is a primatized anti-CD4 antibody (IDEC); IDEC-152 is a primatized anti-CD23 antibody (IDEC / Seikagaku); SMART anti-CD3 is a humanized IgG antibody against CD3 (Protein Design Lab); 5G1.1 is a humanized antibody against complement factor 5 (C5) (Alexion Pharm); D2E7 is a humanized antibody against TNF-alpha (CAT / BASF); CDP870 is a humanized antibody against TNF-alpha. Fab fragment (Celltech); IDEC-151 is a primatized IgG1 antibody against CD4 (IDEC Pharm / SmithKline Beecham); MDX-CD4 is a human IgG antibody against CD4 (Medarex / Eisai / Genmab); CD20-sreptdavidin (+biotin-yttrium 90; NeoRx); CDP571 is a humanized antibody against TNF-alpha. IgG4 antibody (Celltech); LDP-02 is is a humanized antibody against alpha4 beta7 (LeukoSite / Genentech); OrthoClone OKT4A is is a humanized IgG antibody against CD4 (Ortho Biotech); ANTOVA™ is a humanized IgG antibody against CD40L (Biogen); ANTEGREN™ is a humanized IgG antibody against VLA-4 (Elan); and CAT-152 is a human antibody against TGF-beta2 (Cambridge Ab Tech). The rest presented in the following paragraphs. Immunotherapy that can be used in combination with a crystalline salt form of the Compound 1 as described herein includes adjuvant immunotherapy. Examples include cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte- colony-stimulating factor (G-CSF), macrophage inflammatory protein (MIP)-1-alpha, interleukins (including IL-1, IL-2, IL-4, IL-6, IL-7, IL-12, IL-15, IL-18, IL-21 and IL-27), tumor necrosis factors (including TNF-alpha) and interferons (including IFN-alpha, IFN-beta and IFN-gamma); hydroxide aluminum (alum); Bacille Calmette-Guérin (BCG); Keyhole limpet hemocyanin (KLH); Incomplete Freund's adjuvant (IFA); QS-21; DETOX; Levamisole; and Dinitrophenyl (DNP) and their combinations such as combinations of interleukins, such as IL-2, with other cytokines, such as IFN-alpha. In various embodiments, the crystalline salt form of Compound 1 can be combined with immunological therapy and / or immunological therapeutic agent. In various embodiments, immunological therapy and / or immunological therapeutic agent may include one or more of such as: adoptive cell transfer, angiogenesis inhibitor, Bacillus Calmette-Guérin therapy, biochemotherapy, cancer vaccine, chimeric antigen receptor (CAR) T-cell therapy, cytokine therapy, gene therapy, immune checkpoint modulator, immunoconjugate, radioconjugate, oncolytic virus therapy, or targeted drug therapy. Immunological therapy or immunological therapeutic agent is collectively referred to herein as an "immunotherapeutic agent". This disclosure provides a method for preventing, treating, reducing, inhibiting or controlling neoplasia, tumor or cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a crystalline salt form of Compound 1 in combination with immunotherapeutic agent. In one non-limiting embodiment, the method comprises administering a therapeutically effective amount of a combination containing a crystalline salt form Compounds 1, in combination with an immunotherapeutic agent. In various embodiments, the combination provides a cooperative effect, additive effect, or synergistic effect in reducing the number cancer cells when treated with the combination compared to each treatment alone. In some In embodiments, administering a therapeutically effective amount of a combination comprising a crystalline salt form of Compound 1 and an immunotherapeutic agent, results in synergistic antitumor activity and / or antitumor activity that is stronger than the additive effect of administration a crystalline salt form of Compound 1 or one immunotherapeutic agent. Human cancers carry numerous genetic and epigenetic alterations, giving rise to neoantigens that are potentially recognized by the immune system (Sjoblom et al. (2006) Science 314:268- 74). The adaptive immune system, which consists of T and B lymphocytes, has a powerful anti-cancer potential with broad capacity and exceptional specificity to respond to various tumor antigens. In addition, the immune system exhibits significant plasticity and a memory component. Successful use all these properties of the adaptive immune system would make immunotherapy unique among all cancer treatment methods. This disclosure provides a combination of a crystalline salt form of Compound 1 and immunotherapeutic agent. These illustrative combinations can be used to treat a subject suffering from cancer. In various embodiments, immunotherapeutic agents that find uses in these compositions, formulations and methods may include one or more agents or therapies, including adoptive cell transfer, angiogenesis inhibitors, bacillus therapy Calmette-Guérin, biochemotherapy, cancer vaccine, chimeric T-cell therapy antigen receptor (CAR), cytokine therapy, gene therapy, immune modulator checkpoint inhibitors, e.g., immune checkpoint inhibitors, immunoconjugates, radioconjugate, oncolytic virus therapy, or targeted drug therapy. In some embodiments of this disclosure, the therapeutically effective combination comprises a crystalline salt form of Compound 1 and an immunotherapeutic agent. In various related embodiments In one embodiment, the crystalline salt form of Compound 1 enhances the activity of the immunotherapeutic agent. In certain embodiments, each of the above aspects, as well as other aspects and embodiments described in other sections of this document, the immunotherapeutic agent enhances activity of the crystalline salt form of Compound 1 of the present invention. In certain embodiments, each of the above aspects, as well as other aspects and of the embodiments described in other sections of this document, the crystalline salt form Compounds 1 and the immunotherapeutic agent act synergistically. In various embodiments described in herein, an illustrative immunotherapeutic agent is an immune cell modulator (e.g., T cells, dendritic cells, natural killer cells, etc.), selected from an agonist or activator of a costimulatory molecule, while the modulator is a monoclonal antibody, bispecific antibody containing one or more antigen-binding fragments of immune checkpoints, a trispecific antibody or a polyvalent antibody / fusion protein / construct that interact with immune cells are known in the art. In some embodiments, the the immunotherapeutic agent may be an antibody that modulates a costimulatory molecule, binds to an antigen on the surface of an immune cell or a cancer cell. In each of these different In embodiments, the antibody modulator may be a monoclonal antibody, a polyclonal antibody, bispecific antibody, antibody in trispecific or multispecific format, fusion protein or fragment thereof, e.g., diabody, single-chain (sc) diabody (scFv)2, miniantibody, minibody, barnase-barstar, scFv-Fc, sc(Fab)2, three-dimensional antibody construct, antibody construct triabody, antibody design trimerbody, antibody design triabody, antibody design- colabodies, antibody construct (scFv-TNFa)3 or F(ab)3 / DNL. In certain embodiments, each of the above aspects, as well as other aspects and In embodiments described in other sections of this document, the immunotherapeutic agent is is an agent that modulates immune responses, such as a checkpoint inhibitor or agonist checkpoint. In some embodiments, the immunotherapeutic agent is an agent that enhances anti-tumor immune responses. In some embodiments, the immunotherapeutic agent is an agent that enhances cellular immunity. In some embodiments, the immunotherapeutic the agent is an agent that enhances T-cell activity. In some embodiments, the An immunotherapeutic agent is an agent that enhances the activity of cytolytic T cells (CTL). In some embodiments, the methods of treatment of the present invention may include administering a crystalline salt form of Compound 1 in combination with a molecule, e.g., a binding agent, for example, an antibody or its functional fragment that modulates (activates or inhibits) checkpoint protein. A checkpoint inhibitor can be any molecule, agent, treatment and / or method of inhibiting an immune checkpoint and / or stimulating an immune checkpoint inhibitor checkpoint, for example, by stimulating an intrinsic immune checkpoint inhibitor; inhibition of a transcription factor involved in immune checkpoint expression; and / or combined action with some additional external factor. For example, a checkpoint inhibitor may include treatments that inhibit transcription factors involved in the expression of control genes immune response points, or promotes the expression of transcription factors for tumor suppressor genes, for example, BACH2 (Luan et al., (2016). Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence. Blood, 128(22), 5983). Moreover, a checkpoint inhibitor may inhibit transcription of immune checkpoint genes; modification and / or processing of mRNA immune checkpoints; translation of immune checkpoint proteins; and / or molecules that involvement in immunity or immune checkpoint pathways, e.g. PD-1 transcription factors such as HIF-1, STAT3, NF-κΒ and AP-1, or activation of common oncogenic pathways such as JAK / STAT, RAS / ERK, or PI3K / AKT / mTOR (Zerdes et al., Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations, Oncogene volume 37, pages 4639–4661 (2018), the disclosure of which is incorporated herein by reference in its entirety). Checkpoint inhibitors may include treatments, molecules, agents, and / or methods that regulate immune checkpoints at the transcriptional level, for example, using co-suppression of the RNA interference and / or post-transcriptional gene silencing (PTGS) pathways (e.g., microRNA, miRNA, silencing RNA, small interfering RNA, or short interfering RNA) RNA (siRNA). Transcriptional regulation of checkpoint molecules has been shown to include mir-16, which has been shown to target the 3'UTR mRNA of the checkpoints CD80, CD274 (PD-L1), and CD40 (Leibowitz et al., Post-transcriptional regulation of immune checkpoint genes by mir-16 in melanoma, Annals of Oncology (2017) 28; v428-v448). It has also been shown that mir-33a is involved in the regulation of the expression PD-1 in cases of lung adenocarcinoma (Boldini et al., Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma, Cancer Cell Int. 2017; 17: 105, the disclosure of which is incorporated herein by reference using the link in full). T-cell-specific aptamer-miRNA chimeras have been proposed as a highly specific a method of inhibiting molecules in the immune checkpoint pathway (Hossain et al., The aptamer–siRNA conjugates: reprogramming T cells for cancer therapy, Ther. Deliv. 2015 Jan; 6(1): 1–4, the disclosure of which incorporated by reference in its entirety into this document). Alternatively, immune checkpoint pathway participants can be inhibited using treatment that affects associated pathways, such as metabolism. For example, excessive amounts of of the glycolytic intermediate pyruvate in mitochondria from CAD macrophages promoted PD-L1 expression due to induction of a signaling pathway involving bone morphogenetic protein 4 / phosphorylated SMAD1 / 5 / IFN regulatory factor 1 (BMP4 / p-SMAD1 / 5 / IRF1). Accordingly, the use of treatments that modulate the metabolic pathway may lead to further modulation of the immunoinhibitory pathway of the PD-1 / PD-L1 checkpoint (Watanabe et al., Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity, J Clin Invest. 2017 Jun 30; 127(7): 2725–2738). Checkpoint immunity can be regulated by oncolytic viruses, which selectively replicate in tumor cells and induce acute immune responses in the tumor microenvironment, i.e., acting as genetic vectors carrying specific agents (e.g., antibodies, miRNA, kiRNA, etc.) to cancer cells and affecting their oncolysis and secretion of cytokines and chemokines for synergy with immune checkpoint inhibition (Shi et al., Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints, Int J Mol Sci. 2018 May; 19(5): 1389). Currently, there are clinical trials using the following viruses as checkpoint inhibitors: poliovirus, measles virus, adenoviruses, poxviruses, herpes simplex virus (HSV), Coxsackie viruses, reovirus, Newcastle disease virus (NDV), T-VEC (herpes virus encoded by GM-CSF (granulocyte- macrophage colony-stimulating factor)) and H101 (Shi et al., supra). Checkpoint inhibitors can function at the translational level of checkpoint immunity points. The translation of mRNA into protein is a major event in the regulation of gene expression, therefore Inhibition of immune checkpoint translation is a way to inhibit the immune checkpoint pathway. Inhibition of the immune checkpoint pathway can occur at any stage of the process immune checkpoint translation. For example, drugs, molecules, agents, treatments and / or methods can inhibit the initiation process (whereby the 40S ribosomal subunit is recruited to the 5'-end of the mRNA and scans the 5'UTR of the mRNA towards its 3'-end. Inhibition can occur by targeting the initiator anticodon of methionyl transfer RNA (tRNA) (Met-tRNAi), pairing its bases with the start codon or recruitment of the 60S subunit for initiation of elongation and sequential adding amino acids to the translation of genes specific for immune checkpoints. As alternatively, a checkpoint inhibitor can inhibit checkpoints at the translational level, preventing the formation of the ternary complex (TC), i.e. eukaryotic initiation factor (eIF) 2 (or one or more of its subunits α, β and γ); GTP; and Met-tRNAi. Checkpoint inhibition can occur through destabilization of eIF2α by exclusion of its phosphorylation by protein kinase R (PKR), PERK, GCN2 or HRI or by excluding the association of TC with the 40S ribosomal subunit and / or other initiation factors, such thus preventing the formation of the pre-initiation complex (PIC); inhibition of the eIF4F complex and / or its cap-binding protein eIF4E, scaffold protein eIF4G or helicase eIF4A. Methods described in translational control of cancer, are discussed in Truitt et al., New frontiers in translational control of the cancer genome, Nat Rev Cancer. 2016 Apr 26; 16(5): 288–304, disclosure of which is included in this document by reference in its entirety. Checkpoint inhibitors may also include treatments, molecules, agents, and / or methods that regulate immune checkpoints at the cellular and / or protein level, for example, by immune checkpoint receptor inhibition. Checkpoint inhibition can occur due to the use of antibodies, antibody fragments, antigen-binding fragments, small molecules and / or other drugs, agents, treatments and / or methods. Immune checkpoints refer to the inhibitory pathway in the immune system that is responsible for maintaining self-tolerance and modulating the degree of immune system response to reduce minimal damage to peripheral tissues. However, tumor cells can also activate immune system checkpoints to reduce the effectiveness of the immune response ("block" the immune response) relative to tumor tissues. Unlike most anticancer drugs, inhibitors checkpoint inhibitors do not target tumor cells directly, but rather target receptors lymphocytes or their ligands to enhance the endogenous antitumor activity of the immune system. (Pardoll, 2012, Nature Reviews Cancer 12:252-264). In some embodiments, the immunotherapeutic agent is a modulator of PD-1 activity, PD-L1 activity modulator, PD-L2 activity modulator, CTLA-4 activity modulator, modulator CD28 activity modulator, CD80 activity modulator, CD86 activity modulator, 4- 1BB, OX40 activity modulator, KIR activity modulator, Tim-3 activity modulator, modulator LAG3 activity modulator, CD27 activity modulator, CD40 activity modulator, activity modulator GITR, TIGIT activity modulator, CD20 activity modulator, CD96 activity modulator, IDO1 activity modulator, cytokine, chemokine, interferon, interleukin, lymphokine, representative tumor necrosis factor (TNF) family or an immunostimulatory oligonucleotide. In some embodiments implementation of an immune checkpoint modulator, i.e., an inhibitor or antagonist, or an activator or agonist, is, for example, a CD28 modulator, a 4-1BB modulator, an OX40 modulator, a CD27, CD80 modulator, CD86 modulator, CD40 modulator or GITR modulator, Lag-3 modulator, modulator 41BB, modulator LIGHT, modulator CD40, modulator GITR, modulator TGF-beta, TIM-3 modulator, SIRP-alpha modulator, TIGIT modulator, VSIG8 modulator, BTLA modulator, SIGLEC7 modulator, SIGLEC9 modulator, ICOS modulator, B7H3 modulator, B7H4 modulator, FAS modulator and / or BTNL2 modulator. In some embodiments, the immunotherapeutic agent is an immune checkpoint modulator as described above (e.g., an antibody modulator immune checkpoints, which can be presented in the form of a monoclonal antibody, bispecific antibody containing one or more antigen-binding fragments of immune checkpoints, trispecific antibody, or multivalent antibody / fusion proteins / constructs that interact with immune cells known in the art). In some embodiments, the immunotherapeutic agent is an agent that inhibits the activity of PD-1. In some embodiments, the immunotherapeutic agent is an agent that inhibits PD-L1 and / or PD-L2 activity. In some embodiments, the immunotherapeutic agent is an agent that inhibits CTLA-4 activity. In some embodiments, the immunotherapeutic agent is is an agent that inhibits the activity of CD80 and / or CD86. In some embodiments, the The immunotherapeutic agent is an agent that inhibits TIGIT activity. In some embodiments, In some embodiments, the immunotherapeutic agent is an agent that inhibits KIR activity. In some embodiments, the immunotherapeutic agent is an agent that inhibits KIR activity. In embodiments, the immunotherapeutic agent is an agent that enhances or stimulates activity of activating immune checkpoint receptors. PD-1 (also known as programmed cell death protein 1, CD279, PDCD1) is a a cell surface receptor that plays a critical role in regulating the balance between stimulating and inhibitory signals in the immune system and maintenance of peripheral tolerance (Ishida, Y et al. 1992 EMBO J. 11 3887; Kier, Mary E et al. 2008 Annu Rev Immunol 26 677-704; Okazaki, Taku et al. 2007 International Immunology 19 813-824). PD-1 is an inhibitory member of the superfamily immunoglobulins, homologous to CD28. The structure of PD-1 is a monomeric transmembrane type 1 protein consisting of a single extracellular variable domain similar to the variable immunoglobulin region, and a cytoplasmic domain containing an immunoreceptor inhibitory motif tyrosine-based (ITIM) and immunoreceptor tyrosine-based switching motif (ITSM). Expression PD-1 is induced on T cells, B cells, natural killer (NK) cells, and monocytes, e.g. upon activation of lymphocytes through T-cell receptor (TCR)-mediated signaling or B-cell receptor (BCR) (Kier, Mary E et al. 2008 Annu Rev Immunol 26 677-704; Agata, Y et al 1996 Int Immunol 8 765-72). PD-1 is a receptor for the ligands CD80, CD86, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), which are members of the B7 family expressed on the cell surface (Freeman, Gordon et al. 2000 J Exp Med 192 1027; Latchman, Y et al. 2001 Nat Immunol 2: 261) When PD-1 ligand interactions recruit phosphatases such as SHP-1 and SHP-2 to its intracellular motifs tyrosine, which subsequently dephosphorylate effector molecules activated by signaling involving TCR or BCR (Chemnitz, J et al. 2004 J Immunol 173: 945-954; Riley, James L 2009 Immunological Reviews 229: 114-125). Thus, PD-1 transmits inhibitory signals to T and B cells only when it is involved simultaneously with the TCR or BCR. PD-1 has been shown to suppress effector T cell responses by both internal and external functional mechanisms of the cell. Inhibitory signaling by through PD-1 causes a state of immunity in T cells, as a result of which the cells cannot to clonally replicate or produce optimal levels of effector cytokines. PD-1 can also induce apoptosis in T cells due to its ability to inhibit survival signals resulting in costimulation, leading to a decrease in the expression of key anti-apoptotic molecules such as Bcl-XL (Kier, Mary E et al., 2008 Annu Rev Immunol. 26: 677-704). In addition to these direct effects, recent publications indicate that PD-1 is involved in the suppression of effector cells, contributing to the induction and maintenance of regulatory T cells (TREG). For example, it has been shown that PD-L1, which is expressed on dendritic cells, acts synergistically with TGF-β, promoting the induction of CD4+FoxP3+TREG with enhanced suppressor function (Francisco, Loise M et al., 2009 J Exp Med 206: 3015-3029). TIM-3 (also known as T-cell immunoglobulin domain and mucin domain 3, TIM-3, cellular hepatitis A virus receptor 2, HAVCR2, HAVcr-2, KIM-3, TIMD-3, TIMD3, Tim-3 and CD366) is a a single-pass type I membrane protein with a mass of ~33.4 kDa that participates in immune reactions (Sanchez-Fueyo et al., Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance, Nat. Immunol. 4: 1093-1101(2003)). TIM-3 is selectively expressed on Th1 cells and phagocytic cells (e.g. macrophages and dendritic cells). Use of miRNA or blocking antibody to reduce TIM-3 expression human resulted in increased secretion of interferon γ (IFN-γ) by CD4-positive T cells, which suggests an inhibitory role for TIM-3 in human T cells. Analysis of clinical samples obtained from patients with autoimmune disease, did not show the absence of TIM-3 expression in CD4-positive In particular, the level of TIM-3 expression is lower and IFN-γ secretion is higher in T-cell clones derived from cerebrospinal fluid of patients with multiple sclerosis than in clones derived from normal healthy people (Koguchi K et al., J Exp Med. 203: 1413-8. (2006)). TIM-3 is a receptor for the ligand galectin-9, which is a member of the galectin family, whose molecules are ubiquitously expressed on various cell types and which binds β-galactoside; phosphatidylserine (PtdSer) (DeKryff et al., T cell / transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells, J Immunol. 2010 February 15; 184(4): 1918-30); high mobility group 1 protein (also known as HMGB1, HMG1, HMG3, SBP- 1, HMG-1 and high-mobility box-1 groups) (Chiba et al., Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1, Nat Immunol. 2012 Sep; 13(9): 832-42); and cancer-associated cell adhesion molecule 1 embryonic antigen (also known as CEACAM1, BGP, BGP1, BGPI, cell adhesion molecule 1, related to carcinoembryonic antigen) (Huang et al., CEACAM1 regulates TIM-3-mediated tolerance and exhaustion, Nature. 2015 Jan 15; 517(7534): 386-90). BTLA (also known as B- and T- lymphocyte attenuator, BTLA1, CD272 and associated with B and T- lymphocytes) is a single-pass type I membrane protein with a mass of ~ 27.3 kDa, which takes participation in the inhibition of lymphocytes during the immune response. BTLA is constitutively expressed in both B- and and in T cells. BTLA interacts with HVEM (herpes virus entry mediator), a representative tumor necrosis factor receptor (TNF) family (Gonzalez et al., Proc Natl. Natl. Acad. Sci. USA, 2005, 102: 1116-21). The interaction of BTLA, which belongs to the CD28 superfamily immunoglobulins, and HVEM, tumor necrosis factor (TNF) costimulatory receptor (TNFR), unique in that it defines crosstalk between these two receptor families. BTLA contains a membrane-proximal tyrosine-based immunoreceptor inhibitory motif (ITIM) and membrane distal tyrosine-based switching motif (ITSM). ITIM or ITSM disruption abolished the ability of BTLA to recruit SHP1 or SHP2, suggesting that BTLA recruits SHP1 and SHP2 distinct from PD-1, and both tyrosine-based motifs are required to block T-cell activation. The cytoplasmic tail of BTLA also contains a third conserved tyrosine-containing motif in cytoplasmic domain, similar in sequence to the Grb-2 recruitment site (YXN). In addition, a phosphorylated peptide containing this N-terminal tyrosine motif of BTLA can interact with GRB2 and the p85 subunit of PI3K in vitro, although the functional effects of this interaction remain to be determined. unexplored in vivo (Gavrieli et al., Bioochem. Biophysi Res Commun, 2003 312, 1236-43). BTLA is receptor for the ligands PTPN6 / SHP-1; PTPN11 / SHP-2; TNFRSF14 / HVEM; and B7H4. VISTA (also known as V-domain Ig suppressor of T-cell activation VSIR, B7-H5, B7H5, GI24, PP2135, SISP1, DD1-alpha, VISTA, C10orf54, chromosome 10 open reading frame 54, PD-1H and immunoregulatory receptor V-compatibility) is a single-pass type I membrane protein with with a mass of about 33.9 kDa, which is involved in the inhibition of T cells, differentiation of embryonic stem cells by inhibiting signaling involving BMP4 and MMP14- mediated activation of MMP2 (Yoon et al., Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53, Science. 2015 Jul 31; 349(6247): 1261669). VISTA interacts with the ligand VSIG-3 (Wang et al., VSIG-3 as a ligand of VISTA inhibits human T-cell function, Immunology. 2019 Jan; 156(1): 74- 85). LAG-3 (also known as lymphocyte activation gene 3, LAG3, CD223, and lymphocyte activating 3) is is a single-pass type I membrane protein with a mass of ~ 57.4 kDa, which participates in the activation lymphocytes, which also binds to HLA class II antigens. LAG-3 is a representative of the supergene immunoglobulin family and is expressed on activated T cells (Huard et al., 1994, Immunogenetics 39: 213), NK cells (Triebel et al., 1990, J. Exp. Med. 171: 1393-1405), regulatory T- cells (Huang et al., 2004, Immunity 21: 503-513; Camisaschi et al., 2010, J Immunol. 184: 6545-6551; Gagliani et al., 2013, Nat Med 19: 739-746) and plasmacytoid dendritic cells (DC) (Workman et al., 2009 J Immunol 182: 1885-1891). LAG-3 is a membrane protein that is encoded by the gene, located on chromosome 12, and is structurally and genetically linked to CD4. Similar to CD4, LAG-3 can interact with MHC class II molecules on the cell surface (Baixeras et al., 1992, J. Exp. Med. 176: 327-337; Huard et al., 1996, Eur. J. Immunol. 26: 1180-1186). It has been suggested that direct binding of LAG-3 to MHC class II plays a role in inhibiting antigen-dependent CD4+ stimulation T lymphocytes (Huard et al., 1994, Eur. J. Immunol. 24: 3216-3221), and blockade of LAG-3, as also shown to activate CD8+ lymphocytes in both tumor and autoantigen (Gross et al., 2007, J Clin Invest. 117: 3383-3392) and viral models (Blackburn et al., 2009 Nat. Immunol. 10: 29-37). In addition, the intracytoplasmic region of LAG-3 can interact with LAP (LAG-3-associated protein), which is a signaling molecule involved in the inhibition of the CD3 / TCR activation pathway (Iouzalen et al., 2001, Eur. J. Immunol. 31: 2885-2891). Moreover, it has been shown that regulatory CD4+CD25+ T- cells (Treg) express LAG-3 upon activation, which contributes to the suppressor activity of Treg cells (Huang, C. et al., 2004, Immunity 21: 503-513). LAG-3 may also negatively regulate T-cell homeostasis Treg cells in both T-cell-dependent and -independent mechanisms (Workman, CJ and Vignali, D. A., 2005, J. Immunol. 174: 688-695). LAG-3 has been shown to interact with MHC class II molecules (Huard et al., CD4 / major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene-3 (LAG-3)- Ig fusion proteins, Eur J Immunol. 1995 September; 25(9): 2718-21). In addition, some kinases are known to be checkpoint inhibitors, for example, CHEK-1, CHEK-2 and A2aR. CHEK-1 (also known as CHK kinase 1, CHK1, and checkpoint kinase 1) is a serine / threonine protein kinase with a mass of ~54.4 kDa, which participates in the mediated control at the point of blocking the cell cycle and activating DNA repair in response to DNA damage and / or unreplicated DNA. CHEK-2 (also known as CHK2 kinase, CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53, hCds1 and checkpoint kinase 2) is a serine / threonine protein kinase with a mass of ~ 60.9 kDa, which takes in checkpoint-mediated cell cycle inhibition, activation of DNA repair, and double-strand break-mediated apoptosis. A2aR (also known as adenosine receptor A2A, ADORA2A, adenosine receptor A2a, A2aR, ADORA2 and RDC8) is a multipass membrane receptor with a mass of ~ 44.7 kDa for adenosine and other ligands. In some embodiments, exemplary immunotherapeutic agents may include one or more antibody modulators targeting PD-1, PD-L1, PD-L2, CEACAM (e.g., CEACAM-1, -3 and / or -5), CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGF-beta, OX40, 41BB, LIGHT, CD40, GITR, TGF-beta, TIM-3, SIRP-alpha, VSIG8, BTLA, SIGLEC7, SIGLEC9, ICOS, B7H3, B7H4, FAS and / or BTNL2, among others known in the art. In some embodiments, the An immunotherapeutic agent is a drug that increases the activity of natural killer (NK) cells. In In some embodiments, the immunotherapeutic agent is an agent that inhibits the suppression of immune response. In some embodiments, the immunotherapeutic agent is an agent that inhibits suppressor cell activity or suppressor cell activity. In some embodiments In one embodiment, the immunotherapeutic agent is an agent or therapy that inhibits Treg activity. In In some embodiments, the immunotherapeutic agent is an agent that inhibits the activity of inhibitory immune checkpoint receptors. In some embodiments, the combination of this disclosure includes a crystalline salt form. Compounds 1 and an immunotherapeutic agent, wherein the immunotherapeutic agent comprises a T-cell modulator, selected from an agonist or an activator of a costimulatory molecule. In one embodiment, the agonist a costimulatory molecule selected from an agonist (e.g., an agonist antibody or its antigen-binding fragment or soluble fusion protein) of the GITR, OX40, SLAM ligand (e.g. SLAMF7), HVEM, LIGHT, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), CD30, CD40, BAFFR, CD7, NKG2C, NKp80, CD160, B7-H3 or CD83. In others In embodiments, the combination of effector cells includes a bispecific T-cell attractant activator (e.g., a bispecific antibody molecule that binds to CD3 and a tumor antigen (e.g., EGFR, PSCA, PSMA, EpCAM, HER2, among others). In some embodiments, the immunotherapeutic agent is a modulator of PD-1 activity, PD-L1 activity modulator, PD-L2 activity modulator, CTLA-4 activity modulator, modulator CD28 activity modulator, CD80 activity modulator, CD86 activity modulator, 4- 1BB, OX40 activity modulator, KIR activity modulator, Tim-3 activity modulator, modulator LAG3 activity modulator, CD27 activity modulator, CD40 activity modulator, activity modulator GITR, TIGIT activity modulator, CD20 activity modulator, CD96 activity modulator, IDO1 activity modulator, SIRP-alpha activity modulator, TIGIT activity modulator, VSIG8 activity modulator, BTLA activity modulator, SIGLEC7 activity modulator, modulator SIGLEC9 activity modulator, ICOS activity modulator, B7H3 activity modulator, activity modulator B7H4, FAS activity modulator, BTNL2 activity modulator, cytokine, chemokine, interferon, interleukin, lymphokine, a member of the tumor necrosis factor (TNF) family, or an immunostimulatory oligonucleotide. In some embodiments, the immunotherapeutic agent is an immune modulator. checkpoint inhibitors (e.g., immune checkpoint inhibitors, e.g., PD-1 activity inhibitors) 1, PD-L1 activity modulator, PD-L2 activity modulator, CTLA-4 modulator, or CD40 agonist (e.g., an anti-CD40 antibody molecule), (xi) an OX40 agonist (e.g., an anti-CD40 antibody molecule) OX40) or (xii) a CD27 agonist (e.g., an anti-CD27 antibody molecule). In one embodiment the immunotherapeutic agent is an inhibitor of: PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM (e.g., CEACAM-1, -3 and / or -5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and / or TGF-beta, galectin 9, CD69, galectin-1, CD113, GPR56, CD48, GARP, PD1H, LAIR1, TIM-1 and TIM-4. In one In one embodiment, the immune checkpoint inhibitor inhibits PD-1, PD-L1, LAG-3, TIM-3, CEACAM (e.g., CEACAM-1, -3 and / or -5), CTLA-4, or any combination thereof. In one embodiment, the immunotherapeutic agent is an agonist of a protein that stimulates T-cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H. In some embodiments, the immunotherapeutic agent used in combinations, disclosed herein (e.g., in combination with a crystalline salt form of Compound 1 according to of the present invention), is an activator or agonist of a costimulatory molecule. In one embodiment In one embodiment, the agonist of the costimulatory molecule is selected from an agonist (e.g., an agonist antibody) or its antigen-binding fragment or soluble fusion protein) ligand CD2, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83. Inhibition of the inhibitory molecule can be carried out at the DNA, RNA or protein level. In embodiments In the implementation, the inhibitory nucleic acid (e.g., dlRNA, miRNA, or shRNA) may be used to inhibit the expression of an inhibitory molecule. In other embodiments, the inhibitor the inhibitory signal is a polypeptide, e.g., a soluble ligand (e.g., PD-1-Ig or CTLA-4 Ig), or an antibody thereof or an antigen-binding fragment thereof, e.g., a monoclonal antibodies, a bispecific antibody containing one or more antigen-binding fragments of immune checkpoints, trispecific antibody or multivalent antibody / fusion protein / construct, that interact with immune cells known in the art that bind to the inhibitory a molecule; for example, an antibody or fragment thereof (also referred to herein as an "antibody molecule"), which binds to PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM (e.g., CEACAM-1, -3 and / or -5), VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and / or TGF-beta, galectin-9, CD69, galectin- 1, CD113, GPR56, CD48, GARP, PD1H, LAIR1, TIM-1, TIM-4 or a combination thereof. In some embodiments, the combination comprises a crystalline salt form of Compound 1 and an immunotherapeutic agent, wherein the immunotherapeutic agent is a monoclonal antibody or bispecific antibody. For example, a monoclonal or bispecific antibody may specifically bind to a representative of the c-Met pathway and / or an immune checkpoint modulator (e.g., bispecific antibody binds to both the hepatocyte growth factor receptor (HGFR) and the immune checkpoint modulator described herein, such as an antibody that binds PD-1, PD-L1, PD-L2 or CTLA-4, LAG-3, OX40, 41BB, LIGHT, CD40, GITR, TGF-beta, TIM-3, SIRP-alpha, TIGIT, VSIG8, BTLA, SIGLEC7, SIGLEC9, ICOS, B7H3, B7H4, FAS, BTNL2 or CD27). IN In specific embodiments, the bispecific antibody specifically binds human HGFR protein and one with PD-1, PD-L1 and CTLA-4. In some embodiments of the methods described herein, the immunotherapeutic agent is a PD-1 antagonist, a PD-L1 antagonist, a PD-L2 antagonist, a CTLA-4 antagonist, a CD80 antagonist, CD86 antagonist, KIR antagonist, Tim-3 antagonist, LAG3 antagonist, TIGIT antagonist, CD20 antagonist, CD96 antagonist or IDO1 antagonist. In some embodiments, the PD-1 antagonist is an antibody that specifically binds PD-1. In some embodiments, the antibody that binds PD-1 is pembrolizumab (KEYTRUDA®, MK-3475; Merck), pidilizumab (CT-011; Curetech Ltd.), nivolumab (OPDIVO®, BMS-936558, MDX-1106; Bristol Myer Squibb), MEDI0680 (AMP-514; AstraZenenca / MedImmune), REGN2810 (Regeneron Pharmaceuticals), BGB-A317 (BeiGene Ltd.), PDR-001 (Novartis), or STI-A1110 (Sorrento Therapeutics). IN In some embodiments, the antibody that binds PD-1 is described in PCT Publication WO 2014 / 179664, for example, an antibody identified as APE2058, APE1922, APE1923, APE1924, APE 1950 or APE1963 (Anaptysbio), or an antibody containing the CDR regions of any of these antibodies. In other In embodiments, the PD-1 antagonist is a fusion protein that contains the extracellular domain of PD- L1 or PD-L2, e.g., AMP-224 (AstraZeneca / MedImmune). In other embodiments, the antagonist PD-1 is a peptide inhibitor, for example, AUNP-12 (Aurigene). In some embodiments, the PD-L1 antagonist is an antibody that specifically binds PD- L1. In some embodiments, the antibody that binds PD-L1 is atezolizumab (RG7446, MPDL3280A; Genentech), MEDI4736 (AstraZeneca / MedImmune), BMS-936559 (MDX-1105; Bristol Myers Squibb), avelumab (MSB0010718C; Merck KGaA), KD033 (Kadmon), part of the antibody KD033 or STI- A1014 (Sorrento Therapeutics). In some embodiments, the antibody that binds PD-L1 is described in PCT publication WO 2014 / 055897, e.g., Ab-14, Ab-16, Ab-30, Ab-31, Ab-42, Ab-50, Ab-52 or Ab-55, or is an antibody that contains the CDR regions of any of these antibodies, the description of which is complete incorporated by reference in its entirety into this document. In some embodiments, the CTLA-4 antagonist is an antibody that specifically binds CTLA-4. In some embodiments, the antibody that binds CTLA-4 is ipilimumab. (YERVOY®; Bristol Myer Squibb) or tremelimumab (CP-675,206; Pfizer). In some embodiments, the CTLA-4 antagonist is a CTLA-4 fusion protein or a soluble CTLA-4 receptor, e.g. KARR-102 (Kahr Medical Ltd.). In some embodiments, the LAG3 antagonist is an antibody that specifically binds LAG3. In some embodiments, the antibody that binds LAG3 is IMP701 (Prima BioMed), IMP731 (Prima BioMed / GlaxoSmithKline), BMS-986016 (Bristol Myer Squibb), LAG525 (Novartis) and GSK2831781 (GlaxoSmithKline). In some embodiments, the LAG3 antagonist comprises a soluble LAG3 receptor, e.g., IMP321 (Prima BioMed). In some embodiments, the KIR antagonist is an antibody that specifically binds KIR. In In some embodiments, the antibody that binds KIR is lirilumab (Bristol Myer Squibb / Innate Pharma). In some embodiments, the immunotherapeutic agent is a cytokine, such as a chemokine, interferon, interleukin, lymphokine, or a member of the tumor necrosis factor family. In some In embodiments, the cytokine is IL-2, IL15, or interferon-gamma. In some embodiments, implementing any of the above aspects or aspects described in In other sections of this document, the cancer is selected from the group consisting of lung cancer (e.g., non-small cell lung cancer (NSCLC)), kidney cancer (e.g., urothelial renal cell carcinoma), bladder cancer (e.g. urothelial (transitional cell) bladder carcinoma), breast cancer, colorectal cancer (e.g., colon adenocarcinoma), cancer ovarian, pancreatic cancer, gastric carcinoma, esophageal cancer, mesothelioma, melanoma (e.g. skin melanoma), head and neck cancer (e.g. squamous cell carcinoma of the head and neck (HNSCC)), thyroid cancer, sarcomas (e.g. soft tissue sarcomas, fibrosarcomas, myxosarcoma, liposarcoma, osteogenic sarcoma, osteosarcoma, chondrosarcoma, angiosarcoma, endotheliosarcomas, lymphangiosarcomas, lymphangioendotheliosarcomas, leiomyosarcomas or rhabdomyosarcoma), prostate cancer, glioblastoma, cervical cancer, thymic carcinoma, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), chronic eosinophilic leukemia, or chronic lymphocytic leukemia (CLL)), lymphomas (e.g. Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)), myeloma (e.g., multiple myeloma (MM)), mycosis fungoides, Merkel cell carcinoma, hematological malignant neoplasm, cancer of hematological tissues, B-cell cancer, bronchial cancer, stomach cancer, brain or central nervous system cancer, peripheral nervous system cancer, cancer uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, testicular cancer, gallbladder cancer tract, cancer of the small intestine or appendix, cancer of the salivary glands, cancer of the adrenal glands, carcinoma adrenal cortex, adenocarcinoma, inflammatory myofibroblastic tumor, stromal tumor gastrointestinal tract (GIST), colon cancer, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), polycythemia vera, chordoma, synovioma, tumor Ewing's, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, carcinoma sweat glands, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, carcinoma bile duct, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, carcinoma bladder, epithelial carcinoma, glioma, anaplastic astrocytoma, astrocytoma, medulloblastomas, craniopharyngiomas, ependymomas, pinealomas, hemangioblastomas, acoustic neuromas nerve, oligodendroglioma, meningioma, neuroblastoma, diffuse lymphoblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, small cell carcinoma, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial hypereosinophilia, neuroendocrine cancer, or carcinoid tumor. In some embodiments, implementing any of the above aspects or aspects described in other sections herein, the subject's cancer or tumor does not respond to inhibition of immune checkpoint inhibitors (e.g., to any immune checkpoint inhibitor described in this document, such as a PD-1 antagonist or a PD-L1 antagonist) or the subject's cancer or tumor has progressed after an initial response to immune checkpoint inhibition (e.g., to any an immune checkpoint inhibitor described herein, such as a PD-1 antagonist or an antagonist PD-L1). In various embodiments, the immunotherapeutic agent may comprise an antibody or its antigen-binding fragment. Within this definition, immune checkpoint inhibitors include bispecific antibodies and polyvalent antibodies / fusion proteins / constructs that interact with immune cells, known in the art. In some embodiments, immunotherapeutics agents containing bispecific antibodies may include bispecific antibodies that are bivalent and bind either the same epitope of an immune checkpoint molecule, two different epitopes of the same of the same immune checkpoint molecule, or different epitopes of two different immune checkpoints. Those skilled in the art can implement several formats of bispecific antibodies, known in the art, to target one or more of CTLA4, PD1, PD-L1, TIM-3, LAG-3, various ligands B-7, B7H3, B7H4, CHK 1- and CHK 2-kinases, BTLA, A2aR, OX40, 41BB, LIGHT, CD40, GITR, TGF-beta, SIRP-alpha, TIGIT, VSIG8, SIGLEC7, SIGLEC9, ICOS, FAS, BTNL2 and others for application in the combination described in this document. In various embodiments, the immunotherapeutic agent may include polyvalent antibodies / fusion protein / construct that interact with immune cells. In one embodiment of the present disclosure, a checkpoint inhibitor in combination with The crystalline salt form of Compound 1 is used to reduce or inhibit metastasis of the primary tumor or cancer to other sites, or the formation or persistence of metastatic tumors or cancers in other areas distant from the primary cancer tumor, so by itself inhibiting or reducing tumor or cancer recurrence or tumor or cancer progression. In yet another embodiment of this disclosure, a combined a therapy for the treatment of cancer comprising a crystalline salt form of Compound 1 and a control inhibitor points with the ability to induce strong and long-lasting immune responses with increased therapeutic effect and more controlled toxicity. In another embodiment of this disclosure, a combined a therapy for the treatment of cancer comprising a crystalline salt form of Compound 1 and an immune system inhibitor checkpoints. In one embodiment of the present disclosure, a method of treating cancer and / or preventing metastasis by using crystal saline forms of Compound 1 of the present invention that act synergistically with a checkpoint inhibitor. In other embodiments of this disclosure, methods are provided for one or more of such as: 1) reduction or inhibition of growth, proliferation, motility or invasiveness of tumor or cancer cells that potentially or actually lead to the development of metastases, 2) a decrease or inhibition of the formation or survival of metastases arising from the primary tumor or cancer in one or more other locations, positions, or areas other than the primary tumor or cancer; 3) reducing or inhibiting the growth or proliferation of metastases at one or more other sites, positions or areas other than the primary tumor or cancer after metastasis formed or taken root, 4) reduction or inhibition of the formation or survival of additional metastases after formation or survival of metastases, 5) increased overall survival, 6) increased progression-free survival or 7) disease stabilization. Methods comprise administering to a subject in need thereof a crystalline salt form of Compound 1 herein of the invention in combination with a checkpoint inhibitor as described herein. In one embodiment of this disclosure, the introduction of a crystalline salt form of Compound 1 in combination with an immunotherapeutic agent provides a detectable or measurable improvement in the condition a specific subject, such as alleviating or normalizing one or more adverse (physical) symptoms or consequences associated with the presence of a cellular proliferative or cellular hyperproliferative disorder, neoplasia, tumor or cancer or metastasis, i.e. therapeutic effect or beneficial influence. A therapeutic benefit or positive effect is any objective or subjective, transient, temporary or long-term improvement of a condition or pathology, or delayed onset, reduction in the severity, duration, or frequency of adverse symptoms associated with or caused by cell proliferation or cellular hyperproliferative disorder, such as neoplasia, tumor, or cancer or metastasis. They may lead to increased survival. Satisfactory clinical the endpoint of a treatment method according to this disclosure is achieved, for example, when there is a gradual or partial decrease in the severity, duration, or frequency of one or more associated pathologies, undesirable symptoms or complications, or inhibition or withdrawal of one or more physiological, biochemical or cellular manifestations or characteristics of cell proliferation or a cellular hyperproliferative disorder, such as a neoplasm, tumor, or cancer, or metastasis. Thus, therapeutic benefit or improvement may be, but not limited to them, in the destruction of target proliferating cells (e.g., neoplasia, tumors or cancer or metastases) or elimination of one or more, most or all pathologies, unfavorable symptoms or complications associated with cell proliferation or cellular hyperproliferative disorders such as neoplasia, tumor or cancer or metastasis, or related thereto. However therapeutic effect or improvement does not necessarily have to consist of a cure or complete destruction of all target proliferating cells (e.g., neoplasia, tumor or cancer or metastases) or elimination of all pathologies, adverse symptoms or complications associated with cell proliferation or a cellular hyperproliferative disorder, such as neoplasia, tumor, or cancer or metastasis, or related to them. For example, partial destruction of the tumor or cancerous cell mass or stabilization of tumor or cancerous mass, size, or number of cells by inhibiting the progression or exacerbation of a tumor or cancer may reduce mortality and increase life expectancy, even if only by a few days, weeks or months, even if part or the bulk of the tumor or cancer, size or cells are preserved. Specific non-limiting examples of therapeutic effects include reduction of neoplasia, tumor or cancer or metastasis volume (size or mass of cells) or cell number; inhibition or preventing the increase in the volume of a neoplasia, tumor, or cancer (e.g., stabilization); slowing or inhibiting the progression, exacerbation or metastasis of a neoplasia, tumor or cancer; or inhibiting the proliferation, growth or metastasis of a neoplasia, tumor or cancer. In one embodiment of this disclosure, the administration of an immunotherapeutic agent to combination therapy with a crystalline salt form of Compound 1 provides a detectable or measurable improvement or overall response according to irRC (obtained based on assessments responses at a specific time point and based on tumor burden), including one or the greater of the following: (i) complete disappearance, according to irCR, of all lesions, measurable or not are measurable, and the absence of new foci (confirmation of repeated, consistent assessment is not less than 4 weeks after the date of the first documentary confirmation), (ii) a reduction, according to irPR, tumor burden ≥ 50% compared to baseline (confirmed by sequential assessment at least 4 weeks after the first documentary confirmation). Not necessarily any method described in this document may not have an immediate effect. For example, treatment may be followed by an increase in the number or mass of neoplasia, tumorous or cancerous cells, but over time, a possible stabilization or reduction in tumor cell mass may occur, the size or number of cells in a particular subject. Additional adverse symptoms and complications associated with neoplasia, tumor, cancer and metastasis, which can be suppressed, attenuated, reduced, delayed or prevented, include, for example, nausea, lack of appetite, lethargy, pain and discomfort. Thus, partial or complete reduction or reduction in the severity, duration, or frequency of adverse events symptoms or complications associated with a cellular hyperproliferative disorder, or caused by it, improving the quality of life and / or well-being of the subject, for example, increasing energy, appetite, psychological well-being are specific non-limiting examples therapeutic effect. Thus, therapeutic effect or improvement may also include subjective improving the quality of life of the subject to be treated. In a further embodiment, the method prolongs or increases the lifespan (survival) of a subject. In another embodiment, the method improves the subject's quality of life. In one embodiment, the administration of an immunotherapeutic agent in combination therapy with crystalline salt form of Compound 1 results in a clinically significant improvement in one or several markers of disease status and progression selected from one or more of the following: (i) overall survival, (ii) progression-free survival, (iii) overall rate responses, (iv) reduction in metastatic disease, (v) circulating levels of tumor antigens such as carbohydrate antigen 19.9 (CA19.9) and carcinoembryonic antigen (CEA) or others, depending on tumors, (vii) nutritional status (body weight, appetite, serum albumin), (viii) pain control or analgesic use and (ix) CRP / albumin ratio. Treatment with a crystalline salt form of Compound 1 in combination with an immunotherapeutic agent causes more complex immunity, including not only the development of innate immunity and immunity 1 type, but also immunoregulation, which more effectively restores appropriate immune functions. In various illustrative methods, a checkpoint inhibitor antibody (monoclonal or polyclonal, bispecific, trispecific or multivalent antibody / fusion protein / construct, interacting with immune cells), targeting the checkpoint molecule that constitutes interest (e.g., PD-1), can be sequenced and then the polynucleotide sequence can be cloned into a vector for expression or propagation. The sequence encoding the antibody or its the antigen-binding fragment of interest can be maintained in a vector in the host cell, and then the host cell can be propagated and frozen for future use. Recombinant monoclonal antibodies can be produced in cell culture by cloning of antibody genes from B cells by methods known in the art. See, for example, Tiller et al., 2008, J. Immunol. Methods 329: 112; US Patent No. 7314622. Pharmaceutical compositions containing a crystalline salt form of Compound 1 according to this disclosure, will contain an effective amount of the crystalline salt form of Compound 1, immunotherapeutic agent and / or both, usually dispersed in a pharmaceutically acceptable acceptable excipient. The phrase "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not cause unwanted, allergic or other adverse effects reaction when administered to an animal, such as a human, depending on the situation. Preparation of a pharmaceutical composition containing a crystalline salt form of Compound 1 will be known skilled in the art in light of this disclosure, as illustrated in Remington's Pharmaceutical Sciences, 21st Ed., (Lippincott, Williams and Wilkins Philadelphia, PA, 2006). In addition, it should understand that for administration to animals (e.g. humans) drugs must meet standards sterility, pyrogenicity, general safety and purity. A specific example is pharmacologically acceptable excipient for a combination composition containing a crystalline salt form Compound 1 in admixture with an immunotherapeutic agent as described herein is a borate buffer or sterile saline solution (0.9% NaCl). Compositions of an immunotherapeutic agent, e.g., an immune checkpoint modulator antibody The points used in accordance with this description can be prepared for storage by mixing an antibody having the required degree of purity with optional pharmaceutically acceptable fillers or stabilizers, as described in detail and illustrated in Remington's Pharmaceutical Sciences 21st Ed., (Lippincott, Williams and Wilkins Philadelphia, PA, 2006), in in the form of lyophilized compositions or aqueous solutions and / or suspensions. Acceptable excipients, buffers or stabilizers are non-toxic to recipients at the dosages and concentrations used and include acceptable aqueous and / or non-aqueous excipients that can be used in pharmaceutical formulations compositions of the present invention, for example, water, ethanol, polyols (such as glycerin, propylene glycol, polyethylene glycol, etc.) and acceptable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, to help maintain the required size particles in the case of dispersions and through the use of surfactants, buffers, such as phosphate, citrate and other organic acids. Antioxidants may include, for example, (1) water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, etc. and (3) metal ion chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.; preservatives (such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabens such as methyl- or propylparaben; pyrocatechin; resolcin; cyclohexanol; 3-pentanol and m-cresol); low molecular weight substances (less than about 10 residues). Other examples of pharmaceutically acceptable Fillers may include polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium, metal complexes (e.g. Zn-protein complexes) and / or non-ionic surfactants such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG). In one illustrative embodiment, the pharmaceutical compositions may optionally contain pharmaceutically acceptable excipients necessary to approximate physiological conditions such as pH regulators and buffering agents and toxicity regulating agents such as acetate sodium, sodium chloride, potassium chloride, calcium chloride, and sodium lactate. In some embodiments, the checkpoint inhibitor antibodies or antigen-binding fragments thereof according to this disclosure and can be lyophilized for storage and reconstituted in a suitable vehicle before use according to methods of lyophilization and reconstitution known in the art. In one illustrative embodiment a pharmaceutical composition comprising one or more checkpoint inhibitor antibodies or their antigen-binding fragment, the composition is prepared in the form of a sterile solution that does not contain preservatives, one or more checkpoint inhibitor antibodies or their antigen-binding fragments for intravenous or subcutaneous administration. The composition may be supplied in in the form of a disposable, pre-filled pen, in the form of a single-use, for example, containing about 1 ml pre-filled glass syringe, or as a single-use vial for institutional use. Preferably, the pharmaceutical composition comprising the antibody- checkpoint inhibitor or its antigen-binding fragment, was clear and colorless, with pH of about 6.9-5.0, preferably with a pH of 6.5-5.0 and even more preferably with a pH range of about 6.0 to about 5.0. In various embodiments, compositions comprising pharmaceutical compositions, may contain from about 500 mg to about 10 mg, or from about 400 mg to about 20 mg, or from about 300 mg to about 30 mg, or about 200 mg to about 50 mg of inhibitor antibody of the control point or its antigen-binding fragment per ml of solution when diluted and administered to a subject. Illustrative excipients for injection or infusion may include mannitol, citric acid monohydrate, dibasic sodium phosphate dihydrate, monobasic sodium dihydrate phosphate, polysorbate 80, sodium chloride, sodium citrate and water for parenteral administration, for example, intravenous, intramuscular, intraperitoneal, or subcutaneous introduction. In another illustrative embodiment, one or more immunotherapeutic agents or their antigen-binding fragment prepared for intravenous or subcutaneous administration in in the form of a sterile aqueous solution containing 1-75 mg / ml or more preferably about 5-60 mg / ml, or even more preferably about 10-50 mg / ml or even more preferably about 10-40 mg / ml antibodies with sodium acetate, polysorbate 80, and sodium chloride at a pH in the range of about 5 to 6. Preferably, the composition for intravenous or subcutaneous administration is a sterile an aqueous solution containing 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 mg / ml of immunotherapeutic agent, for example, immune checkpoint inhibitor antibodies of the antigen-binding fragment with 20 mM sodium acetate, 0.2 mg / ml polysorbate 80 and 140 mM sodium chloride at pH 5.5. Additionally, a solution containing contains a checkpoint inhibitor antibody or antigen-binding fragment thereof, may contain, among many other compounds, histidine, mannitol, sucrose, trehalose, glycine, polyethylene glycol, EDTA, methionine and any combination thereof, and many other compounds known in the relevant art. In one embodiment, the pharmaceutical composition of the present disclosure comprises the following: components: 5-500 mg of immunotherapeutic agent or antigen-binding fragment thereof according to the present invention opening, 10 mM histidine, 5% sucrose and 0.01% polysorbate 80 at pH 5.8 with crystalline salt form of Compound 1. This composition may be presented as a lyophilized powder. When diluting the powder in full, the composition retains the same composition. As Alternatively, the powder can be diluted in half the volume, in which case the composition contains 10-500 mg of an immunotherapeutic agent or antigen-binding fragment thereof according to this disclosure, 20 mM histidine, 10% sucrose and 0.02% polysorbate 80 at pH 5.8. In one embodiment, part of the dose is administered as an intravenous bolus and the remainder is by infusion of an immunotherapeutic agent composition. For example, from about 0.001 to about 200 mg / kg, for example, from about 0.001 mg / kg to about 100 mg / kg, or from about 0.001 mg / kg to about 50 mg / kg, or from about 0.001 mg / kg to about 10 mg / kg intravenous injection of the immunotherapeutic of the agent or its antigen-binding fragment can be administered as a bolus, and the rest doses of the antibody can be administered by intravenous injection. A predetermined dose The immunotherapeutic agent or antigen-binding fragment thereof can be administered, for example, for a period of one to two hours or up to five hours. In another embodiment, a portion of the dose is administered by subcutaneous injection and / or infusion into as a bolus, and the remainder by infusion of an immunotherapeutic agent composition. In some In illustrative doses, the immunotherapeutic agent composition can be administered subcutaneously at a dose of 0.001 to 200 mg / kg, for example, from about 0.001 mg / kg to about 100 mg / kg, or from about 0.001 mg / kg to about 50 mg / kg, or about 0.001 mg / kg to about 10 mg / kg intravenous injection an immunotherapeutic agent or antigen-binding fragment thereof. In some embodiments In this case, the dose can be administered as a bolus, and the remainder of the immunotherapeutic agent can be administered by subcutaneous or intravenous injection. A predetermined dose The immunotherapeutic agent or antigen-binding fragment thereof can be administered, for example, for a period of one to two hours or up to five hours. The composition herein may also contain more than one active compound, if desired, for the specific indication to be treated, preferably compounds with additional species activities that do not adversely affect each other. For example, it may be necessary to providing one or more immunotherapeutic agents with different specificities. As alternatively or in addition, the composition may contain an anti-inflammatory agent, a chemotherapeutic agent, cytotoxic agent, cytokine, cell growth inhibitory agent, and / or low molecular weight antagonist. Such molecules are present in the appropriate combination in amounts that are effective for intended use. Compositions intended for in vivo administration must be sterile or practically sterile. sterile. This condition is easily achieved by filtration through sterile filter membranes. In various embodiments, illustrative compositions of the pharmaceutical compositions described in herein, can be prepared by methods well known in the art of obtaining pharmaceutical compositions. Typically, such preparation methods may include a step of combining active ingredient with a filler or one or more other auxiliary ingredients, and then, if necessary, packaging the product into the required single-dose or multi-dose container. In some embodiments, a composition comprising a crystalline salt form of Compound 1, can also be delivered in a vesicle, and an immunotherapeutic agent can be delivered in that the liposomal composition itself or in a separate composition compatible with the liposomal composition, which contains a crystalline salt form of Compound 1. In some illustrative examples, a liposome containing contains one or more liposomal surface moieties, e.g. polyethylene glycol, antibodies and antibody fragments that target the desired tumor surface antigen, receptor, growth factor, glycoprotein, glycolipid, or neoantigen that is selectively transported into certain cells or organs, thus improving targeted drug delivery. In another embodiment, the crystalline salt form of Compound 1 can be delivered in vesicles, in particular liposomes (see Langer, Science 249: 1527-1533 (1990); Treat et al., in LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASE AND CANCER, Lopez-Berestein and Fidler (eds.), Liss, NY, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.). In yet another embodiment, a crystalline salt form of Compound 1, or a composition comprising containing a combination, or a composition containing an immunotherapeutic agent, can be delivered in controlled release system. In one embodiment, a pump can be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14: 201 (1987); Buchwald et al., Surgery 88: 507 (1980); Saudek et al., N. Engl. J. Med. 321: 574 (1989)). In another embodiment, the system with controlled release crystalline salt form of Compound 1 may contain polymeric ingredients to provide sustained, intermediate, pulsatile or alternate release (see MEDICAL APPLICATIONS OF CONTROLLED RELEASE, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); CONTROLLED DRUG BIOAVAILABILITY, DRUG PRODUCT DESIGN AND PERFORMANCE, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23: 61 (1983); see also Levy et al., Science 228: 190 (1985); During et al., Ann. Neurol. 25: 351(1989); Howard et al., J. Neurosurg. 71: 105 (1989)). Other systems can be used with controlled release, discussed in the review by Langer (Science 249: 1527-1533 (1990)). The optimal concentration of the active ingredient(s) in the selected medium can be determined empirically, according to procedures well known to the skilled person, and it will depend on the desired primary pharmaceutical composition and the adopted route of administration. This disclosure also provides a pharmaceutical package or kit containing one or more more containers filled with one or more ingredients of the pharmaceutical compositions according to this disclosure, which will, at a minimum, contain a crystalline salt form of Compound 1 and one or more checkpoint inhibitor antibodies or antigen-binding fragment thereof, as described herein document. In other embodiments, the kit may include one or more additional containers, providing a pharmaceutically acceptable excipient, e.g., a diluent. In one embodiment In one embodiment, the kit may comprise at least one container, wherein the container may comprise a crystalline salt form of Compound 1, a checkpoint inhibitor antibody or antigen-binding fragment according to this disclosure. The kit may also include a set of instructions for preparing and administering of the final pharmaceutical composition to a subject in need thereof for the treatment of a disease or Checkpoint molecule-mediated disorders. In some embodiments of this disclosure, the immunotherapeutic agent is a population immune cells, which can be administered in combination with the crystalline salt form of Compound 1 for treating a subject suffering from cancer. In some embodiments, the immunotherapeutic agent is a population of immune cells, such as leukocytes (nuclear leukocytes), that contain (for example, that express) a receptor that binds to the antigen of interest. The leukocyte then The disclosure may be, for example, a neutrophil, eosinophil, basophil, lymphocyte or monocyte. In In some embodiments, the leukocyte is a lymphocyte. Examples of lymphocytes include T- cells, B cells, natural killer (NK) cells, or NKT cells. In some embodiments, T- the cell is a CD4+Th (T-helper) cell, a CD8+ cytotoxic T cell, a γδT cell, or a regulatory (suppressor) T cell. In some embodiments, the immune cell is a dendritic cell. The immune cells of the present invention are in some embodiments genetically engineered from the ability to express an antigen-binding receptor. A cell is considered "engineered" if it contains engineered (exogenous) nucleic acid. Engineered nucleic acids by of this disclosure can be introduced into the cell using any known (e.g., (standard) method. For example, the engineered nucleic acid can be introduced into a cell by electroporation (see, for example, Heiser WC Transcription Factor Protocols: Methods in Molecular Biology.TM. 2000; 130: 117-134), chemical (e.g., using calcium phosphate or lipid) transfection (see, e.g., Lewis WH, et al., Somatic Cell Genet. 1980 May; 6(3): 333-47; Chen C., et al., Mol Cell Biol. 1987 August; 7(8): 2745-2752), fusion with bacterial protoplasts, which contain recombinant plasmids (see, for example, Schaffner W. Proc Natl Acad Sci USA. 1980 April; 77(4): 2163-7), microinjection of purified DNA directly into the cell nucleus (see, for example, Capecchi MR Cell. 1980 November; 22(2 Pt 2): 479-88) or retroviral transduction. In some aspects, the present disclosure provides an "adaptive cell" approach that involves isolating immune cells (e.g., T cells) from a subject suffering from cancer, gene immune cell engineering (e.g., to express an antigen-binding receptor, such as a chimeric antigen receptor), cell expansion ex vivo and then reintroduction of the immune cells into the subject. This the method results in a greater number of engineered immune cells in the subject compared to which can be achieved through conventional methods of gene delivery and vaccination. In some In embodiments, immune cells are isolated from a subject, expanded ex vivo without genetic modifications and then re-administered to the subject. Immune cells of this disclosure contain receptors that bind to antigens, such as antigen encoded by exogenously delivered nucleic acid provided herein document. In some embodiments, the leukocyte is modified (e.g., genetically modified) to express a receptor that binds to the antigen. In some embodiments, the The receptor may be a naturally occurring antigen receptor (usually expressed on an immune cell), recombinant antigen receptor (usually not expressed on an immune cell) or chimeric antigen receptor (CAR). Recombinant antigen receptors and Naturally occurring receptors encompassed by this disclosure include T-cell receptors, B-cell receptors, NK-cell receptors, NKT-cell receptors and receptors dendritic cells. The term "chimeric antigen receptor" refers to a receptor on immune cells that designed to recognize and bind to an antigen expressed by tumor cells. Typically, a CAR is designed for a T cell and is a chimera from the signaling domain of the T-cell complex. cell receptors (TcR) and an antigen-recognition domain (e.g., a single-chain fragment (scFv) antibodies) (Enblad et al., Human Gene Therapy. 2015; 26(8): 498-505), the disclosure of which is incorporated herein by reference. this document by reference in its entirety. In some embodiments, the antigen-binding receptor is a chimeric antigen receptor. receptor (CAR). A T cell that expresses CAR is called a "CAR T cell." CAR T cell the receptor in some embodiments comprises a T-cell receptor (TcR) signaling domain complex and the antigen-recognizing domain (e.g., single-chain fragment (scFv) of an antibody) (Enblad et al., Human Gene Therapy. 2015; 26(8): 498-505), the disclosure of which is incorporated herein by reference. using the link in full. There are four generations of CARs, each containing different components. First-generation CARs attach antibody-derived scFv to the intracellular signaling domain of CD3-zeta (zeta or z) T-cell receptor via hinge and transmembrane domains. Second generation CAR contain an additional domain, such as CD28, 4-1BB (41BB) or ICOS, to provide costimulatory signal. Third-generation CARs contain two costimulatory domains fused to the CD3- The third generation costimulatory domains may contain, for example, a combination of CD3z, CD27, CD28, 4-1BB, ICOS or OX40. CARs in some embodiments comprise ectodomain (e.g., CD3), usually derived from a single-chain variable fragment (scFv), hinge, transmembrane domain and endodomain with one (first generation), two (second generation) or three (third generation) signaling domains derived from CD3Z and / or costimulatory molecules (Maude et al., Blood. 2015; 125(26): 4017-4023; Kakarla and Gottschalk, Cancer J. 2014; 20(2): 151-155, the disclosure of which is incorporated herein by reference in its entirety. In some embodiments, the chimeric antigen receptor (CAR) is a T cell, redirected for universal cytokine destruction (TRUCK), also known as CAR of the fourth generation. TRUCK are CAR-redirected T cells that are used as carriers for the production and release of a transgenic cytokine that accumulates in the target tissue, for example, in the target tumor tissue. The transgenic cytokine is released when the CAR is exposed to target. TRUCK cells can deposit various therapeutic cytokines in the target. This may lead to to therapeutic concentrations in the target area and eliminates systemic toxicity. CARs are usually distinguished by their functional properties. The CD3- signaling domain T-cell receptor zeta upon engagement activates and induces T-cell proliferation, but can lead to anergy (lack of response of the body's defense mechanisms, which leads to direct (induction of tolerance of peripheral lymphocytes). Lymphocytes are considered anergic if they do not respond to a specific antigen. Addition of a costimulatory domain to second-generation CARs improved replicative capacity and stability of modified T cells. Similar antitumor effects observed in vitro in the case of CAR CD28 or 4-1BB, however, preclinical in vivo studies show that CAR 4-1BB may induce higher proliferation and / or resistance. Clinical trials show that both of these second-generation CARs are capable of inducing significant T-cell proliferation in in vivo, but CARs containing the 4-1BB costimulatory domain appear to persist longer. CARs of the third generation combine multiple signaling domains (costimulatory) to increase efficiency. CAR fourth generation are additionally modified by constitutive or inducible expression transgenic cytokine cassette that is released by the CAR T cell to modulate T-cell answers. See, for example, Enblad et al., Human Gene Therapy. 2015; 26(8): 498-505; Chmielewski and Hinrich, Expert Opinion on Biological Therapy. 2015; 15(8): 1145-1154, disclosures of which are incorporated herein by reference. document by reference in full. In some embodiments, an exemplary immunotherapeutic agent is a chimeric a first generation CAR antigen receptor. In some embodiments, the chimeric antigen receptor The receptor is a second generation CAR. In some embodiments, the chimeric antigen receptor is a second generation CAR. The receptor is a third generation CAR. In some embodiments, the chimeric antigen receptor the receptor is a fourth-generation CAR or T cell redirected for universal cytokine destruction (TRUCK). In some embodiments, the chimeric antigen receptor (CAR) comprises an extracellular domain, which includes an antigen-binding domain, a transmembrane domain, and a cytoplasmic domain. In In some embodiments, the CAR is fully human. In some embodiments, the CAR is fully human. the antigen binding domain of the CAR is specific for one or more antigens. In some embodiments In one embodiment, a "spacer" domain or "hinge" domain is located between the extracellular domain (which includes the antigen-binding domain) and the transmembrane domain of CAR or between the cytoplasmic domain and the CAR transmembrane domain. "Spacer domain" refers to any oligopeptide or a polypeptide that functions to link the transmembrane domain to the extracellular domain and / or cytoplasmic domain in a polypeptide chain. "Hinge domain" refers to any oligopeptide or polypeptide that functions to provide flexibility to the CAR or its domains or to prevent steric hindrance of CAR or its domains. In some embodiments In one embodiment, the spacer domain or hinge domain may contain up to 300 amino acids (e.g., from 10 to 100 amino acids or 5 to 20 amino acids). In some embodiments, one or more spacer domains can be included in other regions of the CAR. In some embodiments, the CAR of the present invention comprises an antigen-binding domain, such as single-chain Fv (scFv) specific for tumor antigen. Binding domain selection depends on the type and number of ligands that define the target cell surface. For example, the antigen-binding domain can be selected to recognize a ligand that acts as a cell surface marker on target cells associated with a specific pathological condition, such as- cancer or autoimmune disease. Thus, examples of cell surface markers that can act as ligands for the antigen-binding domain in the CAR of the present invention include markers associated with cancer cells and / or other forms of abnormal cells. In some In embodiments, the CAR is designed to target a tumor antigen that is interest, by designing the necessary antigen-binding domain that specifically binds to an antigen on a tumor cell encoded by an engineered nucleic acid, such as presented in this document. An antigen-binding domain (e.g., scFv) that "specifically binds" to a target or epitope, is a term understood in the art, and methods for determining such specific binding are also known in the art. A molecule is said to exhibit "specific binding" if it reacts or binds more frequently, faster, for longer duration and / or with greater affinity to specific antigen target than with alternative targets. Antigen-binding domain (e.g., scFv) that specifically binds to the first target antigen can specifically to bind or not to bind to the second target antigen. Thus, "specific binding" does not necessarily require exclusive binding (although it may include it). In some embodiments, CAR-expressing immune cells are genetically modified to recognition of multiple targets or antigens, allowing for the recognition of unique expression profiles target or antigen on tumor cells. Examples of CARs that can bind to multiple targets, include "split-signal CARs" that limit full activation of immune cells against tumors expressing multiple antigens; "tandem CARs" (TanCARs), which contain extracellular domains with two scFv; and "universal extracellular domain CARs" that introduce avidin or specific to fluorescein isothiocyanate (FITC) scFv to recognize tumor cells that were incubated with labeled monoclonal antibodies (Mab). A CAR is considered "bispecific" if it recognizes two separate antigens (has two separate domains antigen recognition). In some embodiments, a bispecific CAR consists of two individual antigen recognition domains present in tandem on a single transgenic receptor (which called TanCAR; see, for example, Grada Z et al. Molecular Therapy Nucleic Acids 2013; 2: e105, incorporated by reference in its entirety into this document). Thus, in some In embodiments, the methods include delivering to the tumor a combination comprising a crystalline a salt form of Compound 1 and an immunotherapeutic agent, wherein the immunotherapeutic agent is an engineered nucleic acid encoding an antigen, or delivery of an engineered nucleic acid to the tumor nucleic acid and delivery to the tumor of an immune cell expressing a bispecific CAR, which binds to two antigens, one of which is encoded by an engineered nucleic acid. In some embodiments, the CAR is an antigen-specific inhibitory CAR (iCAR), which can be used, for example, to prevent toxicity outside the tumor (Fedorov, VD et al. Sci. Transl. Med., published online December 11, 2013, incorporated into this document by reference in its entirety). iCARs contain an antigen-specific inhibitory receptor, e.g. to block nonspecific immunosuppression, which may result from additional expression of tumor targets. iCARs can be based, for example, on inhibitory molecules CTLA-4 or PD-1. In some In embodiments, these iCARs block T-cell responses from T cells activated or their endogenous T-cell receptor, or activating CAR. In some embodiments, this inhibitory effect is temporary. In some embodiments, CAR can be used in adoptive cell transfer, wherein immune cells are removed from the subject and modified so that they express receptors specific for an antigen, for example, a tumor-specific antigen. Modified immune cells, which can then recognize and destroy cancer cells, are re-injected into the subject (Pule et al., Cytotherapy. 2003; 5(3): 211-226; Maude et al., Blood. 2015; 125(26): 4017-4023, each of which incorporated by reference in its entirety into this document). According to other aspects of the present invention, the tumor antigen component in the vaccine herein is invention is any natural or synthetic tumor-associated protein or a peptide or combination of tumor-associated proteins and / or peptides or glycoproteins or glycopeptides. In other aspects, the antigenic component may be specific to the patient or common to many or most patients with a particular type of cancer. According to one of the aspects, the antigenic component consists of a cell lysate obtained from tumor tissue, removed from a patient undergoing treatment. In another aspect, the lysate may be constructed or synthesized from an exosome derived from tumor tissue. In another aspect, the antigenic component consists of a cell lysate obtained from tumor tissue isolated from one or more unrelated individuals or tumor cell lines. In various embodiments, an exemplary immunotherapeutic agent comprises one or more anti-cancer vaccines for use in combination with a crystalline salt form of Compound 1. The tumor-associated antigen component of the vaccine can be delivered using any which of various well-known techniques. For individual protein components, the antigenic protein is isolated from tumor tissue or tumor cell line using standard chromatographic methods such as high-performance liquid chromatography or affinity chromatography or, as alternatives, it is synthesized using standard recombinant DNA technology in the appropriate expression system such as E. coli, yeast or plants. Tumor-associated antigen protein then purified from the expression system by standard chromatographic methods. In the case of peptide antigenic components, they are usually obtained using standard automated synthesis. Proteins and peptides can be modified by adding amino acids, lipids, and other agents to improve their introduction into the vaccine delivery system (e.g., multilamellar liposome). For the tumor-associated antigenic component, derived from the patient's own tumor, or tumors of other individuals, or cell lines, tissue A tumor or a suspension of single cells obtained from tumor tissue is usually homogenized in The homogenate can also be fractionated, for example, using centrifugation to isolate specific cellular components, such as cell membranes or soluble material. Tumor material can be applied directly, or associated with Tumor antigens can be extracted for vaccine use using a buffer containing a low concentration of a suitable agent, such as a detergent. An example of a suitable detergent for extraction of antigenic proteins from tumor tissue, tumor cells, and tumor cell membranes is diheptanoyl phosphatidylcholine. Exosomes formed from tumor tissue or tumor cells, regardless of whether they are autologous or heterologous to the patient, can be used for antigenic component for inclusion in a vaccine or as a starting material for extraction tumor-associated antigens. In some embodiments of this disclosure, the combination therapy includes crystalline saline form of Compound 1 in combination with an immunotherapeutic agent based on a cancer vaccine. In various In some examples, the cancer vaccine includes at least one tumor-associated antigen, at least one immunostimulant and optionally at least one cellular immunotherapeutic agent. In some embodiments, the immunostimulatory component in the cancer vaccine herein disclosure is any biological response modifier (BRM) capable of enhancing therapeutic efficacy of anticancer vaccine for induction of humoral and cellular immune responses responses against cancer cells in a patient. In one aspect, the immunostimulant is is a cytokine or combination of cytokines. Examples of such cytokines include interferons such as IFN- gamma, interleukins such as IL-2, IL-15, and IL-23, colony-stimulating factors such as M-CSF and GM-CSF, and tumor necrosis factor. According to another aspect, the immunostimulatory component of the disclosed cancer vaccines include one or more immunostimulatory agents of the adjuvant type, such as APC toll-like receptor agonists or costimulatory / membrane cell adhesion proteins, with with or without immunostimulatory cytokines. Examples of toll-like receptor agonists include lipid A and CpG and costimulatory / adhesion proteins such as CD80, CD86 and ICAM-1. In some embodiments, the immunostimulant is selected from the group consisting of IFN-gamma (IFN-γ), IL-2, IL-15, IL-23, M-CSF, GM-CSF, tumor necrosis factor, lipid A, CpG, CD80, CD86 and ICAM-1 or their combinations. According to other aspects, the cellular immunotherapeutic agent is selected from the group consisting of includes dendritic cells, tumor-infiltrating T lymphocytes modified with chimeric antigen receptor-targeted effector T cells targeting the patient's tumor type, B lymphocytes, natural killer cells, bone marrow cells, and any other cells of the patient's immune system or their combinations. In one aspect, the cancer vaccine immunostimulator comprises one or more cytokines, such as interleukin 2 (IL-2), GM-CSF, M-CSF, and interferon-gamma (IFN-γ), one or more toll-like receptor agonists and / or adjuvants such as monophosphoryl lipid A, lipid A, a lipid conjugate of muramyl dipeptide (MDP) and double-stranded RNA, or one or more costimulatory membrane proteins and / or cell adhesion proteins such as CD80, CD86 and ICAM-1, or any combination of the above. In one aspect, the cancer vaccine comprises an immunostimulant which is a cytokine selected from the group consisting of interleukin 2 (IL-2), GM-CSF, M-CSF and interferon-gamma (IFN-γ). In another aspect, the cancer vaccine comprises an immunostimulant which is a toll-like receptor agonist and / or an adjuvant selected from a group that includes monophosphoryl lipid A, lipid A and muramyl dipeptide (MDP) lipid conjugate and double-stranded RNA. In another aspect, the cancer vaccine includes an immunostimulant that is a costimulatory membrane protein and / or cell adhesion protein selected from the group consisting of consists of CD80, CD86 and ICAM-1. In various embodiments, the immunotherapeutic agent may include a cancer vaccine, and a cancer vaccine includes any tumor antigen that can potentially be used to construct a fusion protein according to the present invention and, in particular, the following: (a) cancer- testicular antigens, including NY-ESO-1, SSX2, SCP1, as well as RAGE, BAGE, GAGE and MAGE family polypeptides, e.g., GAGE-1, GAGE-2, MAGE-1 MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6 and MAGE-12, which can be used, for example, to treat melanoma, tumors lung, head and neck, NSCLC, breast, gastrointestinal and bladder tumors; (b) mutated antigens, including p53, associated with various solid tumors, e.g., colorectal cancer, lung cancer, head and neck cancer; p21 / Ras, associated, for example, with melanoma, pancreatic cancer and colorectal cancer; CDK4, associated, for example, with melanoma; MUM1, associated, for example, with melanoma; caspase-8, associated, for example, with head and neck cancer neck; CIA 0205, associated, for example, with bladder cancer; HLA-A2-R1701, beta-catenin, associated, for example, with melanoma; TCR associated, for example, with T-cell non-Hodgkin's lymphoma; BCR-abl, associated, for example, with chronic myelogenous leukemia; triose phosphatase isomerase; KIA 0205; CDC-27 and LDLR-FUT; (c) antigens that are overexpressed, including including galectin 4, associated, for example, with colorectal cancer; galectin 9, associated, e.g., with Hodgkin's disease; proteinase 3 associated with e.g., chronic myelogenous leukemia leukemia; WT 1, associated, for example, with various types of leukemia; carbonic anhydrase, associated, e.g., with kidney cancer; aldolase A, associated e.g., with lung cancer; PRAME, associated, for example, with melanoma; HER-2 / neu, associated, for example, with breast cancer gland, colon, lung and ovary; mammaglobin, alpha-fetoprotein, associated, for example, with hepatoma; KSA, associated, for example, with colorectal cancer; gastrin, associated, for example, with pancreatic and esophageal cancer; telomerase catalytic protein, MUC-1, associated, for example, with breast and ovarian cancer; G-250, associated, for example, with renal cell carcinoma; p53, associated, for example, with breast cancer, colon cancer intestines; and carcinoembryonic antigen, associated, for example, with breast cancer, cancer lung and gastrointestinal cancers such as colorectal cancer; (d) common antigens, including melanoma and melanocyte differentiation antigens such as MART-1 / Melan A; gpl00; MC1R; melanocyte-stimulating hormone receptor; tyrosinase; tyrosinase-associated protein 1 / TRP1 and tyrosinase-associated protein-2 / TRP2, associated, for example, with melanoma; (e) antigens, associated with the prostate gland, including PAP, PSA, PSMA, PSH-P1, PSM-P1, PSM-P2, associated, for example, with prostate cancer; (f) immunoglobulin idiotypes associated with myeloma and B-cell lymphomas. In some embodiments, one or more TAAs may be selected from pi 5, Hom / Mel-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, virus antigens Epstein-Barr, EBNA, human papillomavirus (HPV) antigens, including E6 and E7, virus antigens B and C, T-cell lymphotropic virus antigens, TSP-180, pl85erbB2, pl 80erbB-3, c-met, mn-23H1, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, pi 6, TAGE, PSCA, CT7, 43-9F, 5T4, 791 Tgp72, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29\BCAA), CA 195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO- 1, RCAS1, SDCCAG16, TA-90 (Mac-2 binding protein / cyclophilin C-related protein), TAAL6, TAG72, TLP, TPS or any combination thereof. In some embodiments, the present disclosure provides a crystalline salt form. Compounds 1 for use in combination with an anti-cancer vaccine which may include a tumor antigen containing the entire amino acid sequence, part of it, or specific immunogenic epitopes human protein. In various embodiments, an exemplary immunotherapeutic agent may include mRNA, capable of encoding any one or more of the above-mentioned cancer antigens suitable for synthesis of a cancer vaccine. In some illustrative embodiments, the cancer vaccine is mRNA may have one or more of the following properties: a) mRNA encoding each cancer gene antigen, interspersed with cleavage-sensitive sites; b) mRNA encoding each cancer antigen, linked directly to each other without a linker; c) mRNA encoding each cancer antigen, linked to each other by a nucleotide linker; d) each cancer antigen includes 20–40 amino acids and centrally located SNP mutation; e) at least 40% of cancer antigens have the highest affinity for MHC class I molecules from the subject; f) at least 40% of the cancer antigens have the highest affinity for MHC class II molecules from the subject; g) at least 40% of the cancer antigens have predicted binding affinity IC>500 nM for HLA-A, HLA-B and / or DRB1; h) mRNA encodes from 1 to 15 cancer antigens; i) 10-60% of cancer antigens have binding affinity to MHC class I, and 10- 60% of cancer antigens have binding affinity to MHC class II; and / or j) mRNA encoding cancer antigens, arranged so that cancer antigens are ordered to minimize pseudoepitopes. In various embodiments, a combination comprising a crystalline salt form of Compound 1 and The immunotherapeutic agent of the cancer vaccine disclosed herein can be used for eliciting an immune response in a subject against a cancer antigen. The method comprises administering to the subject RNA vaccines containing at least one RNA polynucleotide having an open reading frame, which encodes at least one antigenic polypeptide or immunogenic fragment thereof, thus inducing an immune response in the subject specific to the antigenic polypeptide or its immunogenic fragment in combination with the introduction of the crystalline salt form of Compound 1 or in the same compositions, or in a separate composition, administered simultaneously or sequentially, and the antigen titer against the antigenic polypeptide in the subject increases after vaccination compared to the antibody titer against an antigenic polypeptide in a subject vaccinated with a prophylactically effective dose traditional anti-cancer vaccine. The "antibody to the antigenic polypeptide" is a serum an antibody that specifically binds to an antigenic polypeptide. A prophylactically effective dose is a therapeutically effective dose that prevents progression of cancer to a clinically acceptable level. In some embodiments, the therapeutic The effective dose is the dose stated in the vaccine package insert. In the context of this In the document, a traditional vaccine refers to a vaccine other than the mRNA vaccines of the present invention. For example, traditional vaccines include, but are not limited to, live vaccines, killed microorganisms vaccines, subunit vaccines, antigenic protein vaccines, DNA vaccines etc. In illustrative embodiments, the traditional vaccine is a vaccine that has received regulatory approval and / or registered with a national drug regulatory authority means, for example, the Department of Sanitary Supervision of the Quality of Food Products and Medicines (FDA) in the USA or the European Medicines Agency (EMA). In some embodiments, the subject's antibody titer against the antigenic polypeptide is increased. from 1 log to 10 log after vaccination compared to the titer of antibodies against the antigenic polypeptide in subject vaccinated with a prophylactically effective dose of a traditional cancer vaccine. In some In embodiments, the titer of antibodies against the antigenic polypeptide in the subject increases to 1 log after vaccination compared to the titer of antibodies against the antigenic polypeptide in the subject, vaccinated with a prophylactically effective dose of a traditional cancer vaccine. In some embodiments implementation, the titer of antibodies against the antigenic polypeptide in the subject increases to 2 log after vaccination compared to the titer of antibodies against the antigenic polypeptide in a subject vaccinated a prophylactically effective dose of a traditional cancer vaccine. In aspects of the present invention, nucleic acid-based vaccines comprising one or more RNA polynucleotides that have an open reading frame encoding the first antigenic polypeptide, wherein the RNA polynucleotide is present in the composition for administration in vivo to a host that provides an antibody titer exceeding the seroprotection criterion for the first antigen for an acceptable percentage of people. In some embodiments, the antibody titer that produced by the mRNA vaccines of the present invention is the titer of neutralizing antibodies. In some In some embodiments, the titer of neutralizing antibodies is greater than that of the protein vaccine. In other embodiments, performing titers of neutralizing antibodies produced by mRNA vaccines of the present invention, greater than that of an adjuvant protein vaccine. In other embodiments, the neutralizing antibody titer, produced mRNA vaccines according to this invention is 1000–10000, 1200–10000, 1400–10000, 1500–10000, 1000–5000, 1000–4000, 1800–10000, 2000–10000, 2000–5000, 2000–3000, 2000–4000, 3000–5000, 3000–4000 or 2000–2500. The neutralization titer is usually expressed as the maximum Serum dilution required to achieve a 50% reduction in plaque count. In preferred aspects, the RNA vaccine-based immunotherapeutic agents of the present invention (e.g. mRNA vaccines) produce prophylactically and / or therapeutically effective levels, concentrations and / or titers of antigen-specific antibodies in the blood or serum of the vaccinated subject. As defined in this document, the term "antibody titer" refers to the amount of antigen-specific antibody produced in a subject, e.g., a human. In illustrative embodiments In some embodiments, the antibody titer is expressed as the reciprocal of the highest dilution (in serial dilution), which still gives a positive result. In illustrative embodiments, antibody titer is determined or measured using an enzyme-linked immunosorbent assay (ELISA). In illustrative embodiments, antibody titer is determined or measured using neutralization assay, for example, by microneutralization assay. In some aspects The measurement of antibody titer is expressed as a ratio, such as 1:40, 1:100, etc. In illustrative embodiments of the present invention, an effective vaccine provides an antibody titer more than 1:40, more than 1:100, more than 1:400, more than 1:1000, more than 1:2000, more than 1:3000,, more than 1:4000, more than 1:500, more than 1:6000, more than 1:7500, more than 1:10000. In illustrative embodiments antibody titer is produced or reached 10 days after vaccination, 20 days after vaccination, 30 days after vaccination, 40 days after vaccination, or 50 or more days after vaccination. In illustrative embodiments, the titer is produced or achieved after administering a single dose of vaccine to the subject. In other embodiments, the titer is generated or achieved after several doses, for example, after the first and second dose (e.g., a booster dose). In In illustrative aspects of the invention, antigen-specific antibodies are measured in units of μg / ml or measured in units of IU / L (international units per liter) or mIU / mL (international milliunits per ml). In illustrative embodiments of the invention, an effective vaccine provides more than 0.5 μg / ml, more than 0.1 μg / ml, more than 0.2 μg / ml, more than 0.35 μg / ml, more than 0.5 μg / ml, more than 1 μg / ml, greater than 2 μg / ml, greater than 5 μg / ml, or greater than 10 μg / ml. In illustrative embodiments, of the invention, an effective vaccine provides more than 10 mIU / ml, more than 20 mIU / ml, more than 50 mIU / ml, more than 100 mIU / ml, more than 200 mIU / ml, more than 500 mIU / ml or more than 1000 mIU / ml. In In illustrative embodiments, the level or concentration of antibodies is produced or achieved 10 days after vaccination, 20 days after vaccination, 30 days after vaccination, 40 days after vaccination or 50 or more days after vaccination. In illustrative embodiments the level or concentration produced or achieved after administration of a single dose vaccine. In other embodiments, the level or concentration is produced or achieved after multiple doses, for example, after the first and second doses (e.g., a booster dose). In illustrative In embodiments, the level or concentration of antibodies is determined or measured using enzyme-linked immunosorbent assay (ELISA). In illustrative embodiments, the level or the antibody concentration is determined or measured using a neutralization assay, for example, by using microneutralization assay. Nucleic acid-based vaccines have also been proposed, containing one or more RNA polynucleotides having an open reading frame that encodes a first antigenic polypeptide or concatemeric polypeptide, wherein the RNA polynucleotide is present in a composition for administration in vivo to a host to obtain a longer lasting high titer of antibodies, than the antibody titer induced by an mRNA vaccine containing a stabilizing element or consisting of with an adjuvant and encodes a first antigenic polypeptide. In some embodiments, the RNA- polynucleotide designed to produce neutralizing antibodies within one week after single administration. In some embodiments, the adjuvant is selected from a cationic peptide and immunostimulatory nucleic acid. In some embodiments, the cationic peptide is protamine. Immunotherapeutic agents comprising a nucleic acid-based vaccine comprising one or more RNA polynucleotides with an open reading frame containing at least one chemical modification or optionally does not include a nucleotide modification, an open reading frame, which encodes a first antigenic polypeptide or concatemeric polypeptide, and the RNA polynucleotide is present in a composition for administration to a host in vivo, such that the level of antigen expression in hosts significantly exceeds the level of antigen expression produced by the mRNA vaccine, which has a stabilizing element or containing an adjuvant and encoding the first antigenic polypeptide. In other aspects, nucleic acid-based vaccines comprising one or more RNA polynucleotides that have an open reading frame that includes at least one chemical modification or optionally does not include a nucleotide modification, an open reading frame, which encodes a first antigenic polypeptide or concatemeric polypeptide, and the vaccine has at least 10 times less RNA polynucleotide than required for an unmodified mRNA vaccine to obtain an equivalent antibody titer. In some embodiments, the RNA polynucleotide present in a dosage of 25-100 mcg. In aspects of the present invention, a vaccine administration unit is also provided, which comprises from 10 μg to 400 μg of one or more RNA polynucleotides having an open reading frame that includes at least one chemical modification or optionally does not include a modification nucleotides, and the open reading frame encodes the first antigenic polypeptide or a concatemeric polypeptide and a pharmaceutically acceptable carrier or excipient formulated to delivery to a human subject. In some embodiments, the vaccine further comprises a cationic lipid nanoparticle. Aspects of the present invention relate to methods for creating, maintaining or restoring antigenic memory to a tumor in an individual or population of individuals, comprising administering to said individual or a population of nucleic acid antigen vaccine, a memory comprising (a) at least one RNA polynucleotide comprising at least one chemical modification or optionally not comprising nucleotide modification of the nucleotide, and two or more codon-optimized open frames reading, with said open reading frames encoding a set of reference antigenic polypeptides, and (b) optionally a pharmaceutically acceptable excipient. In some embodiments In one embodiment, the vaccine is administered to the individual by a method selected from the group consisting of intramuscular administration, intradermal administration and subcutaneous administration. In some embodiments In one embodiment, the introducing step includes contacting the subject's muscle tissue with the device, suitable for injection of the composition. In some embodiments, the step of administering comprises administering to contacting the muscle tissue of the subject with a device suitable for injecting the composition in combination with electroporation. In aspects of the present invention, methods of vaccinating a subject are provided, comprising administering to the subject a single dose of 25 µg / kg to 400 µg / kg of a nucleic acid-based vaccine containing one or more RNA polynucleotides having an open reading frame that encodes the first antigenic polypeptide or concatemeric polypeptide in an effective amount for vaccinating a subject. In other aspects, nucleic acid-based vaccines are provided comprising one or more RNA polynucleotides that have an open reading frame that includes at least one a chemical modification, an open reading frame encoding the first antigenic polypeptide or concatemeric polypeptide, with the vaccine having at least 10 times less polynucleotide RNA than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 μg. In some embodiments, the crystalline salt form of Compound 1 can be used in combinations with an immunotherapeutic agent based on a bispecific antibody. Bispecific antibody may include a protein construct having a first antigen-binding moiety and a second antigen-binding site that binds to a cytotoxic immune cell. The first the antigen-binding site can bind to the tumor antigen that is being treated combination of the present invention. For example, the first antigen-binding fragment may bind to a non-limiting example of tumor antigens selected from EGFR, HGFR, Her2, Ep- CAM, CD20, CD30, CD33, CD47, CD52, CD133, CEA, gpA33, mucins, TAG-72, CIX, PSMA, folate- binding protein, GD2, GD3, GM2, VEGF. Among others, VEGFR, integrin αVβ3, integrin α5β1, MUC1, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP and tenascin. IN In some embodiments, the first antigen-binding fragment has specificity for a protein or a peptide that is overexpressed in a tumor cell compared to a corresponding non-tumor cell. In some embodiments, the first antigen-binding fragment has specificity for a protein, which is overexpressed in a tumor cell compared to the corresponding non-tumor cell. In In the context of this document, the term "relevant non-tumor cell" refers to a non-tumor cell, which belongs to the same cell type as the original tumor cell. It has been noted that such proteins are not necessarily distinct from tumor antigens. Non-limiting examples include carcinoembryonic antigen (CEA), which is overexpressed in most cases of colon cancer, rectum, breast, lungs, pancreas, and gastrointestinal tract; receptors heregulin (HER-2, neu or c-erbB-2), which are often overexpressed in breast, ovarian, colon, lung, prostate, and cervix; epidermal factor receptor growth factor (EGFR), which is highly expressed in a number of solid tumors, including breast tumors glandular, head and neck, non-small cell lung and prostate tumors; asialoglycoprotein receptor; transferrin receptor; serpin-enzyme complex receptor, which expressed on hepatocytes; fibroblast growth factor receptor (FGFR), which is overexpressed in pancreatic ductal adenocarcinoma cells; vascular endothelial growth factor receptor (VEGFR) for gene therapy against angiogenesis; folate receptor that is selectively overexpressed in 90% of non-mucinous ovarian carcinomas; cell surface glycocalyx; carbohydrate receptors; and polymeric immunoglobulin receptor. The second antigen-binding fragment is any molecule that specifically binds to antigen or protein or polypeptide expressed on the surface of a cytotoxic immune cell (CIK cells). Illustrative non-restrictive antigens expressed on the surface of cytotoxic Immune cells suitable for use in accordance with the present invention may include CD2, CD3, CD4, CD5, CD8, CD11a, CD11b, CD14, CD16a, CD27, CD28, CD45, CD45RA, CD56, CD62L, Fc- receptor, LFA, LFA-1, TCRαβ, CCR7, macrophage inflammatory protein 1a, perforin, PD-1, PD-L1, PD-L2 or CTLA-4, LAG-3, OX40, 41BB, LIGHT, CD40, GITR, TGF-beta, TIM-3, SIRP-alpha, TIGIT, VSIG8, BTLA, SIGLEC7, SIGLEC9, ICOS, B7H3, B7H4, FAS, BTNL2, CD27 and Fas ligand. In some In embodiments, the second antigen-binding fragment binds to CD3 of the cytotoxic immune cell. cells, e.g., CIK cells. In some embodiments, the second antigen-binding fragment binds to CD56 of a cytotoxic immune cell. In some embodiments, the second the antigen-binding fragment binds to the Fc receptor of a cytotoxic immune cell. In some In embodiments, the Fc region of the bispecific antibody binds to the Fc receptor of a cytotoxic immune cell. In some embodiments, the second antigen-binding moiety is any a molecule that specifically binds to an antigen expressed on the surface of a cytotoxic immune cell (e.g., CIK cells). The second antigen-binding fragment is specific for antigen on a cytotoxic immune cell. Examples of cytotoxic immune cells include, but are not limited to limited to, CIK cells, T cells, CD8+ T cells, activated T cells, monocytes, natural killer (NK), NK-T cells, lymphokine-activated killer (LAK), macrophages and dendritic cells. The second the antigen-binding fragment specifically binds to an antigen expressed on the surface cytotoxic immune cells. Illustrative non-limiting antigens expressed on the surface of cytotoxic immune cells suitable for modulation according to the present invention may include CD2, CD3, CD4, CD5, CD8, CD11a, CD11b, CD14, CD16a, CD27, CD28, CD45, CD45RA, CD56, CD62L, Fc receptor, LFA, LFA-1, TCRαβ, CCR7, macrophage inflammatory protein 1a, perforin, PD-1, PD-L1, PD-L2 or CTLA-4, LAG-3, OX40, 41BB, LIGHT, CD40, GITR, TGF-beta, TIM-3, SIRP-alpha, TIGIT, VSIG8, BTLA, SIGLEC7, SIGLEC9, ICOS, B7H3, B7H4, FAS, BTNL2, CD27 and ligand Fas. In other embodiments, the modulator of the bispecific antibodies is an activator a costimulatory molecule (e.g., an OX40 agonist). In one embodiment, the OX40 agonist is is a bispecific antibody molecule to OX40 and another tumor antigen or costimulatory antigen. The OX40 agonist can be administered alone or in combination with other immunomodulators, for example, in combination with an inhibitor (antibody design) of PD-1, PD-L1, CTLA-4, CEACAM (e.g., CEACAM-1, -3 and / or -5), TIM-3 or LAG-3. In some embodiments, the molecule Antibody against OX40 is a bispecific antibody that binds to GITR and PD-1, PD-L1, CTLA- 4, CEACAM (e.g., CEACAM-1, -3 and / or -5), TIM-3 or LAG-3. In one illustrative embodiment In one embodiment, the OX40 antibody molecule is administered in combination with an anti-PD-1 antibody molecule. (e.g., with an anti-PD-1 antibody molecule as described herein). Antibody molecule OX40 and the anti-PD-1 antibody molecule may be in the form of a separate antibody composition or in the form of bispecific antibody molecules. In other embodiments, the OX40 agonist can be administered in combinations with another costimulatory molecule, e.g., GITR, CD2, CD27, CD28, CDS agonist, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand. In some embodiments, the second the antigen-binding fragment binds to an Fc receptor on a cytotoxic immune cell, e.g., CIK cell. In some embodiments, the bispecific antibody-based immunotherapeutic agent has specificity to tumor antigen and CIK cell, which approximates tumor cell expressing tumor antigen, to the CIK cell, which leads to the elimination of the tumor cell due to antitumor cytotoxicity of CIK cells. In some embodiments, the bispecific antibody has specificity for tumor antigen, but lacks specificity for CIK cells, however, the Fc region of the bispecific antibody can bind to the Fc receptor of the CIK cell, which, in turn, in turn, leads to the formation of a tumor cell in close proximity to the CIK cell, which leads to the destruction of the tumor cell due to the antitumor cytotoxicity of the CIK cell. In In some embodiments, the bispecific antibody has specificity for CIK cells but does not have specificity to the tumor cell, however, the Fc region of the bispecific antibody can bind to the Fc- tumor cell receptor, which, in turn, brings the tumor cell closer to the CIK cell, which leads to tumor cell elimination due to the antitumor cytotoxicity of the CIK cell. In some embodiments, the crystalline salt form of Compound 1 can be used in combinations with polyvalent antibody / fusion protein / engineered immunotherapeutic agent, that interacts with immune cells. In various embodiments, an illustrative immunotherapeutic the agent may include a polyvalent antibody / fusion protein / construct that interacts with immune cells that may contain a recombinant structure, for example, all engineered antibodies that are not mimic the original structure of IgG. In this case, different multimerization strategies are used antibody fragments. For example, shortening the peptide linker between the V-domains leads to self-association of scFv into a dimer (diabody; 55 kDa). Bispecific diabodies are formed by non-covalent by the association of two fragments VHA-VLB and VHB-VLA expressed in the same cell. This results in the formation of a heterodimer with two different binding sites. Single-chain dibodies (sc-diabody) are bispecific molecules in which the VHA-VLB and VHB-VLA fragments are linked with each other by an additional third linker. Tandem dibodies (Tandabs) are tetravalent bispecific antibodies that are generated by two sc-diabodies. Also included are di-diathyls, known in the art. This 130 kDa molecule is formed by fusing a dithiol to the N-terminus of the CH3 domain of IgG, resulting in the formation of an IgG-like structures. Other derivatives of diethyl are triethyl and tetraethyl, which are folded into trimer and tetramer fragments by shortening the linker to less than 5 or 0-2 residues. Also presented are constructs (scFv)2, known as "bispecific T-cell capture" (BITE). BITE are bispecific single-chain antibodies consisting of two scFv antibody fragments connected by a flexible linker, which are directed against surface antigen on target cells and CD3 on T cells. Also presented in bivalent (Fab)2 and trivalent (Fab)3 antibody formats. Also presented are mini- bodies and trimer bodies derived from scFv. Illustrative constructs suitable for targeting tumor antigens, may include one or more of: dibody, single-chain (sc)-dibody (scFv)2, miniantibodies, minibodies, barnase-barstar, scFv-Fc, sc(Fab)2, trimeric antibody constructs, constructs thiatyl antibodies, trimertyl antibody constructs, trityl antibody constructs, antibody constructs- colabodies, (scFv-TNFa)3, F(ab)3 / DNL. Examples of cytotoxic immune cells include, but are not limited to limited to, CIK cells, T cells, CD8+ T cells, activated T cells, monocytes, natural killer (NK), NK-T cells, lymphokine-activated killer (LAK), macrophages and dendritic cells. In some embodiments, the crystalline salt form of Compound 1 can be used in combinations with a radioconjugated immunotherapeutic agent. In various embodiments, the radioconjugate is a small molecule or a large molecule. (referred to herein as a "cellular targeting agent"), e.g., a polypeptide, an antibody or fragment thereof that is bound or otherwise attached to a radionuclide or multiple radionuclides in such a way that the binding of the radioconjugate to its target (protein or molecule on or within a cancer cell) will lead to the death or morbidity of the specified cancer cell. In various embodiments, the radioconjugate may be a cell-targeting agent, labeled with a radionuclide, or the cell-targeting agent may be bound or otherwise attached to a particle, either a microparticle or a nanoparticle, containing a plurality of radionuclides, in this case, the radionuclides are the same or different. Methods for synthesizing radioconjugates are known in this regions and may include a class of immunoglobulins or antigen-binding portions thereof that are conjugated to toxic radionuclide. In some embodiments, the molecule that binds to cancer cells may be known as a "cell-targeting agent". In the context of this document, an example of a cell-targeting agent is may allow nanoparticles or radionuclide containing the drug to target the specific cell types of interest. Examples of cell-targeted agents include, but are not limited to not limited to, small molecules (e.g. folate, adenosine, purine) and large molecules (e.g., a peptide or antibody) that binds to or targets a tumor-associated antigen. Examples of tumor-associated antigens include, but are not limited to, receptors, alpha and beta 3, aminopeptidase P, alpha-fetoprotein, cancer antigen 125, carcinoembryonic antigen, caveolin-1, chemokine receptors, clusterin, oncofetal antigens, CD20, epithelial tumor antigen, melanoma-associated antigen, Ras, p53, Her2 / Neu, ErbB2, ErbB3, ErbB4, folate receptor, prostate-specific membrane antigen, prostate-specific antigen, purine receptors, radiation-induced cell surface receptor, serpin B3, serpin B4, antigen squamous cell carcinoma, thrombospondin, tumor-associated antigen 4 glycoprotein 72, tyrosinases and tyrosine kinases. In some embodiments, the cell-targeting agent is a folate or folate derivative that specifically binds to folate receptors acid (FR). In some embodiments, the cell-targeting agent is an antibody, a bispecific antibody, a trispecific antibody, or an antigen-binding construct thereof, which specifically binds to a cancer antigen selected from EGFR, HGFR, Her2, Ep-CAM, CD20, CD30, CD33, CD47, CD52, CD133, CEA, gpA33, mucins, TAG-72, CIX, PSMA, folate-binding protein, GD2, GD3, GM2, VEGF. Among others, VEGFR, integrin αVβ3, integrin α5β1, MUC1, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP and tenascin. The use of folate as a targeting agent in a radioconjugate also provides targeting as on tumor cells and on regulatory T (Treg) cells for destruction. It is well known that a large The number of Treg cells suppresses tumor immunity. In particular, Treg cells suppress (foreign and self) reactive T cells without destroying them, through contact-dependent or cytokine secretion (e.g. IL-10, TGF-beta, etc.). FR4 is selectively activated on Treg cells. It has been shown that The antibody blocks FR4-depleted Treg cells and provokes tumor immunity in tumor-bearing mice. Thus Thus, folate-coated PBM nanoparticles carrying a cytotoxic agent will accept FR- expressing cells for their destruction, which are both directly (i.e., the BrCa cell) and indirectly (i.e. breast tumor-associated and peripheral Treg cells) inhibit tumor progression. In another additional embodiment, the targeting agent is an antibody or peptide, or polyvalent antibody / fusion protein / constructs that interact with immune cells are capable of bind tumor-associated antigens consisting of, but not limited to: adenosine receptors, alpha and beta 3, aminopeptidase P, alpha fetoprotein, cancer antigen 125, carcinoembryonic antigen, caveolin-1, chemokine receptors, clusterin, oncofetal antigens, CD20, hepatocyte growth factor receptor (HGFR), epithelial tumor antigen, melanoma-associated antigen, MUC1, Ras, p53, Her2 / Neu, ErbB2, ErbB3, ErbB4, folate receptor, prostate-specific membrane antigen, prostate-specific antigen, purine receptors, radiation-induced cell surface receptor, serpin B3, serpin B4, squamous cell carcinoma antigens, thrombospondin, tumor antigen 4, tumor-associated glycoprotein 72, tyrosinase, tyrosine kinase, etc. In some embodiments, the crystalline salt form of Compound 1 described herein is can be used in combination with a vaccination protocol for the treatment of cancer. In some embodiments In one embodiment, the crystalline salt form of Compound 1 described herein can be used in combinations with an immunotherapeutic agent, such as a vaccine. In various embodiments, illustrative Vaccines include vaccines that are used to stimulate an immune response to cancer antigens. The amount of both the crystalline salt form of Compound 1 disclosed herein and one or more additional therapeutic agents (in those compositions that contain an additional therapeutic agent as described above), which can be combined with auxiliary materials to obtain of a single dosage form will vary depending on the patient being treated. treatment, and the particular route of administration. In some embodiments, the compositions herein according to the invention are formulated in such a way that a dose of 0.01 to 100 mg / kg body weight / day can be administered according to this invention. Additional therapeutic agent and crystalline salt form of Compound 1 disclosed herein document, may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions may be less than the amount required for monotherapy using only this therapeutic agent, or there may be fewer side effects for the patient when using more low dose. In some embodiments, such combinations may be administered at a dose of 0.01 to 10,000 mcg / kg body weight / day of additional therapeutic agent. In some embodiments, the crystalline salt forms of Compound 1 disclosed herein are can be combined with one or more inhibitors of such kinases to treat the disease, disclosed herein, such as cancer: Akt1, Akt2, Akt3, TGF-βR, PKA, PKG, PKC, CaM kinase, kinase phosphorylases, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, 1NS-R, IGF-1R, IR-R, PDGFαR, PDGFβ / R, CSFIR, KIT, FLK-II, KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR / Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYR, FRK, JAK, ABL, ALK, CDK7, CDK12, CDK13, KRAS and B-Raf. In some embodiments, crystalline forms or salt forms of Compound 1 disclosed herein can be combined with one or more inhibitors of the CD47 and MALT1 proteins for the treatment of cancer. In some embodiments, the crystalline salt forms of Compound 1 disclosed herein are can be used in combination with one or more poly-ADP-ribose polymerase inhibitors (PARP) for the treatment of a disease disclosed herein, such as cancer. Illustrative Inhibitors PARPs include, but are not limited to, olaparib (Lynparza®), rucaparib (Rubraca®), niraparib (Zejula®), talzoparib (Talzenna®), and TPST-1120. In some embodiments, the crystalline salt forms of Compound 1 disclosed herein are can be used in combination therapy with any of the kinase inhibitors disclosed herein document, for the treatment of diseases such as cancer. Illustrative kinase inhibitors include imatinib, baricitinib, gefitinib, erlotinib, sorafenib, dasatinib, sunitinib, lapatinib, nilotinib, pirfenidone, zanubrutinib, upadacitinib, fedratinib, entrectinib, alpelisib, pazopanib, crizotinib, vemurafenib, vandetanib, ruxolitinib, axitinib, bosutinib, regorafenib, tofacitinib, cabozantinib, ponatinib, trametinib, dabrafenib, afatinib, ibrutinib, ceritinib, idelalisib, nintedanib, palbociclib, lenvatinib, cobimetinib, abemaciclib, acalabrutinib, alectinib, binimetinib, brigatinib, encorafenib, erdafitinib, everolimus, fostamatinib, gilter, larotrectinib, lorlatinib, netarsudil, osimertinib, pexidartinib, ribociclib, temsirolimus, XL-147, XL-765, XL-499, and XL-880. In some embodiments In one embodiment, a compound described herein can be used in combination with an HSP90 inhibitor. (e.g., XL888), hepatic X receptor (LXR) modulators, retinoid-associated orphan receptor gamma (RORγ), CK1 inhibitor, CK1-α inhibitor, Wnt pathway inhibitor (e.g., SST-215) or a mineralocorticoid receptor inhibitor (e.g., ezaxerenone or XL-550) for the treatment of a disease described herein, such as cancer. In some embodiments, the crystalline salt forms of Compound 1 disclosed herein are can be used in combination with polatuzumab vedotin to treat the disease, disclosed herein, such as cancer. Labeled compounds and analysis methods Another aspect relates to a labeled crystalline salt form of Compound 1 (radiolabeled, fluorescently labeled, etc.), suitable not only in visualization methods, but also in analyses, such as in vitro, both in vivo, for localization and quantification of TAM kinases in tissue samples, including human, and for the identification of TAM kinase ligands by inhibiting the binding of a labeled compound. Accordingly, This invention includes TAM kinase assays that contain such labeled compounds. This invention also includes isotopically labeled crystalline salt forms of Compound 1. "Isotopically" or A "radiolabeled" compound is a crystalline salt form of Compound 1 in which one or more atoms are substituted or replaced by an atom having an atomic mass or mass number different from atomic mass or mass number that is commonly found in nature (i.e., naturally occurring Suitable radionuclides that can be incorporated into the compounds of this invention include: include, but are not limited to: 2H (also denoted as D for deuterium), 3H (also denoted as T for tritium), 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 18F, 35S, 36Cl, 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I and 131I. The radionuclide incorporated into these radiolabeled compounds will depend on the specific application. of this radiolabeled compound. For example, for labeling metalloproteases and competitive In vitro assays, compounds that include 3H, 14C, 82Br, 125I, 131I will usually be most suitable. or 35S. For radioimaging applications, 11C, 18F, will usually be the most useful. 125I, 123I, 124I, 131I, 75Br, 76Br or 77Br. In some embodiments, the crystalline forms or crystalline salt forms described herein in which one or more hydrogens are replaced by deuterium, for example, hydrogen bonded to a carbon atom. Such compounds exhibit increased resistance to metabolism and thus are useful for increasing the half-life of any compound when administered to a mammal, especially a human. It is understood that a "radiolabeled" or "labeled" compound is a compound that contains at least one radionuclide. In some embodiments, the radionuclide is selected from the group consisting of consists of 3H, 14C, 125I, 35S and 82Br. This invention may further include methods for synthesizing the incorporation of radioisotopes into crystalline salt forms Compounds 1. Methods of synthesis of radioisotopes incorporation into organic compounds are well known in in this field, and one skilled in the art will readily recognize methods applicable to the compounds of the invention. The labeled crystalline salt form of Compound 1 can be used in a screening assay for identification / evaluation of compounds. For example, a newly synthesized or identified compound (i.e. test compound) that is labeled can be evaluated for its ability to bind TAM by monitoring the change in its concentration upon contact with TAM kinases, by tracking the labeling. For example, the investigated a compound (labeled) can be evaluated for its ability to reduce the binding of another compound, which, as known to bind to TAM kinase (i.e., the standard compound). Accordingly, the ability of the tested compounds compete with the standard compound for binding to TAM kinase directly correlates with its binding affinity. Conversely, in some other screening assays for a standard compound labeled, and the test compounds do not contain a label. Accordingly, according to the concentration of the labeled of the standard compound is observed in order to assess the competition between the standard compound and the test compound and, thus, determine the relative binding capacity of the test compound compounds. PREPARATION AND EXAMPLES General experimental techniques Aqueous suspension experiments: salts of Compound 1, which are determined to have solubility in water less than 1 mg / ml, suspended in 20 ml of water at ambient temperature for 1 The solids were then collected by vacuum filtration and analyzed by RPD. Quenching (CC): Concentrated solutions of Compound 1 and various counterions were prepared in MeOH at elevated temperature with stirring. Closed vials containing hot solutions, transferred to a freezer (~ -20 °C) and cooled rapidly. The solids formed In the absence of solids, additional crystallization methods were used. Precipitation (CP): Clear solutions of Compound 1 and coformer were obtained in different solvents at RT. Aliquots of different antisolvents were added to the solution, slowly, with gentle mixing. until the solids precipitated out of solution. The mixtures were left to mix for the specified time. The solids formed were collected by filtration under excessive pressure. Fast cooling (FC): concentrated solutions of Compound 1 and various counterions were prepared in acetone or MeOH at elevated temperature with stirring. Closed vials containing hot solutions were transferred to the work surface at ambient temperature. The formed solids were collected. In the absence of solids, additional methods were used crystallization. Fast evaporation (FE): clear solutions of Compound 1 and coformer were obtained at different The vials were left uncapped and the solvent was evaporated under ambient conditions. environment. Interconversion suspension: A suspension of Form A of Compound 1 was prepared by adding sufficient amount of solids into the given solvent system under ambient conditions medium, so that undissolved solids were present. The mixture was then stirred for additional time to ensure saturation. Then the solids of the forms of interest are was added to an aliquot of the saturated solution (filtered through a 0.2-μm nylon filter), so that undissolved solids were present. The mixture was then stirred at room temperature environment for additional time, and solids were isolated. Isolation methods: Typically, isolation was performed quickly after removing samples from temperature that does not match the ambient temperature, from appropriate temperature control devices for minimizing equilibration with ambient temperature before release solids. Decantation of the liquid phase: some solids isolated by crystallization methods on based on solutions, were collected by centrifuging the suspension (if necessary) and removing the liquid phase, leaving wet solids. The solids were dried quickly (e.g., dried on air or in a nitrogen atmosphere), unless otherwise specified in this document as "analyzed wet". Overpressure filtration: solids were collected on 0.2-μm nylon or PTFE filters by forcing the suspension through a syringe and a Swinnex filter holder assembly. Typically The solids were quickly dried by blowing air through the filter with a 20-ml syringe. If this document states "analyzed wet", the solids remained wet from Before analysis, some samples were additionally quickly dried in a weak stream gaseous nitrogen. Vacuum filtration: solids were collected on paper or nylon filters by vacuum filtration and quickly air-dried on filters under reduced pressure before transfer to bottle. Reactive crystallization (RC): a mixture of Compound 1 and various coformers was combined in a suspension of acetone at elevated temperature, so that the molarity of the coformer was 2 times higher than the API. The solution was stirred for the specified time. If clear solutions were observed, additional crystallization methods. Stability testing: various salts of Compound 1 were placed in open vials in a chamber with a relative humidity of 75% (saturated sodium chloride solution). The chamber with the indicated BB was placed in an oven at 40 °C for 15-16 days. Samples were analyzed for PLM and RPD after the expiration date. Slow cooling (SC): concentrated solutions of Compound 1 and various coformers were prepared in in various solvents at elevated temperatures with stirring. The vials were closed in a block for of heated samples and turned off the hot plate, ensuring gradual cooling of the vials to ambient temperature in the heated vial block. Clear solutions after cooling to room temperature, further cooled in the refrigerator (5 to 7 °C) and / or in a freezer (~-20 °C). In the absence of solids, additional crystallization methods. Slow evaporation: solutions were obtained in various solvents with stirring and, usually, filtered through a 0.2-μm nylon or PTFE filter. Each solution was allowed to evaporate from covered bottle (e.g. loosely closed or covered with perforated aluminum foil) foil) under ambient conditions unless otherwise stated. Solutions were left evaporate to dryness unless indicated as partial evaporation (solid present in a small amount of solvent remaining), in which case the solids were isolated as described in this document. Solubility assessment: aliquots of different solvents were added to measured amounts of Compound 1 at stirring (usually with the use of ultrasound) at the specified temperatures until reaching complete dissolution by visual observation. If dissolution occurred after addition of the first aliquot, values are indicated as ">". If dissolution did not occur, values indicated as "<". Assessment of water solubility: aliquots of water were added to measured amounts of various salts of Compound 1 during ultrasound treatment. Suspension experiments: saturated solutions of Compound 1 and various coformers were prepared in different solvents and solvent mixtures. The mixtures were stirred at ambient temperature and elevated temperatures for the indicated period of time. The solids were collected at the indicated method and, if necessary, additional crystallization methods were used. Solvent removal in a vacuum oven: salts of Compound 1, which were determined to be solvates of various analytical methods, were subjected to a desolvation attempt. The samples were placed in a vacuum oven at temperatures ranging from ambient temperature to 80 °C for a certain period time. Samples were analyzed by RPD and / or TGA to determine the success of desolvation. Vapor diffusion: concentrated solutions were prepared in various solvents and usually filtered through a 0.2-μm nylon or PTFE filter. The filtered solution was dispensed into a small vial, which was then placed inside a larger vial containing the anti-solvent. Small vial was left uncovered, and the larger vial was capped to allow vapor diffusion. Any solids were isolated as described herein. Vapor pressure: The selected solids were transferred to a small vial, which was then placed into a larger vial containing the solvent. The small vial was left uncapped, and the larger vial was capped to maintain vapor pressure at the specified temperature. Coformer means one or more pharmaceutically acceptable bases and / or pharmaceutically acceptable acceptable acids disclosed herein in association with Compound 1. In the context of this document illustrative coformers include benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, HBr, lactic acid, malic acid, maleic acid, methanesulfonic acid, oxalic acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, and toluenesulfonic acid. Instrumental techniques Differential scanning calorimetry (DSC): DSC was performed using Differential Scanning Calorimeter Mettler-Toledo DSC3+ Temperature Calibration was carried out using adamantane, phenylsalicylate, indium, tin and zinc. The sample was placed in hermetically sealed or open aluminum crucible for DSC and the weight was accurately recorded. A weighed aluminum crucible, shaped like a sample crucible, was placed on the reference side of the cell. The samples were analyzed at temperatures from -30 to 250 °C with an increasing rate of 10 °C / min. Despite the fact that the thermograms are plotted against the reference temperature (x-axis), the results are presented according to sample temperatures. Dynamic Vapor Sorption (DVS) a. VTI: Automatic Vapor Sorption (VSO) data is collected on a VTI SGA-100 Vapor Sorption Analyzer. NaCl and PVP were used as calibration standards. Samples were dried before analysis. Data sorption and desorption were collected at relative humidity ranging from 5% to 95% in 10% increments during nitrogen purging. The equilibrium criterion used for the analysis was a weight change of less than 0.0100% in 5 minutes with a maximum equilibration time of 3 hours. Data not corrected for baseline humidity of the samples. b. Intrinsic: Automatic vapor sorption (AVS) data were obtained on a Surface Measurement instrument System DVS Intrinsic. Samples were not dried before analysis. Sorption and desorption data were collected at relative humidity in the range from 5% to 95% in 10% increments while purging with nitrogen. Criterion The equilibrium value used for the analysis was a weight change of less than 0.0100% in 5 minutes from with a maximum equilibration time of 3 hours. The data were not corrected for the initial moisture content of the samples. High-temperature microscopy (HSM): High-temperature microscopy was performed with using a Linkam heating stage (FTIR 600) mounted on a Leica DM LP microscope, equipped with a SPOT Insight™ color digital camera. Temperature calibration was performed with using USP melting point standards. Samples were placed on a coverslip, and a second coverslip was The glass was placed on top of the sample. As the stage heated, each sample was visually observed for using a 20x objective using crossed polarizers and a red compensator first order. Images were obtained using SPOT software (version 4.5.9). Optical microscopy: samples were observed under a Motic or Wolfe optical microscope with crossed polarizers or under a Leica stereomicroscope with a first-order red compensator with crossed polarizers. pKa and logP determination: pKa and logP determinations were performed using Pion Inc. / Sirius Analytical Instruments Ltd. in East Sussex, United Kingdom. Solution proton nuclear magnetic resonance (1H NMR) spectroscopy: 1H NMR spectrum solution was obtained using Spectral Data Services of Champaign, IL. Samples were prepared by dissolving approximately 5-10 mg of sample in DMSO-d6. Data processing parameters are displayed on on the first page of each spectrum in the "Data" section of this report. Thermogravimetric analysis (TGA): Thermogravimetric analyses were performed using Mettler Toledo TGA / DSC3+ analyzer. Temperature calibration was performed using phenylsalicylate, indium, tin and zinc. The sample was placed in an aluminum crucible. Open crucible were inserted into the TG oven. The oven was heated in a nitrogen atmosphere. Each sample was heated from a temperature ambient temperature up to 350 °C with a temperature change rate of 2, 5 or 10 °C / min. Although thermograms are plotted using the reference temperature (x-axis), the results are presented according to sample temperature. X-ray powder diffraction (XPD) a. Display: X-ray diffraction patterns were obtained using a PANalytical X'Pert diffractometer PRO MPD using an incident Cu Kα radiation beam obtained using long-focus source and nickel filter at room temperature (298 Kelvin). The diffractometer is set up using a symmetrical Bragg-Brentano geometry. Before analysis a silicon sample (NIST SRM 640e) was analyzed to verify that the observed The position of the Si 111 peak corresponds to the position certified by NIST. A sample of the sample was placed in the well. Anti-scattering slits (SS) were used to minimize the background created by air. Soller slits for the incident and diffracted rays were used to minimize expansion due to axial divergence. The diffraction patterns were obtained using a scanning a position-sensitive detector (X'Celerator) located at a distance of 240 mm from the sample, and Data Collector software v. 2.2b. Data processing parameters for each diffractometer displayed above the image in the "Data" section of this report, including the divergence gap (DS) and incident beam SS. b. Transmission: X-ray diffraction patterns were obtained using a PANalytical X'Pert diffractometer PRO MPD using an incident Cu radiation beam obtained using Optix long-focus source at room temperature (298 Kelvin). Elliptically graduated a multilayer mirror was used to focus Cu Kα X-rays through sample and to the detector. Before analysis, a silicon sample (NIST SRM 640e) was analyzed to verify that the observed position of the Si 111 peak corresponds to the position certified NIST. The sample was placed between 3 μm thick films and analyzed in transmission geometry. For To minimize the background created by air, a beam limiter, a short extension cable, and cutting edge, which prevent scattering. Soller slits for incident and diffracted light beams were used to minimize broadening due to axial divergence. Diffraction patterns were obtained using a scanning position-sensitive detector (X'Celerator) located at a distance of 240 mm from the sample, and Data Collector software v. 2.2b. Processing parameters data for each diffractogram are displayed above the image in the "Data" section of this report, including the divergence slit (DS) in front of the mirror. Indexing of RPD Indexing and structure refinement are computational studies. Within the figure, which for this indexed RPD diffractogram, the correspondence between the allowed peak positions, indicated by the dashes, and the peaks observed indicate the proper choice of elementary cells. Successful indexing of the diffractogram indicates that the sample consists mainly of single-crystalline phase unless otherwise specified. Space groups that correspond to the designated The extinction symbol, unit cell parameters, and derived quantities are given in the tables. Examples Preparative Example 1: Synthesis of Compound 1 STEP 1: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide (4) N H OH O.O. F NH 2 OH N H N H O.O. Front Office 2 3 EDCl 4 To a solution of Compound 2 (10 g, 44.80 mmol, 1 equiv.) and Compound 3 (5.87 g, 53.8 mmol, 1.2 equiv.) in 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine was added to dimethylacetamide (DMA) (60 ml) hydrochloride (EDCI) (10.31 g, 53.8 mmol, 1.2 equiv.). The mixture was stirred vigorously at 20 °C until completion of the reaction. The mixture was poured into aqueous (aq.) saturated NaHCO3 (400 mL) and extracted EtOAc (4×100 mL). The combined organic phases were washed with aq. saturated NaCl (100 mL), dried over anhydrous (anhydrous) Na2SO4 and concentrated. Compound 4 (21 g, crude) (50% yield) was obtained. purity), 1H NMR (400 MHz, DMSO-d6) δ 10.16 (br s, 1H), 9.72 (br s, 1H), 7.61 (dd, 2H), 7.34 (d, 2H), 7.13 (t, 2H) 6.68 (d, 2H), 1.42 (s, 4H); MS (EI) for C17H15FN2O3, found 314.9 (MH+). STEP 2: Methyl 4-[4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-7- Methoxyquinoline-6-carboxylate (6): N H N H O.O. Front Office N H About N H About FO N About About About Cl N About About About 4 5 Pd(OAc)2 TrixiePhos, Anisole, 110 °C 6 A mixture of Compound 4 (5.99 g, 9.5 mmol, 1.2 equiv.), Compound 5 (2 g, 8.0 mmol, 1.0 equiv.), Pd(OAc)2 (89 mg, 397.4 μmol, 0.05 equiv.), rac-2-(Di-tert-butylphosphino)-1,1′-binaphthyl (TrixiePhos, 316.71 mg, 794.7 μmol, 0.1 equiv.), and K3PO4 (2.53 g, 11.9 mmol, 1.5 equiv.) in anisole (50 mL) were stirred at 110 °C. for 2 hours (hrs) under nitrogen. The mixture was filtered and the filtrate was concentrated. The residue was purified by flash chromatography on silica gel (1:1 petroleum ether: EtOAc to 20:1 EtOAc: MeOH). Compound 6 was obtained (2.6 g, yield 61.8%), 1H NMR (400 MHz, CDCl3) δ 9.38 (s, 1H), 8.80 (s, 1H), 8.63 (d, 2H), 7.64 (d, 2H), 7.54-7.41 (m, 3H), 7.18 (d, 2H), 7.09-7.01 (m, 2H), 6.43 (d, 1H), 4.05 (s, 3H), 3.97 (s, 3H), 1.78-1.72 (m, 2H), 1.69-1.63 (m, 2H); MS (EI) for C29H24FN3O6, found 530.0 (MH+). STEP 3: 4-[4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-7-methoxyquinoline- 6-carboxylic acid (7) N H About N H About FO N NO About About N H About N H About FO N About About About 76 aq. NaOH THF / MeOH To a solution of Compound 6 (1.8 g, 3.4 mmol, 1 equiv.) in tetrahydrofuran (THF) (15 mL) and MeOH (15 mL) 2 M aqueous NaOH (7 mL, 4.1 equiv) was added. The mixture was stirred at 6-13 °C for 4 hours. The mixture was adjusted to pH approximately 8 with 1 M aqueous HCl and concentrated to remove Water (50 ml) was added, the mixture was adjusted to pH approximately 6 with 1 M aqueous HCl. The resulting precipitate was filtered, washed with water (2 × 10 mL) and dried in vacuo. Obtained Compound 7 (1.7 g, yield 97.0%), 1H NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1H), 10.08 (s, 1H), 8.65 (d, 1H), 8.48 (s, 1H), 7.77 (d, 2H), 7.64 (dd, 2H) 7.47 (s, 1H), 7.25 (d, 2H), 7.15 (t, 2H), 6.45 (d, 1H), 3.96 (s, 3H), 1.47 (s, 4H); MS (EI) for C28H22FN3O6, found 516.1 (MH+). STEP 4: 1-N'-(4-Fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4- yl]oxyphenyl]cyclopropane-1,1-dicarboxamide (1) N H About N H About FO N N H About About N H About N H About FO N OH About About 17 MeNH2 .HCl HATU DIEA DMF A solution of Compound 7 (300 mg, 582.0 μmol, 1 equiv.), HATU (332 mg, 873.2 μmol, 1.5 equiv.) and DIEA (301 mg, 2.3 mmol, 406 μL, 4 equiv.) in DMF (10 mL) was stirred at 6-10 °C for 1 h. Methanamine hydrochloride (79 mg, 1.2 mmol, 2.0 equiv.) was added, and the mixture was stirred at 6-10 °C. for 17 hours. The mixture was filtered and the resulting filtrate was purified by preparative HPLC (column: Waters Xbridge 150 mm*25 mm*5 μm, gradient: 33-63% acetonitrile in 10 mM aqueous NH4HCO3, flow rate: 25 mL / min.) Compound 1 was obtained (105.4 mg, yield 34.3%), 1H NMR (400 MHz, DMSO- d6) δ 10.20 (s, 1H), 10.06 (s, 1H), 8.65 (d, 1H), 8.61 (s, 1H), 8.42-8.33 (m, 1H), 7.77 (d, 2H), 7.68-7.61 (m, 2H), 7.51 (s, 1H), 7.25 (d, 2H), 7.19-7.11 (m, 2H), 6.46 (d, 1H), 4.02 (s, 3H), 2.84 (d, 3H) 1.47 (s, 4H); MS (EI) for C29H25FN4O5, found value 529.1 (MH+) Example 1: Preparation of Form A of the besylate of Compound 1 To Compound 1 was added one molar equivalent of benzenesulfonic acid in hot acetone. The resulting suspension was then stirred at ~50 °C for 3 days. The solids were collected filtration under excessive pressure. Example 2: Preparation of Form B of the besylate of Compound 1 Form A of the besylate of Compound 1 was placed under vacuum at 80 °C for 1 day to obtain a mixture of Form A Compound 1 besylate and Compound 1 besylate Form B. Example 3: Preparation of Form A Benzoate of Compound 1 Hot methanol was added to one molar equivalent of benzoic acid and Compound 1. The resulting solution was stirred at ~60 °C for 20 minutes. Then the solution was rapidly cooled to -20 °C and left for 1 day. The solids were filtered by vacuum filtration. Example 4: Preparation of Form A of the Camsylate of Compound 1 To Compound 1 was added one molar equivalent of camphorsulfonic acid in hot acetone. The resulting solution was then stirred at ~50 °C for 3 days. The solids were collected filtration under excessive pressure. Example 5: Preparation of Form B of the camsylate of Compound 1 Form A of the camsylate of Compound 1 was placed in vacuum at 80 °C for 1 day to obtain Form B. Camsylate Compounds 1. Example 6: Preparation of Form A of the Citrate of Compound 1 One molar equivalent of citric acid in acetone was added to compound 1. Then the resulting The solution was stirred at ~50 °C for 4 days. The mixture was then slowly cooled to room temperature. temperature for 2 hours, 3 ml of acetone was added and the solution was stirred for an additional days at room temperature. The solids were collected by filtration under excessive pressure. Example 7: Preparation of Form B Citrate of Compound 1 Two molar equivalents of citric acid in acetone were added to Compound 1. The resulting The solution was stirred at ~50 °C for 6 days. The solids were collected by hot filtration. solution under excessive pressure. Example 8: Preparation of Form A of the Esylate of Compound 1 To Compound 1 was added one molar equivalent of ethanesulfonic acid in hot acetone. The resulting solution was then stirred at ~50 °C for 3 days. The solids were collected filtration under excessive pressure. Example 9: Preparation of the B-esylate Form of Compound 1 Form A of the esylate of Compound 1 was placed in vacuum at 80 °C for 1 day to obtain Form B. Compound 1 esylate. Example 10: Preparation of HBr Form A of Compound 1 To a suspension of Compound 1 in hot acetone was added one molar equivalent of hydrogen bromide. acid. The resulting solution was then stirred at ~50 °C for 3 days. The solids were collected filtration under excessive pressure. Example 11: Preparation of HBr Form B of Compound 1 To the suspension of Compound 1 in hot MEK was added one molar equivalent of hydrogen bromide. acid. The resulting solution was then stirred at ~55 °C for 1 day. The solution was then slowly cooled. Example 12: Preparation of Form A Lactate of Compound 1 To a suspension of Compound 1 in hot acetone was added one molar equivalent of lactic acid. The resulting solution was then stirred at ~50 °C for 3 days. The solids were collected filtration under excessive pressure. Example 13A: Preparation of Form A malate of Compound 1 One molar equivalent of malic acid in acetone was added to Compound 1. The resulting solution stirred at ~50 °C for 4 days, slowly cooled to room temperature over 2 hours, diluted with 3 ml of acetone and stirred at room temperature for 1 day. Solid The substances were collected by filtration under excessive pressure. Example 13B: Preparation of Form A malate of Compound 1 Two molar equivalents of malic acid in acetone were added to Compound 1. The resulting The solution was stirred at ~50 °C for 6 days. The solids were collected by hot filtration. solution under excessive pressure. Example 14A: Preparation of Form A Maleate of Compound 1 One molar equivalent of an aqueous solution of maleic acid was added to a suspension of Compound 1 in MEK to obtain a water / MEK solution of 1:7. The resulting solution was then stirred at ~55 °C for 5 minutes to 1 day, slowly cooled and the solvent was partially evaporated (FE). Example 14B: Preparation of Form A Maleate of Compound 1 Two molar equivalents of maleic acid in hot acetone were added to Compound 1. Then The solution was stirred at ~50 °C for 1 day, and then the solution was rapidly cooled to room temperature. temperature. The solids were collected by filtration of the hot solution under excessive pressure. Example 15: Preparation of Form B Maleate of Compound 1 (enlarged scale) Two molar equivalents of maleic acid and Compound 1 were suspended in in hot acetone at ~50 °C with seed crystals for 2 days. The solids were collected by vacuum filtration to obtain a mixture of forms A and B of the maleate of Compound 1. Example 16: Preparation of Form A of the Mesylate of Compound 1 To a suspension of Compound 1 in THF was added one molar equivalent of methanesulfonic acid. at room temperature. The suspension was stirred at room temperature for 3 days and solids The substances were collected by filtration under excessive pressure. Example 17: Preparation of Form B of the Mesylate of Compound 1 To a suspension of Compound 1 in chloroform was added one molar equivalent of methanesulfonic acid. acid. The suspension was then stirred at ~50 °C for 3 days. The solution was then slowly cooled to room temperature. Heptane was added so that the final solution had The ratio of chloroform to heptane was about 8:1 and the solution was stirred for 5 hours. The solids The substances were collected by filtration under excessive pressure. Example 18: Preparation of Form C Mesylate of Compound 1 One molar equivalent of methanesulfonic acid was added to a solution of Compound 1 in methanol. at ~60 °C. The solution was then rapidly cooled to -20 °C and left to stand for 2 days. Solvent partially evaporated and MTBE was added so that the final solution had a methanol to MTBE ratio of about 2:5, and the solution was stirred for 5 hours. The solids were collected by filtration at excessive pressure. Example 19: Preparation of Form A of Oxalate of Compound 1 To Compound 1 was added one molar equivalent of oxalic acid in hot acetone. The resulting solution was then stirred at ~50 °C for 3 minutes. The solids were collected filtration under excessive pressure. Example 20: Preparation of Form B Oxalate of Compound 1 One molar equivalent of an aqueous solution of oxalic acid at 55 °C was added to the suspension Compound 1 in MEK, resulting in a water / MEK solution of 1:7. The resulting solution was stirred at ~55 °C for 1 day, slowly cooled and the solvent was partially evaporated (FE). Example 21: Preparation of Form C Oxalate of Compound 1 One molar equivalent of oxalic acid TFE was added to Compound 1 at 55 °C. The resulting The solution was then slowly cooled to room temperature over 1 day, placed in refrigerator at 2-8 °C for 2 hours, and then placed in a freezer at -20 °C for 6 days. Then the solution was precipitated sharply with 1 volume of MTBE, stirred at room temperature for 1 day and filtered under excess pressure. Example 22: Preparation of Form A of the Propionate of Compound 1 One molar equivalent of propionic acid was added to Compound 1 in hot acetone. Then The resulting solution was stirred at ~50 °C for 3 days. The solids were collected by filtration. under excessive pressure. Example 23A: Preparation of Form A of the Succinate of Compound 1 One molar equivalent of succinic acid was added to Compound 1 in acetone. The resulting The solution was then stirred at ~50 °C for 4 days, then slowly cooled to room temperature. temperature and stirred for another day. The solids were collected by filtration under excessive pressure. Example 23B: Preparation of Form A of the Succinate of Compound 1 Two molar equivalents of succinic acid were added to Compound 1 in acetone. The resulting The solution was stirred at ~50 °C for 6 days. The solids were collected by filtration at excessive pressure. Example 24: Preparation of Form A of the Sulfate of Compound 1 One molar equivalent of sulfuric acid was added to a suspension of Compound 1 in THF. Then The resulting solution was stirred at room temperature for 3 days. The solids were collected filtration under excessive pressure. Example 25: Preparation of Form B of the sulfate of Compound 1 One molar equivalent of sulfuric acid was added to Compound 1 in methanol at ~60 °C. Then the resulting solution was rapidly cooled to -20 °C and left to stand for 2 days. Then the solvent was evaporated (FE) to give the title form. Example 26: Preparation of Form C of the Sulfate of Compound 1 One molar equivalent of sulfuric acid was added to Compound 1 in chloroform and the resulting The solution was stirred at ~50 °C for 3 days. The resulting solution was then slowly cooled to room temperature and allowed to settle for 1 day. The solids were collected by filtration at excessive pressure. Example 27: Preparation of Form A Tartrate of Compound 1 One molar equivalent of L-tartaric acid was added to Compound 1 in THF, and the resulting solution was stirred at room temperature for 3 days. The solids were collected by filtration at excessive pressure. Example 28: Preparation of Form B of Hemitartrate of Compound 1 One molar equivalent of L-tartaric acid was added to Compound 1 in acetone and the resulting solution was stirred at ~50 °C for 34 days. The resulting solution was then slowly cooled to room temperature and allowed to settle for 1 day. The solids were collected by filtration at excessive pressure. Example 29: Preparation of Form A tosylate of Compound 1 To Compound 1 in acetone was added one molar equivalent of p-toluenesulfonic acid and The resulting solution was stirred at ~50 °C for 3 days. The solids were collected by filtration. under excessive pressure. Example 30: Preparation of Form B of the tosylate of Compound 1 (in enlarged scale) To Compound 1 in acetone at a temperature of ~50 °C was added one molar equivalent of p-toluenesulfonic acid in hot acetone. Then the seed was added crystals, and the resulting solution was stirred at ~50 °C for 2 days. Other implementation options The above disclosure has been described in more detail by way of illustration and example from for the purpose of clarity and understanding. The invention has been described with reference to various specific and preferred embodiments. embodiments and methods. However, it should be understood that many changes and modifications while remaining within the spirit and scope of the invention. It will be apparent to one skilled in the art It is obvious that changes and modifications can be made within the scope of the attached formula. invention. It should therefore be understood that the above description is intended to be illustrative and not exhaustive. limitation. Thus, the scope of the invention should be determined not by reference to the above description, but by by reference to the appended claims below, together with the full scope of equivalents, to which it gives the right.
Claims
1. Crystalline salt form of Compound 1 N H About N H About FO N N H About About , Compound 1 selected from the group consisting of Compound 1 besylate form A, compound 1 camsylate form A Compound 1, camsylate form B Compound 1, citrate form B Compound 1, esylate form A Compounds 1, HBr-form B Compounds 1, maleate form A Compounds 1, mesylate form A Compounds 1, mesylate form B Compounds 1, mesylate form C Compounds 1, oxalate form A Compound 1, oxalate form B Compound 1, oxalate form C Compound 1, sulfate form A Compounds 1, sulfate form B Compounds 1, sulfate form C Compounds 1, sulfate form B Compound 1 hemitartrate, Compound 1 tosylate form A, and Compound 1 tosylate form B, where Form A of the besylate of Compound 1 is characterized by X-ray powder diffraction diffractogram (DPR) including all the following peaks: 3.78, 7.56, 10.42, 20.51, 20.94, 21.60 and 25.30 degrees 2θ (± 0.20 degrees); Form A of the camsylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 5.55, 9.87, 10.26, 16.16, 16.82, 20.87, 22.36, and 23.71 degrees 2θ (±0.20 degrees); Form B of the camsylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 5.25, 10.52, 16.15, 21.13, 21.56, and 21.89 degrees 2θ (±0.20 degrees); Form B of the citrate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.58, 5.95, 8.88, 11.93, 13.79, 14.29, 16.64, 18.90, 21.47, 23.80, 24.25 and 25.85 degrees 2θ (±0.20 degrees); Form A of the esylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 3.97, 7.95, 9.89, 10.62, 13.27, 15.08, 16.17, 16.92, 17.01, 20.65, 20.78, 21.44, 22.08, 23.99, 25.43 and 26.52 degrees 2θ (±0.20 degrees); HBr-form B of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 5.26, 9.91, 10.72, 20.55, 20.69, 21.18, 22.09, 23.24, 24.56 and 25.80 degrees 2θ (±0.20 degrees); Form A of the maleate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 10.92, 15.13, 15.78, 16.43, 18.09, 18.71, 20.30, 21.99, 22.30, 22.49, 23.32, 23.56, 24.79, 26.41, 26.92 and 29.01 degrees 2θ (±0.20 degrees); Form A of the mesylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 5.06, 7.66, 14.79, 15.42, 16.23, 17.20, 17.59, 18.40, 19.33, 19.53, 20.38, 20.73, 21.83, 22.16, 23.14, 24.06 and 24.77 degrees 2θ (±0.20 degrees); Form B of the mesylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 14.61, 15.21, 16.17, 17.18, 17.41, 18.46, 19.13, 19.54, 20.15, 20.53, 20.75, 20.98, 21.27, 21.60, 22.03, 23.32, 24.16, 24.42, 24.87 and 25.13 degrees 2θ (±0.20 degrees); Form C of the mesylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 7.55, 9.53, 11.49, 12.51, 14.44, 19.04, 20.54, 21.12, 21.24 and 23.15 degrees 2θ (±0.20 degrees); Form A of the oxalate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.90, 5.25, 9.87, 10.54, 12.29, 15.35, 18.67, 19.40, 19.81, 20.26, 22.93 and 24.66 degrees 2θ (±0.20 degrees); Form B of the oxalate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.20, 7.59, 10.53, 15.06, 15.23, 19.52, 21.18, 21.43, 22.59, 24.21 and 25.85 degrees 2θ (±0.20 degrees); Form C of the oxalate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 7.70, 10.29, 10.59, 13.09, 13.70, 15.33, 17.83, 18.15, 20.11, 21.07, 21.91 and 22.56 degrees 2θ (±0.20 degrees); Form A of the sulfate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.74, 5.85, 9.47, 10.04, 11.74, 11.95, 16.48, 20.22, and 22.74 degrees 2θ (±0.20 degrees); Form B of the sulfate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.27, 8.57, 9.32, 16.94, 19.99, 21.03, 21.44, 22.00, and 26.02 degrees 2θ (±0.20 degrees); Form C of the sulfate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 3.19, 5.35, 9.62, 12.27, 16.33, 17.11, 18.75, 18.99, 19.36, 19.47, 20.55, 21.01, 21.52, 21.62, 21.89, 22.19, 23.79, 25.07 and 26.06 degrees 2θ (±0.20 degrees); Form B of the hemitartrate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all the following peaks: 5.17, 5.66, 10.10, 10.40, 11.37, 11.55, 14.51, 17.09, 21.23, 21.83, 23.53, 24.26, 25.26 and 26.78 degrees 2θ (±0.20 degrees); Form A of the tosylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 8.52, 9.74, 14.28, 16.03, 17.55, 18.94, 19.26, 20.31, 21.02, 21.43, 22.11, 22.44, 22.66, 23.07, 24.55 and 27.70 degrees 2θ (±0.20 degrees); and Form B of the tosylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.61, 9.25, 12.44, 15.47, 17.76, 19.01, 19.35, 25.91, 26.33 and 27.63 degrees 2θ (±0.20 degrees).
2. The crystalline salt form of claim 1, wherein: Form A of the besylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 3.78, 7.56, 10.08, 10.42, 11.70, 11.78, 12.00, 12.71, 13.20, 13.92, 14.06, 14.44, 14.93, 15.18, 15.96, 16.21, 16.40, 16.73, 16.86, 17.38, 18.32, 19.07, 20.07, 20.26, 20.51, 20.94, 21.45, 21.60, 22.30, 22.90, 23.05, 23.28, 23.71, 24.28, 24.97, 25.30, 25.69, 26.33, 26.71, 27.29, 27.65, 28.07, 29.22 and 29.50 degrees 2θ (±0.20 degrees); Form A of the camsylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 5.55, 7.90, 8.25, 8.38, 9.55, 9.87, 10.26, 11.12, 11.34, 12.50, 12.94, 13.40, 13.65, 14.79, 15.83, 16.16, 16.41, 16.54, 16.82, 17.10, 17.69, 18.02, 18.22, 18.47, 18.91, 19.10, 19.47, 20.04, 20.87, 21.05, 22.16, 22.36, 22.93, 23.71, 24.55, 25.33, 26.02, 26.40, 27.09, 27.33, 27.97, 28.32, 28.68 and 28.98 degrees 2θ (±0.20 degrees); Form B of the camsylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 5.25, 8.32, 8.51, 8.76, 9.05, 9.58, 9.88, 10.00, 10.52, 10.80, 11.06, 11.96, 12.24, 12.58, 13.98, 15.62, 15.81, 16.15, 16.70, 17.12, 17.42, 17.71, 18.41, 19.37, 19.55, 20.63, 21.13, 21.56, 21.89, 22.50, 23.04, 24.43, 26.08, 27.07, 27.97, 28.22 and 28.73 degrees 2θ (±0.20 degrees); Form B of the citrate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.58, 5.95, 7.61, 8.88, 9.19, 9.94, 11.93, 13.26, 13.79, 14.29, 14.68, 15.26, 15.95, 16.64, 17.11, 17.87, 18.21, 18.43, 18.90, 19.36, 19.67, 20.14, 20.57, 21.47, 22.30, 22.64, 23.06, 23.80, 24.25, 24.55, 24.81, 25.10, 25.45, 25.54, 25.85, 26.35, 26.51, 26.83, 27.16, 27.57, 27.85, 28.08 and 28.47 degrees 2θ (±0.20 degrees); Form A of the esylate of Compound 1 is characterized by a diffraction pattern (RDP) that includes all of the following peaks: 3.97, 7.95, 9.89, 10.62, 10.92, 11.03, 11.34, 11.77, 12.03, 12.53, 12.71, 13.27, 14.00, 14.70, 15.08, 15.94, 16.17, 16.92, 17.01, 17.19, 17.35, 17.61, 18.15, 18.76, 19.03, 19.66, 19.89, 20.26, 20.65, 20.78, 21.44, 22.08, 23.14, 23.27, 23.99, 24.32, 25.43, 25.66, 25.85, 26.52, 26.87, 27.61, 27.96, 28.18, 28.40 and 28.91 degrees 2θ (±0.20 degrees); HBr-form B of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 5.26, 8.29, 9.75, 9.91, 10.56, 10.72, 12.25, 12.50, 12.75, 13.31, 13.54, 14.11, 14.72, 14.89, 15.87, 16.29, 16.50, 17.36, 17.78, 18.09, 18.44, 18.75, 19.12, 19.24, 19.56, 19.92, 20.40, 20.55, 20.69, 21.18, 22.09, 22.64, 23.24, 24.56, 25.80, 26.52, 27.23, 27.43, 28.13, 28.46, 28.76, 29.08, 29.66 and 30.07 degrees 2θ (±0.20 degrees); Form A of the maleate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 7.58, 8.34, 10.92, 12.38, 12.87, 14.17, 15.13, 15.78, 16.43, 16.91, 17.51, 18.09, 18.71, 20.30, 21.60, 21.99, 22.30, 22.49, 23.32, 23.56, 23.92, 24.79, 26.04, 26.41, 26.92, 27.62, 28.18, 28.54 and 29.01 degrees 2θ (±0.20 degrees); Form A of the mesylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 5.06, 6.65, 7.66, 8.35, 10.16, 10.72, 11.98, 12.62, 13.32, 14.41, 14.79, 15.42, 15.72, 15.89, 16.23, 16.77, 17.20, 17.59, 18.08, 18.40, 18.81, 19.33, 19.53, 19.71, 20.14, 20.38, 20.73, 21.05, 21.56, 21.83, 22.16, 23.14, 24.06, 24.54, 24.77, 25.75, 26.82, 27.71, 27.94, 28.71, 29.27 and 29.85 degrees 2θ (±0.20 degrees); Form B of the mesylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 5.14, 6.62, 7.72, 7.89, 10.33, 10.73, 12.74, 13.31, 13.88, 14.23, 14.61, 15.21, 15.52, 15.87, 16.17, 17.18, 17.41, 17.88, 18.15, 18.46, 18.73, 19.13, 19.54, 20.15, 20.53, 20.75, 20.98, 21.27, 21.60, 22.03, 22.28, 23.07, 23.32, 24.16, 24.42, 24.87, 25.13, 25.64, 26.24, 26.95, 27.17, 27.49, 27.77, 28.42 and 29.54 degrees 2θ (±0.20 degrees); Form C of the mesylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 7.55, 9.53, 10.25, 11.04, 11.49, 11.65, 12.24, 12.51, 13.88, 14.44, 15.36, 15.66, 16.29, 16.58, 17.16, 17.54, 19.04, 19.20, 19.79, 20.54, 21.12, 21.24, 21.62, 22.22, 23.15, 23.57, 23.99, 24.61, 24.77, 25.22, 25.61, 25.99, 26.60, 26.89, 27.29, 27.91, 29.03 and 29.29 degrees 2θ (±0.20 degrees); Form A of the oxalate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.90, 5.25, 6.20, 8.05, 9.87, 10.54, 12.29, 14.79, 15.35, 15.84, 16.49, 16.89, 17.55, 18.27, 18.67, 19.12, 19.40, 19.81, 20.26, 20.50, 21.06, 21.74, 22.17, 22.93, 23.26, 23.50, 23.81, 24.66, 25.06, 25.95, 26.90, 27.82 and 28.24 degrees 2θ (±0.20 degrees); Form B of the oxalate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.20, 7.59, 8.02, 8.42, 10.53, 12.36, 12.66, 13.09, 13.35, 13.88, 14.15, 14.46, 15.06, 15.23, 17.42, 17.75, 18.28, 19.07, 19.52, 20.33, 21.18, 21.43, 21.74, 22.08, 22.59, 23.53, 24.21, 24.52, 24.71, 25.24, 25.85, 26.24, 26.55, 26.90, 27.43, 28.56, 29.30 and 29.51 degrees 2θ (±0.20 degrees); Form C of the oxalate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.13, 7.70, 10.29, 10.59, 13.09, 13.70, 14.13, 15.33, 15.87, 16.57, 17.19, 17.50, 17.83, 18.15, 18.61, 19.24, 19.42, 20.11, 20.34, 20.64, 21.07, 21.47, 21.59, 21.91, 22.56, 22.92, 23.37, 23.87, 24.35, 25.35, 25.91, 26.47, 26.68, 27.74, 28.47 and 29.14 degrees 2θ (±0.20 degrees); Form A of the sulfate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.74, 5.85, 9.47, 10.04, 11.74, 11.95, 13.77, 14.99, 15.42, 15.71, 16.48, 17.36, 17.66, 17.92, 18.59, 18.95, 19.36, 19.74, 20.22, 20.77, 21.38, 21.86, 22.74, 23.30, 23.70, 24.33, 25.07, 25.32, 25.67, 26.23 and 27.00 degrees 2θ (±0.20 degrees); Form B of the sulfate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.27, 8.57, 9.32, 10.95, 11.29, 12.07, 12.87, 13.25, 13.82, 14.13, 14.67, 16.94, 17.21, 17.64, 19.99, 20.26, 21.03, 21.44, 22.00, 22.71, 23.85, 25.20 and 26.02 degrees 2θ (±0.20 degrees); Form C of the sulfate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 3.19, 5.35, 9.04, 9.62, 10.73, 11.31, 11.60, 12.27, 12.67, 13.76, 14.31, 14.65, 15.21, 15.63, 16.11, 16.33, 16.63, 17.11, 18.32, 18.75, 18.99, 19.36, 19.47, 20.16, 20.55, 21.01, 21.52, 21.62, 21.89, 22.19, 22.53, 23.19, 23.79, 24.23, 24.81, 25.07, 25.41, 26.06, 26.73, 27.58, 28.16, 28.63, 28.90, 29.22, 29.47 and 29.73 degrees 2θ (±0.20 degrees); Form B of the hemitartrate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all the following peaks: 5.17, 5.66, 7.22, 9.27, 10.10, 10.40, 11.37, 11.55, 12.77, 13.94, 14.51, 15.60, 16.06, 16.48, 17.09, 17.69, 17.90, 18.27, 18.94, 19.15, 19.59, 19.81, 20.06, 20.32, 21.23, 21.83, 22.34, 22.84, 23.53, 24.26, 24.70, 25.26, 25.80, 26.78, 27.29, 27.90, 29.04 and 29.45 degrees 2θ (±0.20 degrees); Form A of the tosylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 5.81, 7.05, 8.52, 9.74, 10.40, 10.99, 11.26, 11.66, 12.58, 12.81, 14.28, 14.62, 15.30, 15.80, 16.03, 16.34, 17.12, 17.55, 18.03, 18.94, 19.26, 19.67, 20.31, 20.65, 21.02, 21.43, 22.11, 22.44, 22.66, 22.94, 23.07, 23.54, 23.79, 24.55, 24.88, 25.42, 25.83, 26.10, 26.53, 27.70, 28.11, 28.62, 29.18, 29.40, 29.66 and 29.83 degrees 2θ (±0.20 degrees); Form B of the tosylate of Compound 1 is characterized by a diffraction pattern (DRF) that includes all of the following peaks: 4.61, 8.69, 9.25, 10.68, 12.44, 12.69, 13.76, 14.42, 14.81, 15.47, 16.08, 16.57, 17.45, 17.76, 18.44, 18.83, 19.01, 19.35, 20.42, 20.84, 21.15, 21.69, 22.09, 22.86, 23.12, 24.08, 24.53, 24.86, 25.22, 25.91, 26.33, 26.82, 27.63, 28.61, 29.11 and 29.77 degrees 2θ (±0.20 degrees).
3. The crystalline salt form of claim 1 or 2, wherein: Form A of the besylate of Compound 1 is characterized by a first endothermic peak at a temperature of around 144 °C and a second endothermic peak at around 170 °C on the thermogram differential scanning calorimetry (DSC); Form A of the camsylate of Compound 1 is characterized by the first endothermic peak at temperature of about 110 °C and a second endothermic peak at a temperature of about 174 °C on DSC thermograms; Form B of the citrate of Compound 1 is characterized by an endothermic peak with an onset temperature of about 175 °C on the DSC thermogram; Form A of the esylate of Compound 1 is characterized by a first endothermic peak at a temperature of about 69 °C, a second endothermic peak at a temperature of about 156 °C, and a third an endothermic peak at a temperature of about 190 °C on the DSC thermogram; Form A of the maleate of Compound 1 is characterized by an endothermic peak at a temperature of about 117 °C on the DSC thermogram; Form C of the mesylate of Compound 1 is characterized by a first endothermic peak at a temperature of about 69 °C, with the lower limit of the first endothermic peak being about 36 °C, and the upper limit is about 96 °C, and a second endothermic peak at a temperature of about 208 °C, and the lower limit of the second endothermic peak is about 169 °C, and the upper limit is about 219 °C; Form B of the hemitartrate of Compound 1 is characterized by the first endothermic peak at temperature of about 111 °C and a second endothermic peak at a temperature of about 148 °C on DSC thermograms; Form A of the tosylate of Compound 1 is characterized by an endothermic peak with a temperature of beginning around 214 °C on the DSC thermogram; and Form B of the tosylate of Compound 1 is characterized by a sharp endothermic peak with a temperature the peak onset is -183 °C on the DSC thermogram.
4. The crystalline salt form according to any one of claims 1-3, wherein: Form A of the besylate of Compound 1 is characterized by a mass loss of about 7.9 wt. % in the range temperatures of 39-177 °C on the TGA thermogram; Form A of the camsylate of Compound 1 is characterized by a mass loss of about 5.9 wt. % in the range temperatures of 38-170 °C on the TGA thermogram; Form B of the citrate of Compound 1 is characterized by a mass loss that begins at a temperature about 159 °C and ends at a temperature of about 220 °C on the TGA thermogram; Form A of the esylate of Compound 1 is characterized by a mass loss of about 8.5 wt. % in the range temperatures of 38-188 °C on the TGA thermogram; Form A of the maleate of Compound 1 is characterized by a mass loss of approximately 3.1 wt. % in temperature range 42-146 °C on the TGA thermogram; Form C of the mesylate of Compound 1 is characterized by a mass loss of 0.5 to 3.0 wt. % in the range temperatures of 36-130 °C on the TGA thermogram; Form B of the hemitartrate of Compound 1 is characterized by a mass loss of approximately 7.4 wt. % in temperature range 39-157 °C on the TGA thermogram; Form A of the tosylate of Compound 1 is characterized by a mass loss of approximately 0.9 wt. % in temperature range 72-231 °C on the TGA thermogram; and Form B of the tosylate of Compound 1 is characterized by a mass loss of approximately 0.7 wt. % in temperature range 39-214 °C on the TGA thermogram.
5. The crystalline salt form according to any one of claims 1-4, wherein: Form B of the citrate of Compound 1 is characterized by an increase of approximately 4.1 wt. %, measured by the dynamic vapor sorption (DVS) method, when moving from an environment with a relative humidity of 5% in an environment with a relative humidity of 95%; Form A of the maleate of Compound 1 is characterized by an increase of approximately 2.5 wt. %, measured by the DSP method, when moving from an environment with a relative humidity of 5% to environment with a relative humidity of 95%; Form C of the mesylate of Compound 1 is characterized by an increase of approximately 5.1 wt. %, measured by the DSP method, when moving from an environment with a relative humidity of 5% to environment with a relative humidity of 95%; Form A of the tosylate of Compound 1 is characterized by an increase of approximately 0.9 wt. %, measured by the DSP method, when moving from an environment with a relative humidity of 5% to environment with a relative humidity of 95%; Form B of the tosylate of Compound 1 is characterized by a mass increase of approximately 0.9 wt. %, measured by the DSP method, when transferred from an environment with a relative humidity of 5% to environment with a relative humidity of 95%.
6. A pharmaceutical composition comprising a crystalline salt form according to any one of claims 1-5. and a pharmaceutically acceptable excipient.
7. A crystalline salt form according to any one of claims 1-5 for use in the treatment of cancer.
8. The pharmaceutical composition according to claim 6 for use in the treatment of cancer.
Citation Information
Patent Citations
Quinoline derivative, pharmaceutically acceptable salt or solvate thereof, application thereof, medicines and pharmaceutical compositions
CN109761899A
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
US20180009758A1
C-met modulators and methods of use
WO2005030140A2
Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-YL) OXY]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2018218233A1
Compounds for the treatment of kinase-dependent disorders
WO2019148044A1
